 
 
Official Title:    APOLLO:  A Phase 3 Multicenter,  Multinational,  Randomized,  Doubleblind,  
Placebo‐controlled  Study to Evaluate the Efficacy  and Safety of 
ALN‐TTR02  in Transthyretin  (TTR)‐Mediated  Polyneuropathy  
(Familial Amyloidotic  Polyneuropathy ‐FAP) 
 
NCT  Number:    [STUDY_ID_REMOVED]  
Document  Date:    Protocol Version 6, 08 September  2015 
  
 
 
 
CLINICAL STUDY PROTOCOL  
ALN-TTR02- 004 
 
APOLLO:  A Phase 3 Multicenter, Multinational, Randomized, Double -
blind, Placebo -controlled Study to Evaluate the Efficacy and Safety of 
Patisiran ( ALN-TTR02 ) in Transthyretin (TTR) -Mediated 
Polyneuropathy ( Familial Amyloidotic Polyneuropathy-FAP) 
 
Protocol Version  Version 6.0 (Incorporating Amendment 5) 
Protocol Date 08 September  2015 
IND Number  117395 
EudraCT Number 2013-002987-17 
Sponsor: Alnylam Pharmaceuticals, Inc . 
300 Third Street 
Cambridge, MA  02142  USA 
Sponsor Contact:   
 
 
CONFIDENTIAL  
The concepts and information contained in this document or generated during the study 
are considered proprietary and may not be disclosed in whole or in part without expressed 
written authorization of Alnylam Pharmaceuticals, Inc.  
The study will be completed according to guidelines of Good Clinical Practice.  
Compliance with this prac tice provides public assurance that the rights, safety, and 
well-being of study patients are protected consistent with the principles that have their 
origin in the Declaration of Helsinki.  
 

Patisir an (ALN-TTR02) 
ALN -TTR02-004 
08 September 2015 
AUTHORIZED SIGNATORIES 
INVESTIGATOR'S STATEMENT: I agree to conduct this study as outlined in the 
protocol and in accordance with the guidelines and all applicable government regulations. 
I have read all parts of the protocol. 
Principal Investigator 
Signature 
Name (print) 
Sponsor 
Signature 
Name (print)  
 
 
Version History: 
Version Number Date 
1.0 (Original) 15 August 2013 
2.0 18 October 2013 
3.0 21 March 2014 
4.0 24 April 2014 
5.0 04 August 2014 
6.0 08 September 2015 
Final Protocol (Version 6.0) 
Page 2 of 109 Date 
Date 
Comment 
Initial Release 
Incorporating Global Amendment 1 
Incorporating Global Amendment 2 
Incorporating Global Amendment 3 
Incorporating Global Amendment 4 
Incorporating Global Amendment 5 
Confidential 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 3 of 109 
Table of Contents 
 
Table of Contents ...............................................................................................................3  
List of Tables  ......................................................................................................................7  
List of Appendices  ..............................................................................................................7  
PROTOCOL Synopsis  .......................................................................................................8  
1 Introduction ..........................................................................................................32  
1.1 Background and Rationale ........................................................................ 32  
1.1.1  Disease Overview  ......................................................................... 32  
1.1.2  RNA Interference  .......................................................................... 33  
1.1.3  PATISIRAN  .................................................................................. 34  
1.1.4  Therapeutic Hypothesis  ................................................................ 34  
1.2 Summary of Patisiran Nonclinical Data  ................................................... 34  
1.3 Summary of Clinical Data with Patisiran  ................................................. 35  
1.4 Study Design Rationale............................................................................. 36  
1.5 Dose Selection and Dosing Schedule Rationale ....................................... 37  
1.6 Risk-Benefit Assessment  .......................................................................... 37  
2 Study Objectives ...................................................................................................40  
2.1 Primary Objective  ..................................................................................... 40  
2.2 Secondary Objectives ................................................................................ 40  
2.3 Exploratory Objectives ............................................................................. 40  
3 Study Plan .............................................................................................................42  
3.1 Overall Design  .......................................................................................... 42  
3.2 Effica cy Assessments ................................................................................ 44 
3.3 Safety Assessments  ................................................................................... 44  
3.4 Pharmacodynamic Assessments  ............................................................... 44  
3.5 Pharmacokinetic Assessments  .................................................................. 44  
3.6 Other Assessments  .................................................................................... 45  
4 Patient Population  ................................................................................................46  
4.1 Eligibility of Patients  ................................................................................ 46  
4.2 Inclusion Criteria  ...................................................................................... 46  
4.3 Exclusion Criteria  ..................................................................................... 47  
4.4 Assignment to Treatment Group/Patient Number  .................................... 48  
4.4.1  Randomization Procedures ........................................................... 48  
4.4.2  Patient Numbering  ........................................................................ 48  
4.4.3  Blinding Procedure ....................................................................... 48  
4.4.4  Breaking the Blind  ........................................................................ 49  
4.5 Early Patient Discontinuation or Withdrawal ........................................... 49  
4.5.1  Reasons for Treatment Discontinuation or Withdrawal  ............... 50  
4.5.2  Handling of Withdrawals or Patients who Discontinue from 
Treatment  ...................................................................................... 50  
4.5.3  Replacements  ................................................................................ 51  
4.6 Discontinuation Due to Rapid Disease Progression ................................. 51  
4.7 Pregnancy and Breastfeeding Restrictions / Contraception Requirements 51 
5 Study Medication  .................................................................................................53  

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 4 of 109 
5.1 Presen tation of Study Drug ....................................................................... 53  
5.2 Preparation of Study Drug ........................................................................ 53  
5.2.1  Preparation of Patisiran  ................................................................. 53  
5.2.2  Preparation of Placebo  .................................................................. 53  
5.3 Drug Administration  ................................................................................. 54  
5.3.1  Premedication  ............................................................................... 54  
5.3.2  Study Drug Administration  ........................................................... 55  
5.4 Storage of Study Drug  .............................................................................. 55  
5.5 Labeling and Packaging of Study Drug .................................................... 56  
5.6 Measurement of Patient Compliance ........................................................ 56  
5.7 Study Drug  Accountability ....................................................................... 56  
5.8 Concomitant Medication / Treatment  ....................................................... 57  
5.9 Suggested Guidelines for Management of Infusion- related Reactions ..... 57  
6 Study Visits  ...........................................................................................................59  
6.1 Screening, Screening/Baseline, and Baseline Visits (Days –42 to Day 0) 59  
6.1.1  Screening ....................................................................................... 59  
6.1.2  Screening/Baseline Visit  ............................................................... 60  
6.1.3  Baseline Visit ................................................................................ 61  
6.2 Treatment Visits  ........................................................................................ 63  
6.2.1  Day 0  ............................................................................................. 63  
6.2.2  Routine Study Visits  ..................................................................... 64  
6.2.3  Efficacy Assessment Visits (9 Months and 18 Months) ............... 65  
6.2.4  Follow- Up Visits  ........................................................................... 67  
6.3 Early Withdrawal Visit and Follow -up Visits for Patients who 
Permanently Discontinue Study Treatment  .............................................. 68  
6.3.1  Early Withdrawal Visit ................................................................. 68  
6.3.2  Follow-up Visits for Patients who Permanently Discontinue Study 
Treatment  ...................................................................................... 69  
6.4 Modified Visit Schedule for Patients who Discontinue Study Drug for Rapid Disease Progression at Month 9 ..................................................... 70
 
6.4.1  Modified Day 273 ......................................................................... 70  
6.4.2  Modified Day 294 ......................................................................... 71  
6.4.3  Modified Day 378 and Day 462 .................................................... 71  
6.4.4  Modified Day 546 ......................................................................... 71  
6.4.5  Modified 18- Month Efficacy Assessment Visit  ........................... 72  
6.4.6  Modified Twenty- One-Day Follow -up Visit (End of Study) ....... 73  
6.4.7  Modified Early Withdrawal Visit ................................................. 73  
6.5 Unscheduled Visits ................................................................................... 74  
7 Study Assessments  ...............................................................................................75  
7.1 Demographic Data and Medical History  .................................................. 75  
7.2 Efficacy Assessments ................................................................................ 75  
7.2.1  Modified Neurological Impairment Score +7  ............................... 75  
7.2.2  Neurological Impairment Score +7  ............................................... 76  
7.2.3  Familial Amyloidotic Polyneuropathy Stage and Polyneuropathy Disability Score  ............................................................................. 76
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 5 of 109 
7.2.4  Intraepidermal Nerve Fiber Density and Sweat Gland Nerve Fiber 
Density  .......................................................................................... 76  
7.2.5  Modified Body Mass Index .......................................................... 76  
7.2.6  Timed Ten -meter Walk Test  ......................................................... 76  
7.2.7  Grip Strength Test ......................................................................... 77  
7.2.8  Composite Autonomic Symptom Score........................................ 77  
7.2.9  Norfolk Quality of Life - Diabetic Neuropathy Questionnaire  ..... 77  
7.2.10  EuroQoL Quality of Life Questionnaire ....................................... 77  
7.2.11  Rasch -built Overall Disability Scale  ............................................. 77  
7.2.12  Echocardiogram and Biomarkers of Cardiac Function ................. 77  
7.3 Pharmacodynamic Assessments  ............................................................... 78  
7.3.1  Transthyretin  ................................................................................. 78  
7.3.2  Retinol Binding Protein  ................................................................ 78  
7.3.3  Vitamin A ...................................................................................... 78  
7.3.4  Exploratory Biomarkers ................................................................ 78  
7.4 Pharmacokinetic Evaluations  .................................................................... 78  
7.4.1  Plasma Pharmacokinetics .............................................................. 79  
7.4.2  Urine Pharmacokinetics  ................................................................ 79  
7.5 Safety Assessments  ................................................................................... 79  
7.5.1  Physical Examination .................................................................... 79  
7.5.2  Body Weight and Height .............................................................. 79  
7.5.3  Vital Signs  ..................................................................................... 79  
7.5.4  Electrocardiogram  ......................................................................... 79  
7.5.5  Clinical Laboratory Tests  .............................................................. 80  
7.5.6  Ophthalmology Examination  ........................................................ 82  
7.5.7  Adverse Events and Study- Procedure- Related Adverse Events  ... 82  
7.5.8  Concomitant Medications and Treatments ................................... 82  
7.6 Other Assessments  .................................................................................... 82  
7.6.1  Pharmacoeconomics Questionnaire .............................................. 82  
7.6.2  Suicidality Questionnaire  .............................................................. 82  
7.6.3  Phone Contact for Health Status Update and FAP Treatment ...... 83  
8 Reporting Adverse Events  ...................................................................................84  
8.1 Adverse Event Definition  ......................................................................... 84  
8.2 Serious Adverse Event Definition ............................................................ 84  
8.3 Eliciting Adverse Event Information  ........................................................ 84  
8.4 Adverse Event Reporting .......................................................................... 85  
8.5 Adverse Event Reporting Period .............................................................. 85  
8.6 Assessment of Causality  ........................................................................... 86  
8.7 Assessment of Severity  ............................................................................. 86  
8.8 Action Taken for Adverse Event .............................................................. 87  
8.9 Outcome of Adverse Event ....................................................................... 87  
8.10  Coding of Adverse Events ........................................................................ 87  
8.11  Serious Adverse Event Reporting ............................................................. 87  
8.12  Pregnancy Reporting  ................................................................................. 88  
9 Statistical Methods  ...............................................................................................90  
9.1 Sample Size  ............................................................................................... 90  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 6 of 109 
9.2 Statistical Methodology  ............................................................................ 90  
9.2.1  Populations to be Analyzed .......................................................... 90  
9.2.2  Baseline Evaluations  ..................................................................... 90  
9.2.3  Efficacy Analyses  ......................................................................... 90  
9.2.4  Safety Analyses  ............................................................................. 91  
9.2.5  Pharmacodynamics  ....................................................................... 92  
9.2.6  Pharmacokinetics  .......................................................................... 92  
9.2.7  Summary of Efficacy Assessments  ............................................... 92  
9.2.8  Other Assessments  ........................................................................ 93  
9.2.9  Interim Analysis  ............................................................................ 93  
9.2.10  Missing Data  ................................................................................. 93  
10 Study Management  ..............................................................................................94  
10.1  Data Handling and Quality Assurance  ...................................................... 94  
10.1.1  Case Report Forms  ........................................................................ 94  
10.1.2  Monitoring .................................................................................... 94  
10.1.3  Inspections .................................................................................... 94  
10.2  Regul atory Guidelines  .............................................................................. 94  
10.2.1  Institutional Review Board/Independent Ethics Committee ......... 95  
10.2.2  Regulatory Authorities  .................................................................. 95  
10.2.3  Modification of the Protocol ......................................................... 95  
10.2.4  Informed Consent Form ................................................................ 95  
10.2.5  Study Reporting Requirements ..................................................... 96  
10.2.6  Financial Disclosure Reporting Obligations  ................................. 96  
10.3  Study Committees  ..................................................................................... 96  
10.3.1  Data Monitoring Committee  ......................................................... 96  
10.3.2  Clinical Adjudication Committee  ................................................. 96  
10.3.3  Interim Analysis Committee  ......................................................... 96  
10.4  Ancillary Research  .................................................................................... 97  
10.5  Study Record Retention ............................................................................ 97  
10.6  Discontinuation of the Study by Alnylam ................................................ 97  
10.7  Study Documentation ................................................................................ 97  
10.8  Confidentiality  .......................................................................................... 98  
10.9  Publications/Reports  ................................................................................. 99  
11 References  ...........................................................................................................100  
12 Appendices  ..........................................................................................................104  
 
  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 7 of 109 
List of Tables  
Table 1 -1: Schedule of Assessments; Screening to 9 -Month Efficacy Assessment  .. 17  
Table 1 -2: Schedule of Assessments; Week 39 to Week 86 (Follow- up) / Early 
Withdrawal  ................................................................................................................... 21  
Table 1 -3: Modified Schedule of Assessments for Patients who Discontinue Study 
Drug for Rapid Disease Progression; Week 39 to End of Study ...................................... 26  
 
 
List of Figures  
Figure 1:  Study Schematic ........................................................................................ 43  
 
 
List of Appendices  
Appendix 1:  Karnofsky Scale  ...................................................................................... 104  
Appendix 2:  New York Heart Association Classification of Heart Failure  ................ 105  
Appendix 3:  Categorization of Infusion- Related Reactions  ........................................ 106  
Appendix 4:  Neuropathy Scores and Their Components ............................................ 107  
Appendix 5:  Polyneuropathy Disability Score  ............................................................ 108  
Appendix 6:  Familial Amyloidotic Polyneuropathy Stage  .......................................... 109  
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
 
 
Final Protocol  (Version 6 .0)  Confidential  
Page 8 of 109 
 
PROTOCOL  SYNOPSIS  
Protocol Title  APOLLO:  A Phase 3 Multicenter, Multinational, Randomized, 
Double-blind, Placebo- controlled Study to Evaluate the Efficacy 
and Safety of Patisiran ( ALN -TTR02 ) in Transthyretin (TTR)-
Mediated Polyneuropathy (Familial Amyloidotic 
Polyneuropathy- FAP) 
Indicatio n Treatment of transthyretin -mediated amyloidosis (ATTR) in 
patients with symptomatic polyneuropathy  
Protocol Number  ALN -TTR02 -004 
Phase of 
Development  3 
Design This is a multicenter, multinational, randomized, double -blind  
study comparing patisiran ( ALN -TTR02 ) to placebo in ATTR 
patients  with symptomatic Familial Amyloidotic P olyneuropathy 
(FAP) . 
Consented eligible p atients will be randomized to receive either 
0.3 mg/ kg patisiran  or placebo in a 2:1 ratio  (patisiran  to placebo ) 
in a blinded manner .  Treatment arms will be balanced at entry 
for Neuropathy Impairment Score (NIS; 5-49 vs 50-130), early 
onset V30M (<50 years of age at onset) vs. all other mutations 
(including late onset V30M), and previous tetramer stabilizer use (tafamidis or diflunisal) vs no previous tetramer stabilizer use.   
Patients will receiv e patisiran  or placebo once every 2 1 days for 
78 weeks.  
Patients will have baseline efficacy  assessments and efficacy 
assessments at 9 and  18 months.  The study personnel performing 
these assessments will be blinded to the results of any previous assessments (e.g., Screening/Baseline, Baseline, or 9 -month 
assessments).  
At the 9 -month time point, if the clinical adjudication committee 
determines that a patient is exhibit ing rapid di sease progression  
(defined as ≥24 point increase in modified NIS+7 (mNIS+7) from baseline [based on an average of 2 measurements] and  FAP 
stage progression relative to baseline) , the patient ’s treating 
physician  will provide the patient with the option of 
discontinuing study drug and receiving local standard of care treatment for FAP .  Patients who discontinue study drug will 
remain on study, following a modified schedule of visits, through completion of the 18- month efficacy  assessments (blinding will 
be maintained throughout). 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 9 of 109 
Patients  who complete the 18 -month efficacy assessments can 
elect to participate in an extension study  in which patients would 
receive open -label administration of 0. 3 mg/kg patisiran  once 
every 21 days. 
A Data Monitoring Committee (DMC)  will be implemented for 
the study and will operat e under a prespecified charter .  
Study Sites  This study will be conducted at multiple  sites worldwide . 
Investigational 
Drug Patisiran  (comprising a small interfering ribonucleic acid 
[siRNA ] targeting mutant and wild -type TTR mRNA , in a lipid 
nanoparticle formulation for intravenous [ IV] administration)  
Dosage, Route of 
Administration 
and Duration of Treatment of 
Investigational Drug Patients randomized to the active treatment group will receive 
0.3 mg/kg patisiran  once every 21 (±3) days administered as an 
IV infusion over 70 minutes (approximately 1 mL/min ute for the 
first 15 minutes followed by approximately 3  mL/ minute  for the 
remainder of the infusion) by a controlled infusion device.  
Prior to each dose of study drug, patients will receive the following premedications at least 60 minutes prior to the infusion: 
• Intravenous dexamethasone (10 mg) or equivalent; 
• Oral paracetamol/acetaminophen (500 mg) or equivalent; 
• Intravenous H2 blocker (e.g., ranitidine 50 mg, famotidine 
20 mg, or equivalent other H2 blocker dose); and 
• Intravenous H1 blocker: diphenhydramine 50 mg (or equivalent other IV H1 blocker available at the stud y site).  
Hydroxyzine or fexofenadine 25 mg per oral suspension 
(PO, orally) or cetirizine 10 mg PO may be substituted for any patient who does not tolerate intravenous 
diphenhydramine or other intravenous H1 blocker.  
Control Drug  Placebo (normal saline 0 .9% for IV administration)  
Dosage, Route of 
Administration and Duration of Treatment of Control Drug  Patients randomized to placebo will receive IV normal saline 
(0.9%) using the same dosing schedule and infusion rate as the 
active treatment group.   
Placebo patients will also receive the same premedication regimen as the active treatment group.  
Time on Study  The duration of patient participation in this study is 
approximately 21 months (inclusive of a 42- day screening 
window and up to a 56-day post last dose study visit ). 
Primary 
Objective  The primary objective of the study is to determine the efficacy of 
patisiran  by evaluating the difference between the patisiran  and 
placebo groups in the change from baseline of mNIS+7 score at 18 months. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 10 of 109 
Secondary 
Objectives  The secondary objectives of the study are to determine the effect 
of patisiran  on various clinical parameters by assessing the 
difference between patisiran  and placebo in the change from 
baseline in the following measurements at 18  months: 
• Norfolk Quality of Life- Diabetic Neuropathy 
(Norfolk  QOL -DN) questionnaire; 
• NIS-weakness (NIS -W) score ; 
• Modified body mass index ( mBMI) ; 
• Timed 10-meter walk test ; 
• Autonomic symptoms questionnaire (Composite Autonomic 
Symptom Score [COMPASS-31]). 
Exploratory 
Objectives : The exploratory objectives of the study are: 
• To determine the difference between the patisiran  and 
placebo groups in the change from baseline in the following 
measurements  at 18 months: 
• NIS+7  score; 
• Grip strength ; 
• EuroQOL (EQ -5D) questionnaire; 
• Level of disability (Rasch -built Overall Disability Scale 
[R-ODS] ); 
• Large vs small nerve fiber function including nerve conduction studies (NCS) 5 attributes (Σ5), quantitative 
sensory testing by body surface area including touch pressure an d heat pain (QST) , vibration detection 
threshold ( VDT ), heart rate response to deep breathing 
(HRdb), postural blood pressure; 
• Pathologic evaluation of sensory and autonomic innervation through voluntary skin punch biopsies and analysis of intraepidermal nerve fiber density (IENFD) 
and sweat gland nerve fiber  density (SGNFD) ; 
• Assessment of ambulation through FAP s tage and 
Polyneuropathy Disability ( PND ) score; 
• Cardiac assessment through echocardiogram, troponin I,  
and N-terminal prohormone of B- type natriuretic 
peptide ( NT-proBNP ) levels; 
• Pharmacodynamic (PD) biomarkers ( TTR, retinol 
binding protein [ RBP ], vitamin  A); 
• To compare the p roportion of patients in the patisiran  and 
placebo groups who meet the pre-defined criterion for rapid disease progression (defined as ≥24 point increase in 
mNIS+7 from baseline [based on an average of 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 11 of 109 
2 measurements] and FAP stage progression relative to 
baseline) at 9 months. 
Sample Size:  Approximately 200 patients will be enrolled in this study.  Of 
those 200 patients, no more than 40 patients will have a NIS 
range of 101 to 130.  An mNIS+7  progression rate  (primary 
endpoint) in the placebo group of 24 ± 16 points in 18 months was estimate d using natural history data from  FAP patients .  A 
sample of 154 patients provides 90% power for a 2- sided test 
with an 8.95 point (37.5%) mean difference between treatment groups in the primary endpoint at 2-sided alpha = 0.05.  
Assuming a 25% random premature discontinuation rate (due to liver transplantation or other factors), the sample size for this study is approximately 200.  Additional patients may be enrolled based on a recommendation to increase the sample size in the interim analysis.  
Inclusion and 
Exclusion 
Criteria:  To be enrolled in the study, each patient must meet the following 
criteria  at the Screening  visit, except where specified : 
1. Male or female of 18 to 85 years of age (inclusive);  
2. Have a diagnosis of FAP with documented TTR mutation;  
3. Have an NIS of 5 to 130 (inclusive) and a PND score of ≤3b 
(Note:  This criterion must be met at the Screening/Baseline 
visit);  
4. Have an NCS sum of the sural s ensory nerve action potential 
(SNAP),  tibial compound muscle action potential (CMAP), 
ulnar SNAP , ulnar CMAP, and peroneal CMAP of ≥2 
points; (Note:  This criterion must be met at the 
Screening/Baseline visit);  
5. Have a Karnofsky performance status of ≥60%; 
6. Have an absolute neutrophil count (ANC) ≥1500 cells/mm³, 
and a platelet count ≥50,000 cells/mm³; 
7. Have aspartate transaminase (AST) and alanine 
transaminase (ALT) levels ≤2.5 × the upper limit of normal (ULN), total bilirubin  within normal limits , international 
normalized ratio (INR) ≤2.0 (patients on anticoagulant therapy  with a n INR of ≤3.5 will be allowe d). Patients with 
total bilirubin ≤ 2 X ULN are eligible if the elevation is secondary to documented Gilbert’s syndrome 
(elevation of 
unconjugated bilirubin with normal conjugated bilirubin) and 
the patient has ALT and AST levels within normal ranges; 
8. Have a serum creatinine ≤ 2 × ULN;  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 12 of 109 
9. No a ctive infection with hepatitis B or hepatitis C by 
serology; 
10. Women of child- bearing potential must h ave a negative 
pregnancy test, cannot be breastfeeding, and must be using 
2 highly effective methods of contraception prior to screening, throughout study participation, and for 75 days after the last dose of study drug .  Highly effective methods 
of birth control are defined in Section 4.7; 
11. Males with partners of child -bearing potential  must agree to 
use 1 barrier method (e.g., condom) and 1 additional method (e.g., spermicide) of contraception throughout study 
participation and for 75 days after the last dose of study 
drug; males must also abstain from sperm donation after the 
first dose of study drug through study participation and for 75 days after the last dose of study drug; 
12. Must be willing and able to comply with protocol-required 
visit schedule and visit requirements and provide written informed consent. 
 
A patient will be excluded if they meet any of the following 
criteria at the time of the Screening  visit: 
1. Had a prior liver transplant or is planning to undergo liver 
transplant during the study period;  
2. Has other known causes of sensorimotor or autonomic 
neuropathy (e.g., autoimmune disease, monoclonal gammopathy ); 
3. Has known primary amyloidosis or leptomeningeal 
amyloidosis; 
4. Has known type I diabetes; 
5. Has had type II diabetes mellitus for ≥5 years; 6. Has vitamin B12 levels below the lower limit of normal 
(LLN);  
7. Has untre ated hypo - or hyperthyroidism; 
8. Has had a major surgery within the past 3 months or has a 
major surgery planned during any point of the study period; 
9. Has known human immunodeficiency virus (HIV) infection; 10. Has an active infection requiring systemic antiviral or 
antimicrobial therapy that will not be completed prior to the first dose of study drug administration;  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 13 of 109 
11. Had a malignancy within 2 years, except for basal or 
squamous cell carcinoma of the skin or carcinoma in situ of 
the cervix that has been successfully treated;  
12. H as a New York Heart Association heart failure 
classification >2;  
13. Had acute coro nary syndrome within the past 3 months; 
14. Has uncontrolled cardiac arrhythmia or unstable angina; 
15. Has a known history of alcohol abuse within  the past  2 years 
or daily heavy alcohol consumption (females: more than 14 
units of alcohol per week; males: more than 21 units of alcohol per week [unit: 1 glass of wine [125 mL] = 1 
measure of spirits = ½ pint of beer]); 
16. Received an investigational agent or device wi thin 30 days 
of anticipated study drug administration or 5 half- lives of the 
investigational drug, whichever is longer; 
17. Participated in a clinical trial with antisense oligon ucleotide, 
must have completed a 3 -month wash-out prior to start of 
the study drug administration in this study; 
18. Is currently taking tafamidis, doxycycline, or 
tauroursodeoxycholic acid; if previously on any of these agents, must have completed a 14 -day wash -
out prior to start 
of study drug administration in this study ; 
19. Is currently taking diflunisal; if previously on this agent, 
must have at least a 3 -day wash -out prior to start of study 
drug administration in this study;  
20. Had a prior severe reaction to a liposomal product or a 
known hypersensitivity to oligonucleotides or any component of patisiran ; 
21. Is unable to take the required premedications;  
22. Anticipated survival is less than 2 years, in the opinion of 
the Investigator;  
23. Is considered unfit for the study by the Investigator; 
24. Is under legal protection (defined as “any person who 
becomes incapable of protecting his/her  interests due to a 
medically diagnosed impairment of his /her mental faculties 
that may limit or prevent the expression of his /her will” ). 
Efficacy 
Assessments  Efficacy parameters will include the following ( baseline evaluations 
will be conducted as well as evaluations at  9 and 18 months): 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 14 of 109 
• Neurologic impairment will be assessed using the mNIS+7 
composite score.  The mNIS+7 includes the modified NIS 
(weakness and reflexes), NCS  Σ5, QST , as well as 
autonomic assessment th rough postural blood pressure; 
• Patient -reported QOL will be evaluated using the Norfolk  
QOL -DN and the EQ -5D.  Disability will be reporte d by 
patients using the R- ODS;  
• Autonomic symptoms will be assessed using the 
COMPASS -31; 
• Motor function assessments to be evaluated include NIS -W, 
timed 10-meter walk test , and grip strength test ; 
• PND score and FAP stage; 
• Nutritional status will be assessed using mBMI;  
• Pathologic evaluation of sensory and autonomic innervation 
will be evalu ated by IENFD analysis and quantitation of 
dermal SGNFD via tandem 3 mm skin punch biopsies taken from the leg; 
• Neurologic impairment will also be assessed by NIS+7 
(including full NIS, NCS, VDT, and HRdb); 
• Cardiac structure and function will be assessed through 
echocardiograms as well as measurement of serum levels of 
NT-proBNP and troponin I. 
Pharmaco -
dynamic Assessments  Pharmacodynamic markers  assessed serially  will include serum 
TTR, vitamin A , and RBP.  Additional blood samples will be 
collected for exploratory biomarkers  related to FAP.  
Pharmacokinetic 
Assessments  The plasma pharmacokinetic ( PK) evaluation will include , 
whenever possible, plasma -concentration time profiles for siRNA 
and the novel lipid components in patisiran: DLin -MC3 -DMA 
and polyethylene glycol (PEG) 2000-C-DMG.  The siRNA, DLin -
MC3 -DMA, and PEG 2000-C-DMG concentrations will be 
determined for all patients at time points specified in  Table 1-1, 
Table 1-2, and Table 1-3.  
Urine will be collected with void volume recorded for all patients 
at time points specified in  Table 1-1, Table 1-2, and Table 1-3 
and to determine renal clearance (CL R) of siRNA and 
4-dimethylaminodibutyric acid (the metabolite of DLin -
MC3 -DMA) after dosing with study drug. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 15 of 109 
Safety 
Assessments  Safety will be assessed throughout the study by collecting 
adverse events (AEs; including serious adverse events [SAEs]); 
clinical laboratory tests, including hematology, clinical chemistry 
(including liver function tests), thyroid function parameters, and 
urinalysis; measurement of anti-drug antibodies; electrocardiograms; vital signs; physical examination findings; and ophthalmology exam ination s. 
Other 
Assessments  Disease burden and healthcare utilization will be assessed using a 
patient -reported pharmacoeconomics questionnaire.  The 
investigator will periodically assess mental status as it relates to suicidal ideation and behavior by using the Columbia–Suicide 
Severity Rating Scale (C -SSRS) questionnaire.   
Follow-Up Patients  who complete the 18 -month efficacy assessments can 
elect to participate in an extension study in which patients would receive open -label administration of 0. 3 mg/kg patisiran  once 
every 21 days .  Eligible patients who elect to participate will 
return for a follow-up visit 21 days after last dose of study drug. 
If the patient decides not to participate in the extension study, the 
patient will complete 2 follow -up visits at 21 and 56 days after 
the last dose of study drug .  Each follow-up visit includes safety 
assessments and the 21 -day follow -up also includes PD 
measurements.  
Statistical 
Methods A full statistical analysis plan (SAP) will be finalized prior to 
database lock.  
The primary analysis will compare patients administered patisiran  versus those administered placebo in the modified 
intent- to-treat (mITT) population.  Specifically, patients who are 
randomized and receive at least 1 dose of study drug will be included in this analysis.  The primary analysis will compare change in mNIS+7 from baseline at 18 months between patisiran  
and placebo groups, adjusted for the stratification factors.  Analysis of covariance (ANCOVA) will be used to analyze the 
primary endpoint.  Primary endpoint data that are missing will be 
inferred using multip le imputations.  Sensitivity analyses, 
including mixed model repeated measures (MMRM) analyses, will assess the robustness of the primary analysis for the mITT and per protocol (PP) populations.  
Type I error control for secondary endpoints will be achieved by a hierarchical ordering procedure.  Briefly, endpoints will be evaluated  in order to control for multiplicity.  
An independent interim analysis committee (IAC) will conduct a 
blinded interim analysis when approximately 50% of patients 
have compl eted their 9-month  mNIS+7 assessments .  This 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol  (Version 6.0)   Confidential  
Page 16 of 109 
interim analysis will estimate the overall variance in the mNIS+7 
score .  Based on the results of the interim analysis, the committee 
can recommend either increasing the study sample size or making 
no adjustment to the sample size.  
PK analyses will be conducted using non-compartmental and/or 
compartmental evaluation.  The PK parameters of siRNA, DLin -
MC3 -DMA, and PEG 2000-C-D MG in plasma will be evaluated.  
Population PK analyses will be performed whenever possible on 
available siRNA, DLin -MC3 -DMA, and PEG 2000-C-DMG from 
sparse samples collected at various time points during the duration of the study. 
Inferential statistics of PD and PK/PD parameters, correlation 
between siRNA, DLin -MC3 -DMA or PEG
2000C-DMG exposure 
versus TTR, RBP, or v itamin A, and between TTR versus RBP 
and vitamin A will be provided. 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 17 of 109 
Table 1-1: Schedule of Assessments ; Screening to 9-Month Efficacy Assessment  
Procedure  Visit Type  
Screening (a) 
Screening/  
Baseline (a) 
Baseline (a) 
Predosing  
Dosing  
9-Month 
Efficacy 
Assessment(y) 
Study Day  Day -42 to 0 
D0 
Predose 
D0 
D21 
D42 
D63 
D84 
D105 
D126 
D147 
D168 
D189 
D210 
D231 
D252 
D253-
D272 
Study Week  NA 0 0 3 6 9 12 15 18 21 24 27 30 33 36 36-39 
Windows  NA 0 0 ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D NA 
Informed Consent  X                  
Inclusion/Exclusion Criteria  X X (a)                 
Medical History  X X (b) X (b)                
Demographics  X                  
Review Documentation of TTR Genotype  X                  
HIV Status Review  X                  
Karnofsky Performance Status  X                  
New York Heart Classification  X                  
Serology Testing (c) X                  
Paraprotein by IFE  X                  
Vitamin B12  X                  
Efficacy Assessments  
NIS (d) / NCS (d) X                  
mNIS+7 (e)  X X               X X 
NIS + 7 (f)  X X               X X 
PND Score and  FAP Stage   X (g) X               X 
Skin Punch Biopsy (IENFD and SGNFD) (h)   X               X 
mBMI (i)   X               X 
10-meter Walk Test (j)  X (z)              X X 
Grip Strength Test (k)  X (z)             X X 
Norfolk QOL -DN; COMPASS 31 
Questionnaires   X (z)               X 
EQ-5D; R-ODS Questionnaires   X (z)             X 
Echocardiogram   X (z)             X 
NT-proBNP and Troponin I    X               X 
Pharmacodynamic  Assessments (l) 
TTR Protein, Vitamin A, and RBP    X X  X     X      X X 
Obtain Blood Sample for Long -term Storage   X X X  X     X      X X 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 18 of 109 
Table 1-1: Schedule of Assessments ; Screening to 9 -Month Efficacy Assessment  (continued) 
Procedure  Visit Type  
Screening (a) 
Screening/  
Baseline (a) 
Baseline (a) 
Predosing  
Dosing  
9-Month 
Efficacy 
Assessment(y) 
Study Day  Day -42 to 0 
D0 
Predose 
D0 
D21 
D42 
D63 
D84 
D105 
D126 
D147 
D168 
D189 
D210 
D231 
D252 
D253-
D272 
Study Week  NA 0 0 3 6 9 12 15 18 21 24 27 30 33 36 36-39 
Windows  NA 0 0 ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D ±3D NA 
Safety Assessments (m) 
Physical Examination  X                X  
Weight (n) X X X X  X X X X X X X X X X X X X X 
Height  X                  
Vital Signs (o) X X X X X X X X X X X X X X X X X X X 
12-Lead ECG (p)  X (z)        X       X 
Serum Chemistry  X   X     X     X     
Hematology, Urinalysis  X                X  
Thyroid Function Tests  X                X  
Coagulation Studies  X                  
Anti-drug Antibody Testing (q)    X  X     X      X  
Pregnancy Test (r) X                  
Ophthalmology Exam (s)  X          X 
Concomitant Medications  X X X X 
Adverse Events     X 
Pharmacokinetic  Assessments  
Plasma PK Sampling (t)    X X X     X      X  
Urine PK Sampling (u)    X  X     X      X  
Other Assessments  
Pharmacoeconomic Questionnaire   X (z)            X 
C-SSRS Questionnaire   X (z)               X 
Drug Administration  
Randomization (v)    X               
Premedication Administration (w)    X  X X X X X X X X X X X X  
Study Drug Administration (x)     X X X X X X X X X X X X X  
      
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 19 of 109 
Table 1-1 Footnotes:  
Abbreviations:  COMPASS 31 = Composite Autonomic Symptom Score ; EQ-5D = Euro QOL -5 Dimensions ; ECG = electrocardiogram; FAP = f amilial amyloidotic 
polyneuropathy ; HIV  = human immunodeficiency virus; IENFD = Intraepidermal nerve fiber density ; IFE = i mmunofixation electrophoresis ; mBMI = m odified body mass 
index ; mNIS = Modified Neuropathy Impairment Score ; NCS = n erve conduction studies ; NIS = Neuropathy Impairment Score ; NT-proBNP = N-terminal prohormone of B-
type natriuretic peptide ; PND =  polyneuropathy disability ; QOL -DN = Quality of Life -Diabetic Neuropathy ; RBP = r etinol binding protein ; R-ODS = Rausch -built Overall 
Disability Scale ; SGNFD = Sweat gland nerve fiber density ; TTR  = transthyretin . 
a. The Sc reening/Baseline and Baseline visits will be performed on separate days.  The Screening/Baseline visit must be performed with in 21 days prior to the first dose of study 
drug (Day 0).  The Baseline visit must be conducted at least  24 hours  (approximately ), but not more than 7 days , after the Screening/Baseline visit.   In conjunction with the 
decision of the Medical Monitor (s), patients  may be allowed to rescreen after a minimum of 5 days have elapsed from their last screening assessment.   Note:  Inclusion 
Criteria 3 (i.e., NIS of 5 to 1 30 [inclusive]  and PND score ≤3b) and 4 (i.e., NCS sum of the sural sensory nerve action potential  [SNAP ], tibial compound muscle action 
potential [ CMAP ], ulnar SNAP, ulnar CMAP, and peroneal CMAP of ≥2 points) must be met at the Screening/Baseline visit.  All other entry criteria (inclusion and exclusion) 
will be assessed at the Screening visit only. 
b. An interval medical history will be collected at the Screening/Baseline and Baseline visit.  O nly cha nges since the Screening visit will be collected . 
c. Serologies will include hepatitis B surface an tibody (HbsAb), hepatitis B surf ace ant igen (HbsAg), and anti –hepatitis C virus antibody (anti-HCV Ab) . 
d. The NIS and NCS will be assessed for the likelihood of a patient meeting the NIS and NCS eligibility criteria  at the S creening/ Baseline visit. The documented results of 
previously performed NIS and NCS may be used to qualify a patient for this  study  if these tests  were performed within 60 days prior to the date of informed consent . 
e. The mNIS+7 consists of the modified NIS tool (weakness and reflexes), NCS 5 attributes ( Σ5), quantitative sensory testing (QST) by body surface area including touch 
pressure (TP) and heat pain (HP), and postural blood pressure.   At the 9 -month efficacy assessment , 2 assessments of the mNIS+7 will be performed on separate days 
(1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (appro ximately)  after the first assessment , but not more than 7 days apart.   
Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each assessment (e. g., the weakness component should not 
be performed more than once on any given day).  
f. The NIS+7 consists of the NIS tool (weakness, sensation, and reflexes), NCS Σ5, vibration detection threshold  (VDT ), and heart rate response to deep breathing  (HRdB ).  At 
the 9 -month efficacy assessment , 2 assessments of the NIS+7 will be performed on separate days (1 assessment on each day).  The second (repeat) assessment must be 
conducted at least 24 hours (approximately)  after the first assessment, but not more than 7 days apart.  Components that are shared between the mNI S+7 and NIS+7 (including 
NIS and NCS) will be performed once at each assessment (e.g., the weakness component should not be performed more than once on any given day).  
g. At the S creening /Baseline visit, only PND score is required.  
h. If the patient has provided separate informed consent  for skin biopsies , 2 sets of  tandem 3-mm skin punch biopsies are to be obtained (4 biopsies total) .  One set of biopsies 
will be taken from the distal lower leg, when a patient’s clinical status allows, and one set from the  distal thigh at each time point.   Skin b iopsies will be performed at a central 
assessment site (C AS). 
i. The mBMI calculation  will take place programmatically in the clinical database; the site will not perform the calculation.  
j. The patient will be aske d to walk 10 meters.  The walk must be completed without assistance from another person; ambulatory aids such as canes and wa lkers are permitted.  
The time required for the patient to walk 10 meters will be recorded.   At the 9 -month efficacy assessment, 2 assessments of the 10 -meter walk test will be performed on 
separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  after the first assessment, but not more than 
7 days apart.  
k. G rip strength will be measured in triplicate using a dynamometer held in the dominant hand.  Every effort will be made to use the same device for a patient throughout the  
duration of the study.   At the 9 -month efficacy assessment, 2 assessments of the grip strength will be performed on separate days (1 assessment on each day).  The second 
(repeat) assessment must be conducted at least 24 hours (approximately)  after the first assessment, but not more than 7 days apart.  
l. On dosing days, blood samples for PD assessments will be obtained prior to dosing and vitamin A supplementation.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 20 of 109 
Table 1-1 Footnotes (continued): 
m. On dosing day s, all safety assessments are performed pre-dose.  
n. Weight from previous visit should be used for calculating dose.   Weight must be collected pre-dose. 
o. Vital signs to include: blood pressure, pulse rate, temperature, and respiratory rate.  Parameters are to be measured in the supine position using an automated instrument after 
the patient has rested comfortably for 10 minutes.   Vital signs must be collected pre -dose.   On Day 0, vital signs will also be collected post-dose.  
p. All ECGs are to be obtained in triplicate.  
q. Blood samples for anti-drug antibody testing will be collected prior to study drug dosing . 
r. A pregnancy test (urine- or serum -based) will be performed on all female s of child -bearing potential.  
s. The baseline ophthalmology examination may be performed any time after the patient is deemed eligible for participation in the study  through Day 21.   The 9 -month 
ophthalmology examination will be performed between Days 231(±3)  and 272  at a CAS.  
t. P lasma PK samples will be collected as follows:  Day 0:  pre -dose (within 1 hour of planned study drug dosing)  and at the end of infusion (+5 minutes).  Day 2 1 and Day 252: 
pre-dose (within 1 hour of planned study drug dosing) and 30  minutes after the end of the infusion (+15 minutes).  Day 126: pre-dose (within 1 hour of planned study drug 
dosing) and at the end of infusion (+5 minutes) .  
u. Urine PK samples w ill be collected pre -dose (within 1 hour of planned study drug dosing).  
v. Randomization procedures are described in Section  4.4.1 . 
w. P rior to dosing, all patients will receive premedications administered a t least 60 minutes prior to the start of infusion of study drug.  The regimen is described in Section 5.3.1.  
x. The patient’s infusion site should be assessed for signs of any localized reaction during the infusion and for 30 minutes after the end of the infusion.   The patient will remain 
at the study site for 1 hour following completion of dosing for observation and completion of assessments.  
y. Patients who discontinue study drug due to rapid disease progression based on the 9-month efficacy assessments will continue on to the Modified  Visit Schedule  (See Table  
1-3). 
z. Assessment must be completed at a single time point during one of the specified vi sits, at the discretion of the investigator.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 21 of 109 
Table 1-2: Schedule of Assessments; Week 39 to Week 86 (Follow-up) / Early Withdrawal 
Procedure  Visit 
Type Dosing 
18-Month  Efficacy 
Assessment  
End of Study(a) 
Follow-up(a) 
Early Withdrawal(b) 
Follow-up for 
Patients who 
Discontinue 
Treatment but  
Return at 9 
and/or 18 mo(c) 
Study Day 
D273 
D294 
D315 
D336 
D357 
D378 
D399 
D420 
D441 
D462 
D483 
D504 
D525 
D546 
D553-
D560 
D567 
D602 
NA D253-
D272 D553-
D560 
Study Week 39 42 45 48 51 54 57 60 63 66 69 72 75 78 79-80 81 86 NA 36-39 79-80 
Windows  +3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3D ±3D ±3D ±3D ±3D ±3D ±3D NA ±7D ±10D 2D to 
7D ±10D ±10D 
Efficacy Assessments  
mNIS+7(d)               X X   X X X X X X 
NIS+7(e)               X X   X X X X X X 
PND  Score  and FAP 
Stage                X   X X X 
Skin Punch  Biopsy  
(IENFD  and SGNFD)(f)               X   X   
mBMI(g)               X   X X X 
10-meterWalkTest(h)               X X   X X   
Grip Strength  Test(i)               X X   X X   
Norfolk  QOL -DN; EQ-
5D; R-ODS  Disability; 
COMPASS31  
Questionnaires                X   X X(j) X(j) 
Echoca rdiogram                X   X   
NT-pro BNP  and 
Troponin  I               X   X   
Pharmacodynamic Assessments(k) 
TTR  Protein,  Vitamin  A, 
and RBP  X      X       X X X  X X X 
Obtain  Blood  Sample  
for Long -term Storage  X      X       X X X  X   
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 22 of 109 
Procedure  Visit 
Type Dosing 
18-Month  Efficacy 
Assessment  
End of Study(a) 
Follow-up(a) 
Early Withdrawal(b) 
Follow-up for 
Patients who 
Discontinue 
Treatment but  
Return at 9 
and/or 18 mo(c) 
Study Day 
D273 
D294 
D315 
D336 
D357 
D378 
D399 
D420 
D441 
D462 
D483 
D504 
D525 
D546 
D553-
D560 
D567 
D602 
NA D253-
D272 D553-
D560 
Study Week 39 42 45 48 51 54 57 60 63 66 69 72 75 78 79-80 81 86 NA 36-39 79-80 
Windows  +3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3D ±3D ±3D ±3D ±3D ±3D ±3D NA ±7D ±10D 2D to 
7D ±10D ±10D 
Safety Assessment(l) 
Physical  Examination               X  X X X X X 
Weight(m) X X X X X X X X X X X X X X X X X  X X X X 
Vital  Signs(n) X X X X X X X X X X X X X X X X X X X X   
12-Lead  ECG(o)       X        X   X   
Serum  Chemistry      X     X    X   X X   
Coagulati on(w)              X       
Hematolog y, Urinalysis               X    X   
Thyroid  Function  Tests               X    X   
Anti-drug Antibody  
Testing(p)       X       X    X   
Pregna ncy Test(q)                X X X   
Ophthalmo logy(r)              X      
Concomitant  
Medications  X 
Adverse  Events  X   
Pharmacokinetic Assessments  
Plasma  Pharmacokinetic 
Sampling(s)       X       X    X X X 
Urine  Pharmacokinetic 
Sampling(t)       X       X    X   
Other Assessments                      
Pharmacoe conomic  
Questionnaire                X   X   
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 23 of 109 
Procedure  Visit 
Type Dosing 
18-Month  Efficacy 
Assessment  
End of Study(a) 
Follow-up(a) 
Early Withdrawal(b) 
Follow-up for 
Patients who 
Discontinue 
Treatment but  
Return at 9 
and/or 18 mo(c) 
Study Day 
D273 
D294 
D315 
D336 
D357 
D378 
D399 
D420 
D441 
D462 
D483 
D504 
D525 
D546 
D553-
D560 
D567 
D602 
NA D253-
D272 D553-
D560 
Study Week 39 42 45 48 51 54 57 60 63 66 69 72 75 78 79-80 81 86 NA 36-39 79-80 
Windows  +3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3
D ±3D ±3D ±3D ±3D ±3D ±3D ±3D NA ±7D ±10D 2D to 
7D ±10D ±10D 
C-SSRS  Questionnaire                X   X   
Drug Administration  
Premedication  
Administration(u) X X X X X X X X X X X X X X       
Study  Drug 
Administration(v) X X X X X X X X X X X X X X       
Karnosky performance 
status                    X X 
NYHA class                    X X 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 24 of 109 
Table 1-2 Footnotes:  
Abbreviations:  COMPASS 31 = Composite Autonomic Symptom Score; C-SSRS = Columbia –Suicide Severity Rating Scale; EQ-5D =  EuroQ OL; ECG = electrocardiogram; 
FAP = familial amyloidotic polyneuropathy; IENFD = Intraepidermal nerve fiber density; mB MI = modified body mass index; mNIS = Modified Neuropathy Impairment 
Score; NIS = Neuropathy Impairment Score; NT -proBNP = N -terminal prohormone of B -type natriuretic peptide; PND = polyneuropathy disability; QOL -DN = Quality of 
Life-Diabetic Neuropathy; R BP = retinol binding protein; R -ODS = Rausch -built Overall Disability Scale; SGNFD = Sweat gland nerve fiber density; TTR  = transthyretin.  
a.  If a patient enrolls in the extension study, the patient will only have to complete the 21-day follow -up assessments (EOS; Day 567) and not the 56- day follow -up assessments 
(Day  602).  Patients who do not enroll in the extension study will need to complete both follow -up visits (Days 567 and 602). 
b.  The Early Withdrawal visit will take place over 2 days  to allow for the repeat assessment of the mNIS+7 , NIS+ 7, timed 10-meter w alk, and grip strength t est. 
c. Patients who discontinue treatment may  return for follow -up visits at 9 and /or 18 months . 
d.  The mNIS+7 consists of the modified NIS tool (weakness a nd reflexes), NCS Σ5, QST by body surface area including TP and HP, and postural blood pressure.   Two 
assessments will be performed on separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  after the 
first assessment, but not more than 7 days apart.  Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each 
assessment (e.g., the weakness component should not be performed more  than once on any given day).   
e.  The NIS+7 consists of the NIS tool (weakness, sensation, and reflexes), NCS  Σ5, VDT, and heart rate response to deep breathing.   Two assessments will be performed on 
separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  after the first assessment, but not more than 
7 days apart.  Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each assessment (e.g., the weakness 
component should not be performed more  than once on any given day).   
f.  If the patient has provided separate informed consent  for skin biopsies , 2 sets of tandem 3-mm skin punch biopsies are to be obtained (4 biopsies total) .  One set of biopsies 
will be taken from the distal lower leg, when a patient’s clinical status allows, and 1 set from the distal thigh at each tim e point.  
g.  The mBMI calculation will take place programmatically in the clinical database; the site will not perform the calculation.   
h.  The patient will be asked to walk 10 meters.  The walk must be completed without assistance from another person; ambulatory a ids such as canes and walkers are permitted.  
The time required for the patient to walk 10 meters  will be rec orded.  Two assessments will be performed on separate days (1 assessment on each day).  The second (repeat) 
assessment must be conducted at least 24 hours (approximately)  after the first assessment, but not more than 7 days apart.   
i.  G rip strength will be measured using a dynamometer held in the dominant hand.  Every effort will be made to use the same device for a patient throughout the duration of the 
study.   Two assessments will be performed on separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  
after the first assessment, but not more than 7 days apart.   
j. Only the Norfolk and EQ -5D are to be performed for patients who discontinue treatment and return for the 9 and 18 month vi sits. 
k. On dosing days, blood samples for PD assessments will be obtained prior to dosing and vitamin A supplementation.  
l.  On dosing day, all safety assessments are performed pre-dose.  
m.  Weight from previous visit should be used for calculating dose.   Weight must be collected pre-dose.  
n.  Vital signs to include: blood pressure, pulse rate, temperature, and respiratory rate.  Parameters are to be measured in the supine position using an automated instrument after 
the patient has rested comfortably for 10 minutes.   Vital signs must be collected pre -dose.  
o. All ECGs are to be obtained in triplicate.  
p.  On study drug dosing days, blood samples for anti -drug antibody testing will be collected pre -dose.  
q.  A pregnancy test (urine - or serum -based) will be performed on all females of child-bearing potential.  
r. The 18-month ophthalmology examination will be performed between Days 546(±3) and 560 at a CAS.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 25 of 109 
Table 1-2 Footnotes (continued): 
s. P lasma PK samples will be collected as follows:  Day 399: pre -dose (within 1 hour of planned study drug dosing) and at the end of infusion (+5 minutes).  Day 546: pre -dose 
(within 1 hour of planned study drug dosing) and 30 minutes after the end of the infusion (+15 minutes).   Early Withdrawal:  any time within the visit w indow.  
t. U rine PK samples will be collected as follows:  Day 399 and Day 546:  pre-dose (within 1 hour of planned study drug dosing) .  Early Withdrawal:  any time within the visit 
window.  
u. P rior to dosing, all patients will receive  premedications administered a t least 60 minutes prior to the start of infusion of study drug.  The regimen is described in  Section 5.3.1. 
v.  The patient’s infusion site should be assessed for signs of any localized reaction during the infusion and for 30 minutes after the end of the infusion.  The patient will remain 
at the study site for 1 hour following completion of dosing for observation and completion of assessments.  
w. INR assessment only, which is to be used for qualification  for Study TTR02-006.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 26 of 109 
Table 1-3: Modified Schedule of Assessments  for Patients who Discontinue Study Drug for Rapid Disease  Progression ; 
Week 39 to End of Study 
Procedure  Visit Type  Dosing 
18-Month Efficacy 
Assessment  
End of Study  
Early Withdrawal (a)  
Study Day  
D273 (b) 
D294 
D378 
D462 
D546 
D553-
D560 
D567 
NA 
Study Week  39 42 54 66 78 79-80 81 NA 
Windows  +3D ±3D ±3D ±3D ±3D NA ±7D 2D to 7D  
Consultation on treatment options (c) X          
Efficacy Assessments  
   mNIS+7  (d)      X X  X X 
   NIS + 7 (e)      X X  X X 
   PND Score and FAP Stage       X  X 
   Skin Punch Biopsy (IENFD and SGNFD) (f)      X  X 
   mBMI (g)      X  X 
   10-meter Walk Test (h)      X X  X X 
   Grip Strength Test (i)      X X  X X 
   Norfolk QOL -DN; EQ-5D; R-ODS Disability; COMPASS 31 
Questionnaires       X  X 
    Echocardiogram       X  X 
    NT-proBNP and Troponin I       X  X 
PD Assessments  
    TTR Protein, Vitamin A, and RBP   X   X  X X 
    Obtain Blood Sample for Long -term Storage   X   X  X X 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 27 of 109 
Table 1-3: Modified Schedule of Assessments for Patients who Discontinue Study Drug for Rapid Disease Progression; 
Week 39 to End of Study  (continued)  
Procedure  Visit Type  Dosing 
18-Month Efficacy 
Assessment  
End of Study  
Early Withdrawal (a)  
Study Day  
D273 (b) 
D294 
D378 
D462 
D546 
D553-
D560 
D567 
NA 
Study Week  39 42 54 66 78 79-80 81 NA 
Windows  +3D ±3D ±3D ±3D ±3D NA ±7D 2D to 7D  
Safety Assessments  
    Physical Examination   X   X  X X 
    Weight      X X X X X X 
    Vital Signs (j) X X   X X X X X X 
 12-Lead ECG (k)      X  X 
    Serum Chemistry   X   X   X 
   Coagulation (r)     X    
    Hematology, Urinalysis      X    
    Thyroid Function Tests      X   X 
    Anti-drug Antibody Testing      X   X 
    Pregnancy Test (l)  X   X   X 
    Concomitant Medications (m) X       
    Adverse Events (n) X       
    Study -procedure -related Adverse Events (o)   X 
PK Assessments  
    Plasma PK Sampling   X   X    
    Urine PK Sampling   X   X    
Other Assessments  
    Pharmacoeconomic Questionnaire      X   X 
    C-SSRS Questionnaire       X  X 
   Collect Data on Subsequent FAP Treatment Regimens   X X(p) X(p) X  X X 
Phone Contact to Obtain Health Status Update (q)   X X     
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0) Confidential  
Page 28 of 109 
Table 1-3 Footnotes:  
Abbreviations:  COMPASS 31 = Composite Autonomic Symptom Score; C -SSRS = Columbia –Suicide Severity Rating Scale; EQ-5D = EuroQ OL; ECG = electrocardiogram; 
FAP = familial amyloidotic polyneuropathy;  IENFD = Intraepidermal nerve fiber density; mNIS = Modified Neuropathy Impairment Score; NIS = Neuropathy Impairment 
Score; NT -proBNP = N -terminal prohormone of B -type natriuretic peptide; PND = polyneuropathy disability; QOL -DN = Quality of Life -Diabetic Neuropathy; RBP = retinol 
binding protein; R -ODS = Rausch -built Overall Disability Scale; SGNFD = Sweat gland nerve fiber density; TTR = transthyretin. 
a. The Early Withdrawal visit will be conducted for any patient  who discontinues from the study after the Day 273 visit (e.g., from  Day 274 onward).  This visit will take place 
over 2 days (at least 24 hours [approximately] , but not more than 7 days apart) to allow for the repeat assessment of the mNIS+7 , NIS+7 , timed 10-meter walk, and grip 
strength test. 
b. Patients who discontinue study drug and also decide to discontinue from the study at the time of this visit will not have any additional visits after the Day 273 assessments are 
completed.  
c.  The patient will consult with the Investigator on a subsequent plan of care, which may include receiving  therapy for FAP as per the local standard of care.  
d The mNIS+7 consists of the modified NIS tool (weakness and reflexes), NCS  Σ5, QST by body surface area including TP and HP, and postural blood pressure.  Two 
assessments will be performed on separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  after the 
first assessment, but not more than 7 days apart.   Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each 
assessment (e.g., the weakness component should not be performed more than once on any given day).  
e. The NIS+7 consists of the NIS tool (weakness , sensation, and reflexes), NCS Σ5, VDT, and heart rate response to deep breathing.  Two assessments will be performed on 
separate days (1 assessment on each day).  The second (repeat) assessment must be condu cted at least 24 hours (approximately)  after the first assessment, but not more than 
7 days apart. Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each assessment (e.g., the weakness 
component shoul d not be performed more  than once on any given day).  
f. If the patient has provided separate informed consent  for skin biopsies , 2 sets of tandem 3 -mm skin punch biopsies are to be obtained (4 biopsies total).  One set of biopsies 
will be taken from the distal lower leg, when a patient’s clinical status allows, and 1 set from the distal thigh at each time point.  
g. The mBMI calculation will take place programmatically in the clinical database; the site will not perform the calculation.  
h. The patient will be asked to walk 10 meters.  The walk must be completed without assistance from another person; ambulatory a ids such as canes and walkers are permitted.  
The time required for the patient to walk 10 meters will be recorded.   Two assessment s will be performed on separate days (1 assessment on each day).  The second (repeat) 
assessment must be conducted at least 24 hours (approximately)  after the first assessment, but not more than 7 days apart.   
i. G rip strength will be measured using a dynamometer held in the dominant hand.  Every effort will be made to use the same device for a patient throughout the duration of the 
study.   Two assessments will be performed on separate days (1 assessment on each day).  The second (repeat) assessment must be conducted at least 24 hours (approximately)  
after the first assessment, but not more than 7 days apart.   
j. Vital signs to include: blood pressure, pulse rate, temperature, and respiratory rate.  Parameters are to be measured in the supine position using an automated instrument after 
the patient has rested comfortably for 10 minutes.  
k. All ECGs are to be obtained in triplicate.  
l. A pregnancy test (urine - or serum -based) will be performed on all females of child-bearing potential.  
m. Concomitant medicat ions/treatments  will be collected through Day 294 (Week 42) only.  Data on subsequent FAP treatment regimens will be collected separately.  
n. Adverse events will be collected through Day 294 (Week 42) only.   See Section 8.5 for SAE reporting periods.  
o.  F ollowing the Day 294 (Week 42) visit, only adverse events that are considered related to the study procedures will be collected (e.g., skin biopsies, venipunctures) . 
p. At these time points, data will be collected through phone contact.  
q. Study personnel will contact p atients by phone to query  for general health status and information on subsequent FAP treatment regimens.  
r. INR assessment only, which is to be used for qualification visit for Study TTR02-006.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 29 of 109 
ABBREVIATIONS  
Abbreviation  Definition  
Σ5 5 attributes  
ADA  Anti-drug antibodies  
AE Adverse event  
ALT  Alanine transaminase  
ANC  Absolute neutrophil count  
ANCOVA  Analysis of covariance  
aPTT  Activated partial thromboplastin time  
AST  Aspartate transaminase  
ATTR  Transthyretin -mediated amyloidosis  
BUN  Blood urea nitrogen  
CAS  Central Assessment Site  
CC Complete case  
CFR  Code of Federal Regulations  
CL R Renal clearance  
CMAP  Compound muscle action potential  
COMPASS -31 Composite Autonomic Symptom Score  
CRF  Case Report Form  
CRO  Contract research organization  
C-SSRS  Columbia –Suicide Severity Rating Scale  
DEHP  di(2-ethylhexyl)phthalate  
DLin -MC3 -DMA  1,2-Dilinoleyloxy -N,N-dimethylpropylamine  
DSPC  1,2-Distearoyl -sn-glycero -3-phosphocholine  
EQ-5D Euro QOL  
ECG  Electrocardiogram  
EDC  Electronic data capture  
ELISA  Enzyme linked immunosorbent assay  
ERG  Electroretinography  
EU European Union  
FAC  Familial amyloidotic cardiomyopathy  
FAP Familial amyloidotic polyneuropathy  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
H1/H2 blocker  Histamine H1/H2 receptor antagonist  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 30 of 109 
Abbreviation  Definition  
HIPAA Health Insurance Portability and Accountability Act of 
1996  
HIV Human immunodeficiency virus  
HP Heat pain  
HPLC  High performance liquid chromatography  
HRdb  Heart rate response to deep breathing  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IENFD  Intraepidermal nerve fiber density  
IFE Immunofixation electrophoresis  
INR International normalized ratio  
IRB Institutional Review Board  
IRR Infusion -related reaction  
IRS Interactive response system  
IV Intravenous(ly)  
LLN  Lower limit of normal  
LOCF  Last observation carried forward  
LNP  Lipid nanoparticles  
mBMI  Modified body mass index  
MedDRA Medical Dictionary for Regulatory Activities  
mITT  Modified Intent to Treat  
MMRM  Mixed model repeated measures  
mNIS  Modified Neuropathy Impairment Score  
mRNA  Messenger ribonucleic acid  
NIS Neuropathy Impairment Score  
NCS  Nerve conduction studies  
NOAEL  No observed adverse effect limit  
Norfolk QOL -DN Norfolk Quality of Life -Diabetic Neuropathy  
NSAID  Nonsteroidal anti-inflammatory  
NT-proBNP  N-terminal prohormone of B -type natriuretic peptide  
OTC  Over -the-counter  
PCS Patient Care Site  
PD Pharmacodynamic  
PEG 2000-C-DMG 3-N- [(ω-methoxy poly(ethylene glycol)2000) carbamoyl] -
1,2-dimyristyloxy -propylamine  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 31 of 109 
Abbreviation  Definition  
PI Principal Investigator  
PK Pharmacokinetic(s)  
PND  Polyneuropathy disability  
PO Per os (orally)  
PP Per protocol  
PVC  Polyvinyl chloride  
PT Prothrombin time  
QST  Quantitative sensory testing  
QTc QT interval corrected for heart rate  
RBC  Red blood cell  
RBP  Retinol binding protein  
RNAi  RNA interference  
R-ODS  Rausch -built Overall Disability Scale  
SAE  Serious adverse event  
SGNFD  Sweat gland nerve fiber density  
siRNA  Small interfering ribonucleic acid  
SNAP  Sensory nerve action potential  
SUSAR  Suspected unexpected serious adverse reaction  
T3 Triiodothyronine  
T4 Thyroxine  
TP Touch pressure  
TSH  Thyroid stimulating hormone  
TTR  Transthyretin  
TUDCA  Tauroursodeoxycholic acid  
ULN  Upper limit of normal  
US/USA  United States  
USP/EP  United States Pharmacopeia/European Pharmacopoeia  
V30M  Val30Met  
VDT  Vibration detection threshold  
WBC  White blood cell  
WHO  World Health Organization  
WT Wild type  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 32 of 109 
1 INTRODUCTION 
1.1 Background and Rationale 
1.1.1 Disease Overview  
Transthyretin -mediated amyloidosis (ATTR) is an  inherited, autosomal dominant, 
systemic disease caused by a mutation in the transthyretin (TTR) gene.1  Transthyretin is 
a tetrameric 127 amino acid protein th at is secreted predominantly (>95%) by 
hepatocytes, with a smaller fraction produced by the choroid plexus and retina.2  
Physiologically, TTR is a major serum carrier for retinol binding protein (RBP) and a 
minor carrier of thyroxine (T4).  Mutations in the TTR protein lead to destabilization of 
the tetrameric form and dissociation into dimers and monomers; misfolding of mutated 
monomers from the α-helical to the β-pleated sheet structure results in tissue  deposition 
of amyloid fibrils .3  Amyloid deposits typically contain both mutant and wild- type (WT) 
TTR.   The particular TTR mutation and site of amyloid deposition determines the clinical 
manifestations of the disease, which include sensory and motor neuropathy, autonomic neuropathy, and/or cardiomyopathy.  ATTR  is a progressive disease associated with 
severe morbidity, with a life expectancy lim ited to 5 to 15 years from symptom onset.
4  
There are over 100 reported TTR mutations which are associated with 2 clinical 
syndromes: familial amyloidotic polyneuropathy (FAP) and familial amyloidotic 
cardiomyopathy (FAC).5,6,7   
“Patisiran ” (the International Nonproprietary Name [INN] name for the drug product 
previously referred to as ALN -TTR02 ) is being developed for the treatment of ATTR 
patients with symptomatic FAP.  
The estimated worldwide prevalence of FAP is 5,000 to 10,000, with the ma jority of 
cases in Portugal, Sweden, France, Japan, Brazil, and the United States.8,9  The most 
common causative mutation of FAP is TTR Val30Met (V30M), with the onset of 
symptoms  typically occurring between 30 and 55 years  of age .10  Amyloid deposition 
occurs largely in the peripheral nerves, starting as a nerve length -dependent sensory 
polyneuropathy in the feet causing numbness and pain and progressing to painful 
dysesthesias.  Disabling motor neuropathy follows, characterized by leg weakness and eventual  inability to walk.  Autonomic neuropathy is another common feature of the 
disease, resulting in severe gastrointestinal pathology (including diarrhea or constipation and malabsorption, leading to severe malnutrition), orthostatic hypotension, and bladder dysfunction with recurring urinary tract infections.
11,12,13,14  For several mutations, 
cardiac pathology also occurs due to amyloid infiltration of the sinus node, atrioventricular conduction system, and infiltration of the myocardium.
15,16  Involvement 
of the conduction system can lead to sudden death due to dysrhythmias, and myocardial 
infiltration can lead to diastolic dysfunction and right- sided heart failure.17  The 
cardiomyopathy proceeds inexorably, leading to death typically within 10 years.18 
There are multiple lines of evidence demonstrating that reduction of circulating TTR improves outcomes in patients with ATTR.  Because the liver is the primary source of 
WT and mutant TTR, orthotopic liver transplantation has been used since 1990 in an 
attempt to treat FAP ,
19 and is the current standard of care in patients who are eligible for 
transplant (patients with minimal neuropathy symptoms and no cardiac involvement).  

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 33 of 109 
When liver transplantation is performed early in the course of the disease , it can stabilize 
and slow the course of neuropathic disease in patients with FAP due to V30M, but is less 
effective in patients with other TTR mutations.20  However, it is less effective in patients 
with more advanced disease, especially those with heart involvement, due to the continued production and deposition of WT TTR in tissues with pre- existing 
amyloid .
21,22,23 
It is estimated that approximately two -thirds of FAP patients are not transplant- eligible.  
Furthermore, liver transplant poses risks from the surgical procedure and from life-threatening complications due to graft rejection or infections.  The 1- year mortality rate 
post-transplant is 10%.
24 
Nonsurgical options that are used for the treatment of FAP (depending on geographic 
location) include tafam idis (Vyndaqel®) and diflunisal.  Tafamidis is a small molecule 
TTR stabilizer that binds to the thyroxine binding sites of the TTR tetramer, thus preventing its dissociation to monomers and potentially preventing fibril formation.  While tafamidis is approved in the European Union (EU) for the treatment of ATTR in 
adult patients with Stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment, it is not considered the standard of care throughout the EU and  it has not 
been approved for use outside the EU.
25 
Diflunisal is a generic, nonsteroidal anti- inflammatory drug (NSAID) that is also  a 
tetramer stabilizer and binds to TTR in a similar manner as tafamidis.  A multinational, 
placebo -controlled Phase 3 study in patients with all stages of FAP was recently 
completed; however, the results have not been released.  Due to the restricted use of liver 
transplant ation  and tafamidis in  patients with early stage of disease, and the non-standard 
use of diflunisal among practitioners , there remains an unmet medical need for a potent 
and effective therapy for FAP that will have an impact on patients across a broad  range of 
neurologic impairment, regardless of their mutation (V30M or non-V30M). 
1.1.2 RNA Interference  
Ribonucleic acid  interference (RNAi) is a naturally occurring cellular mechanism for 
regulating gene expression that is mediated by “small interfering ribonucleic acids” (siRNAs).
26  Typically, synthetic siRNAs are 19 to 23 base pair double- stranded 
oligonucleotides in a staggered duplex with a 2-nucleotide overhang at one or both of the 
3' ends.  Such siRNAs can be designed to target an endogenous or virally- expressed gene.  
When introduced into cells, the net effect of an RNAi- based pharmacological approach is 
the binding of the siRNA to its complementary messenger ribonucleic acid (mRNA) sequence, cleavage of this target mRNA, and suppression of the target protein.
27  The 
ability to selectively and potently degrade the mRNA encoding the TTR protein using an 
siRNA offers a potent and specific approach for the treatment of ATTR.  
Unformulated siRNAs, and those without chemical modification, are rapidly degraded and eliminated upon systemic administration, and thus do not achieve significant tissue distribution.
28  As a result, various formulations are used to target siRNA distribution to 
tissues, and to facilitate their uptake into the relevant cell type.  One approach that has been used successfully in vivo , including in rodents, non-human primates, and humans, 
employs IV deliv ery of siRNAs in lipid nanoparticles (LNPs).
29,30,31,32  These LNPs, with 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 34 of 109 
their small size (<100 nm) and low surface charge, can pass through the fenestrated 
vascular endothelium of the liver.  Endocytosis of the intact LNPs, followed by fusion with the endosomal membrane and release of the siRNA into the cytoplasm, results in the 
siRNA engaging the endogenous RNAi machinery described above leading to targeted 
degradation of the mRNA, and a consequent reduction in target protein levels.
 33,34 
1.1.3 PATISIRAN  
Patisiran  comprises a small interfering ribonucleic acid (siRNA)  which is specific for 
TTR, and  is formulated in a hepatotropic lipid nanoparticle (LNP) for intravenous ( IV) 
administration.35  This TTR siRNA  has a target region within the 3’UTR region of TTR 
gene to ensure and confirm homology with WT TTR as well as all reported TTR 
mutations.  Following LNP- mediated delivery to the liver, patisiran  targets TTR mRNA 
for degradation, resulting in the potent and sustained reduction of mutant and WT TTR 
protein via the RNAi mechanism.   
Since circulating TTR is almost exclusively synthesized in the liver, the IV administration of patisiran  is postulated to reduce the level of precursors that lead to 
amyloid fibri l deposition, resulting in clinical benefit to patients with FAP.   
1.1.4 Therapeutic Hypothesis  
Patisiran  is a novel investigational agent intended for the treatment of FAP, a serious and 
life-threatening orphan disease. The therapeutic hypothesis that systemic  amyloidoses can 
be managed by reduction in circulating levels of amyloidogenic protein has been 
validated in other acquired (e.g., immunoglobulin light chain systemic [AL], or amyloid 
A [AA]) and hereditary (e.g. Fibrinogen A α-chain, ApoA1) amyloidosis.  The experience from these systemic amyloidotic disorders,
36,37,38,39 as well as the liver 
transplant data in FAP, suggest that lowering of the circulating amyloidogenic protein by at least 50% is required to impact the clinical course of the disease, with reductions in 
protein beyond 50% providing further incremental improvements in outcomes.  It is 
therefore postulated that the >80% suppression in both WT and mutant TTR observed upon administration of 0.3 mg/kg patisiran  once every 21 days will result in clinical 
benefit in FAP patients with mild to moderate polyneuropathy.  This hypothesis is further 
supported by evidence from tafamidis suggesting that reduction in free TTR monomer can slow neuropathy progression in early-stage V30M patients with FAP .
10   
1.2 Summary of Patisiran Nonc linical Data  
 
 
 
 
 
 
 
 
 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 35 of 109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Furt
her information can be found in the patisiran ( ALN -TTR02 ) IB. 
1.3 Summary of Clinical Data with Patisiran 
A Phase 1 multicenter, randomized, placebo-controlled, single-blind, single- ascending 
dose clinical study of patisiran  in healthy volunteers was completed in the UK.  Patisiran  
was administered as a single 60 -minute IV infusion to healthy volunteers at doses of 0.01 
to 0.05 mg /kg.  Patients were premedicated with dexamethasone, H1 and H2 blockers, 
and paracetamol/acetaminophen  prior to dosing t o minimize the risk of infusion -related 
reaction s (IRRs) .  Significant pharmacology in terms of TTR protein lowering (>80% 
reduction from pretreatment ba seline) was observed at doses ≥0.15 mg/kg.  Transthyretin  
levels showed evidence of recovery beginning at around Day  21 to 28, returning to 
baseline by Day 70. 
An open- label , Phase 2 , multiple -ascending dose study of patisiran  in ATTR patients with 
FAP (Study ALN -TTR0 2-002) to determine the safety and tolerability, pharmacokinetics 
(PK), and pharmacodynamics ( PD) of a 60-70 minute IV infusion of patisiran  
administered once every 3 or 4 weeks for 2 doses has completed enrollment (N= 29).  
Preliminary data show >80% TTR knockdown with 0.3 mg/kg after the first and second 
doses (p<0.001), with better  sustained suppression of >80% observed throughout the 
dosing interval with the once every 3 week dosing schedule compared with once every  4 
weeks.   In V30M patients, both mutant and wild- type TTR were suppressed to the same 
extent.  Multiple doses of patisiran  have been  generally safe and well -tolerated, including 
0.3 mg/kg administered once every  3 or 4 weeks with either a 60-minute infusion and 
original premedication regimen (total of 28 mg dexamethasone or equivalent, 
administered the night before and morning of infusion) or a 70- minute step-wise infusion 
(approximately 1  mL/minute for the first 15 minutes followed by approximately 
3 mL/minutes for the remainder of th e infusion) and a simplified premedication regimen 
(total of 10 mg dexamethasone or equivalent, administered at least 60 minutes prior to 
infusion). 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 36 of 109 
Patients completing Study ALN -TTR02 -002 are eligible to  enroll into a Phase 2, 
open-label, extension study (ALN -TTR02 -003) designed to evaluate the safety and 
tolerability of long -term patisiran  dosing administered to patients with FAP; additional 
information will be evaluated includ ing PK, PD, and clinical activity.  Patients will 
receive 0.3 mg/kg patisiran  once every 21 days for approximately 2 years.   Data from this 
study of March 13, 2015 demonstrate a sustained mean serum TTR knockdown of 
approximately 80%, with mean nadir up to 88% between doses, for approximately 16 months 
in patients receiving patisiran 0.3 mg/kg once every 3 weeks (n=20). Neuropathy impairment scores were stable through 12 months with mean change in mNIS+7 and NIS of -2.5 and +0.4 
points, respectively.
 
Further details on the se clinical studies can be found in the patisiran ( ALN -TTR02 ) IB. 
1.4 Study Design Rationale 
This is a Phase 3 randomized, double-blind, placebo- controlled, multicenter , 
multinational study of patisiran  in FAP patients.  The patients proposed for this study are 
reflective of the FAP population encountered by clinicians in  various different countries 
worldwide, including patients with a range of neuropathy severity and broad spectrum of 
TTR mutations .  Disease progression will be assessed by neurological measures and 
functional tests; therefore, the range of baseline neurop athy severity (NIS of 5-130) is 
selected such that the lower end is advanced enough to show significant progression in 
the placebo group, while the upper end is not so advanced as to preclude detection of 
change as a result of  a ceiling effect of neuropathy measures or to be confounded by other 
comorbidities.  
The inclusion of placebo as a control allows for a rigorous analysis of the treatment effect of patisiran .  However, given the 18-month duration of the study, those patients who have 
evidence of rapid disease progression at 9 months (defined as ≥24 point increase in 
mNIS+7 from baseline [based on an average of 2 measurements] and  FAP stage 
progression relative to baseline) will be given the option of discontinuing study drug  and 
receiv ing local  standard of care treatment for their FAP .  Such patients will be asked to 
follow a modified study visit schedule and return for their 18 -month efficacy assessment  
(blinding will be maintained throughout).  It is expected that fewer than 5% of patients 
involved in the ALN- TTR02 -004 study will meet th e definition of rapid disease 
progression at 9 months. 
Given the orphan nature of the disease and the significant, progressive morbidities associated with FAP, randomization to patisiran  or placebo will be performed in a 
2:1 ratio  (patisiran :placebo) to increase the probability that patients will receive active 
drug.  Treatment groups will be balanced at entry for NIS (5-49 vs 50-130), early onset 
V30M (<50 years of age at onset) vs all o ther mutations (including late onset V30M), and 
previous tetramer stabilizer use (tafamidis or diflunisal) vs no previous tetramer stabilizer use. 
The primary endpoint for this study is the change from baseline at 18 months in a 
composite measure of neurologic impairment termed modified NIS+7 (mNIS+7), which 
includes a clinical exam -based assessment of neurologic impairment (NIS) combined 
with electrophysiologic measures of small and large nerve fiber function (NCS and QST), 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 37 of 109 
and measurement of autonomic function (postural blood pressure).  The utility of  various 
neuropathy endpoints in  demonstrating a treatment effect in randomized, controlled 
clinical trials in patients with FAP has been established through Phase 3 studies using the 
small molecule TTR tetramer stabilizers tafamidis and diflunisal.   For these studies, the 
primary efficacy endpoint utilized variations of NIS (NIS -Lower Limbs  in the case of 
tafamidis and NIS+7 for diflunisal).  Composite endpoints, such as NIS+7, have been 
found to be more sensitive in detecting abnormalities in patients with generalized 
peripheral neuropathy, such as diabetic polyneuropathy and chronic idiopathic demyelinating polyneuropathy, and the reproducibility of composite scores has been 
shown to be greater than for individual tests .  The use of mNIS+7 in this study is 
expected to increase the sensitivity and reproducibility of the measurement of neuropathy 
progression in a heterogeneous group of FAP patients presenting with a broad spectrum 
of disease severity and TT R mutations.  
The 18-month endpoint was selected based on the expected rate of neuropathy 
progression in patients with FAP, derived from a global natural history dataset of 
283 patients from Alnylam collaborators in the USA, Portugal, France, and Italy.  From 
these data, it is estimated that a patient’s mNIS+7 score will have increased by approximately 24 points in the placebo group after 18 months, thereby providing 
adequate disease progression for the detection of a treatment effect in the patisiran  group. 
1.5 Dose Selection and Dosing Schedule Rationale 
Given the fundamental role of TTR in the pathogenesis of the disease and the data from 
liver transplantation in FAP, it is postulated that the optimal dose and schedule for 
patisiran  is one that will result in  the greatest level of sustained TTR suppression with an 
acceptable safety profile.  Based on the data to date from the nonclinical and clinical 
studies with patisiran , >80% maintained suppression of circulating TTR is consistently 
achieved at the 0.3 mg/kg dose administered  once every 3 weeks, and this dose was 
generally well tolerated.  Patisiran  will be administered every 21 days as a 70 -minute IV 
infusion (approximately 1 mL/min ute for the first 15 minutes followed by approximately 
3 mL/min ute for the remainder of the infusion) with a premedication regimen consisting 
of IV dexamethasone and H1/H2 blockers along with oral paracetamol /acetaminophen  
given at least 60  minutes prior to each infusion.   
The chronic toxicology studies in rodents (6 -month duration) and monkeys (9-month 
duration), in which animals safely tolerated 14 doses of patisiran  at ≥0.3 mg/kg once 
every 2 or 3 weeks ( rats or monkeys , respectively ), also supports long-term dosing in 
FAP patients at 0.3 mg/kg once every 21 days. 
1.6 Risk-Benefit Assessment  
Patisiran is a novel investigational agent intended for the treatment of FAP, a serious and life-
threatening orphan disease with limited treatment options. The therapeutic hypothesis that 
systemic amyloidoses can be managed by reducing circulating levels of amyloidogenic 
protein has been established in other acquired and hereditary amyloidoses.  The experience from these systemic amyloidotic disorders, as well as the liver transplant data in FAP, 
suggest that lowering of the circulating amyloidogenic protein could impact the clinical 
course of the disease.   Based on nonclinical and clinical data that showed suppression in 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 38 of 109 
levels of WT and mutant TTR upon administration of 0.3 mg/kg patisiran once every 21 
days, it is possible that long t erm treatment with patisiran may have a clinical benefit in FAP 
patients with mild to moderate polyneuropathy and that further study is warranted. 
In completed and ongoing clinical studies (ALN- TTR02 -001, ALN- TTR02 -002 and 
ALN -TTR02 -003), single and multiple doses of patisiran have been generally well 
tolerated.  Potential risks of patisiran include the following:  
• Infusion- Related Reactions  
Infusion- related reactions (IRRs) can occur with systemic administration of certain 
biological agents such as liposomes or monoclonal antibodies.  In order to reduce the 
potential for an IRR with patisiran, all patients in this study will be premedicated 
prior to dosing with patisiran  or placebo.  The step-wise infusion regimen over 
approximately 70 minutes (starting with a slower infusion rate of approximately 
1 mL/minute for the first 15 minutes before increasing to 3 mL/minute for the 
remainder of the in fusion), may further reduce the risk of an IRR. 
• Liver function test abnormalities   
In preclinical studies, patisiran -related increased serum liver markers and 
histopathology in the liver w ere observed at dosages > 0.1 mg/kg in rats and > 1.0 
mg/kg in monk eys.  In general, all of the findings were not observed or were 
observed at lower severity at the end of the 60-90 day dose free period, indicating that 
the toxicities were reversible.   In clinical studies to date, there have been  no clinically 
significant changes in liver function tests  in either the single -dose or multiple-dose 
studies. Patients in the study are monitored for liver function via serial laboratory assessments.  
• Vitamin A Lowering  
The suppression of serum levels of TTR and RBP is expected to result in the lowering 
of circulating vitamin A levels.  Preclinical and clinical data have shown that the 
lowering of circulating vitamin A associated with suppression of RBP does not result in severe vitamin A deficiency.  Furthermore, there are individuals with RBP/TTR 
mutations who have life- long low levels of circulating vitamin A and are essentially 
in good health, suggesting that there are compensatory transport mechanisms for 
vitamin A that are yet undescribed.
40  This has also been confirmed in TTR knockout 
mice, which do not exhibit any manifestations of vitamin A deficiency, with vitamin A uptake by most tissues continuing in the absence of RBP.
41  Provided there is 
adequate vitamin A in the diet, tissue stores of vitamin A should not be affected by 
the lowering of TTR and RBP.  However, as the vitamin A content of the diet may 
vary between different countries and different individuals within a country, all patients on the study will be asked to take a daily supplement containing the 
recommended dail y allowance of vitamin A .  Patients should have started vitamin A 
supplementation by the time they start his/her first dose of patisiran or placebo. 
• Osteoporosis 
Patients with FAP may be at risk for osteoporosis.
42 In addition, as part of the 
premedication regimen administered prior to patisiran dosing every three weeks, FAP 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 39 of 109 
patients participating in this study are given glucocorticoids, a drug known to have 
the potential to reduce bone mineralization.  If there are no medical contraindication s, 
and per investigator judgment and local standard of care, study participants should, if 
appropriate,  receive therapy for the prevention and early treatment of osteoporosis 
such as: calcium and vitamin D supplementation, bisphosphonates, calcitonin, 
parathyroid hormone, estrogen agonist/antagonist or combination therapies. 
Further guidance to the investigator can be found in the IB. 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 40 of 109 
2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary objective of the study is to determine the efficacy of patisiran ( ALN -TTR02 ) 
by evaluat ing the difference between the patisiran  and placebo groups in the change from 
baseline of mNIS+7 score at 18 months.   
2.2 Secondary Objectives  
The secondary objectives of the study are to determine the effect of patisiran  on various 
clinical parameters by assessing the difference between patisiran  and placebo in the 
change from baseline in the following measurements at 18 months: 
• Norfolk Quality of Life- Diabetic Neuropathy (Norfolk QOL -DN) questionnaire; 
• NIS-weakness (NIS -W) score; 
• Modified body mass index (mBMI) ; 
• Timed 10- meter walk test ; 
• Autonomic symptoms questionnaire (Composite Autonomic Symptom Score 
[COMPASS -31]). 
2.3 Exploratory Objectives  
The exploratory objectives of the study are:  
• To determine the difference between the patisiran  and placebo groups in the change 
from baseline in the following measurements at 18 months: 
• NIS+7 score;  
• Grip strength ; 
• EuroQOL (EQ -5D) questionnaire; 
• Level of disability (Rasch -built Overall Disability S cale [R -ODS] ); 
• Large vs small nerve fiber function including nerve conduction studies (NCS) 5 attributes (Σ5), quantitative sensory testing (QST) by body surface area 
including touch pressure (TP) and heat pain  (HP),  vibration detection threshold 
(VDT), heart rate response to deep breathing (HRdb), postural blood pressure; 
• Pathologic evaluation of sensory and autonomic innervation through voluntary 
skin punch biopsies and analysis of intraepidermal nerve fiber density (IENFD) 
and sweat gland nerve fiber density (SGNFD);  
• Assessment of ambulation through FAP s tage and Polyneuropathy Disability 
(PND) score;  
• Cardiac assessment through echocardiogram, troponin I, and N terminal prohormone of B- type natriuretic peptide (NT -proBNP) levels;  
• Pharmacodynamic (PD) biomarkers (TTR, RBP, vitamin A); 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 41 of 109 
• To compare the p roportion of patients in the patisiran  and placebo groups who meet 
the pre-defined criterion for rapid disease progression (defined as ≥24 point increase 
in mNIS+7 from baseline [based on an average of 2 measurements] and  FAP stage 
progression relative to baseline) at 9 months. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 42 of 109 
3 STUDY PLAN  
3.1 Overall Design  
This is a multicenter, multinational, randomized, double-blind, placebo-controlled, 
Phase 3 study designed to demonstrate the clinical efficacy of patisiran ( ALN -TTR02 ) 
and to establish the safety of chronic dosing in adult  patients with FAP.   A schematic of 
the study design is presented in Figure 1. 
The duration of pati ent participation in this study is approximately 21 months.  Patients 
will be screened within 42 days  prior to administration  of study drug.  Consented eligible 
patient s will be  randomized to receive either patisiran  or placebo (2:1 ratio,  patisiran  to 
placebo)  once every 21 days for 78 weeks.  Treatment groups will be balanced at entry 
for NIS (5-49 vs 50-130), early onset V30M (<50 years of age at onset) vs all other 
mutations (including late onset V30M), and previous tetramer stabilizer use (tafamidis or 
diflunisal) vs no previous tetramer stabilizer use.  
Prior to dosing, patients will receive premedication s in order to reduce the risk of 
experiencing an IRR.  The premedications will be administered at least 60 minutes prior 
to the start of infusion of study drug.  Blinded study drug will be administered as a 70 -
minute IV infusion (approximately 1 mL/min ute for the first 15 -minutes followed by 
approximately 3  mL/min ute for the remainder of the infusion).  In addition to returning to 
the site for dosing of study drug  once every 21 days, patients will also return for out-
patient visits at 9 and 18 months for efficacy assessments (see Section  6 for details).   The 
study personnel performing these assessments will be blinded to the results of any 
previous assessments (e.g., Screening/Baseline, Baseline, or 9 -month assessments ). 
At the 9 -month time point, if the clinical adjudication committee determines that a patient 
is exhibiting rapid disease progression (defined as ≥24 point increase in mNIS+7 from 
baseline [based on an average of 2 measurements] and  FAP stage progression relative to 
baseline, see Section  4.6), the patient’s treating physician will provide the patient with the 
option of discontinuing study drug and receiving local standard of care treatment for FAP.  Patients who discontinue study drug will remain on study through completion of 
the 18- month efficacy assessments , following a modified visit schedule as shown in 
Table 1-3 and described in Section 6.4.  Blinding will be maintained throughout. P atients 
who complete the 18- month efficacy assessments can elect to participate in an extension 
study in which patients will receive open -label admi nistration of 0.3 mg/kg patisiran  once 
every 21 days. 
A Data Monitoring Committee (DMC) will be implemented for the study and will operate under a prespecified charter.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 43 of 109 
Figure 1: Study Schematic  
 
 
   
 
Screening and 
Baseline  
(Day -42 
to Day 0)  
Screening  (Preliminary Eligibility)  
Screening (Eligibility Confirmation) / Baseline 1  
*Screening tests for confirmation of eligibility include NIS and NCS.  
 
Baseline 2  
First Dose  
(Day 0)  
Randomize (2:1; Patisiran  or placebo)  
and 
Administer the first double -blind dose of study drug  
Treatment 
Period  
 
(Day 1  
 To 
 Day 560)  
End of Study and 
Follow -up 
 
(Day 561  
To 
 Day 602)  
Day 21 to 252: Continue the double -blind dosing – every 3 weeks  
9-Month Efficacy Assessments – Day 253 to Day 272 
Rapid Disease Progression?  
(defined as ≥ 24 po int increase in mNIS+7 from baseline [based on an average of 2 
measurements] and FAP stage progression relative to baseline, based on clinical 
adjudication committee review; blinding will be maintained)  
No 
 Yes 
Patient will 
continue to receive 
study drug  
Decision to continue 
study drug  
Decision to  discontinue 
study drug (and many 
receive additional therapy 
as per the local standard of 
care)  
Day 273 to 546: Continue the double -blind dosing – every 3 weeks  
Continue on study 
(modified visit schedule)  
18-Month Efficacy Assessments – Day 553 to Day 560  
Day 567 : End of Study Visit  
Participate in the open -label extension?  
No 
 Yes 
Day 602: Follow -up Visits  (not required for those who 
had Rapid Disease Progression and discontinued study 
drug at Month 9)  
Provide informed consent and enter the open -label 
extension study  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 44 of 109 
3.2 Efficacy Assessments  
Efficacy parameters will include the following ( baseline evaluations will be conducted as 
well as evaluations at  9 and 18 months): 
• Neurologic impairment will be assessed using the mNIS+7 composite score.  The 
mNIS+7 includes the modified NIS (weakness and reflexes) , NCS Σ5, QST, as well 
as autonomic assessment through postural blood pressure; 
• Patient -reported QOL will be evaluated using the Norfolk  QOL -DN and the EQ -5D.  
Disability will be repor ted by patients using the R- ODS;  
• Autonomic symptoms will be assessed usi ng the COMPASS -31; 
• Motor function assessments to be evaluated include NIS-W, timed 10-meter walk 
test, and grip strength test; 
• PND score and FAP stage;  
• Nutritional sta tus will be assessed using mBMI;  
• Pathologic evaluation of sensory and autonomic innervation will be evaluated by 
IENFD analysis and quantitation of SGNFD via tandem 3 mm skin punch biopsies taken from the leg ; 
• Neurologic impairment will also be assessed by NIS+7 (includin g full NIS, NCS, 
VDT, and HRdb); 
• Cardiac structure and function will be a ssessed through echocardiograms as well as 
measurement of serum levels of NT -proBNP and troponin I. 
3.3 Safety Assessments 
Safety will be assessed throughout the study by collecting adverse events (AEs; including serious adverse events [SAEs]); clinical laboratory tests, including hematology, clinical 
chemistry (including liver function tests), thyroid function parameters, and urinalysis; 
measurement of anti -drug antibodies; electrocardiograms; vital signs; physical 
examination findings; and ophthalmology exam ination s.   
3.4 Pharmacodynamic Assessments  
Pharmacodynamic markers assessed serially will include serum TTR, vitamin A , and 
RBP.  Additional blood samples will be collected for exploratory biomarkers related to FAP. 
3.5 Pharmacokinetic Assessments  
The plasma PK evaluation will include, whenever possible, plasma- concentration time 
profiles for siRNA and the novel lipid components in patisiran: DLin -MC3 -DMA and 
polyethylene glycol (PEG)
2000-C-DMG.  The siRNA, DLin -MC3 -DMA, and PEG 2000-C-
DMG concentration will be det ermined for all patients at time points specified in  Table 
1-1, Table 1-2, and Table 1-3.  
Urine will be collected with void volume recorded for all patients at time points specified 
in Table 1-1, Table 1-2, and Table 1-3 and to determine renal clearance (CL R) of siRNA 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 45 of 109 
and 4- dimethylaminodibutyric acid (the metabolite of DLin -MC3 -DMA) after dosing 
with study drug. 
3.6 Other Assessments  
Disease burden and healthcare utilization  will be assessed using a patient -reported 
pharmacoeconomics questionnaire.  The investigator will periodically assess mental 
status as it relates to suicidal ideation and behavior by using the Columbia–Suicide 
Severity Rating Scale (C -SSRS) questionnaire.   
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 46 of 109 
4 PATIENT POPULATION  
4.1 Eligibility of Patients  
Approximately 200 patients are expected to be enrolled  at multiple  centers worldwide.  
All centers will be  selected on the basis of their experience in the treatment of patients 
with FAP. 
4.2 Inclusion Criteria  
To be enrolled in the study, each patient must meet the following criteria at the Screening 
visit, except where specified : 
1. Male or female of 18 to 85 years of age (inclusive);  
2. Have a diagnosis of FAP with documented TTR mutation;  
3. Have an NIS of 5 to 130 (inclusive) and a PND score of ≤3b (Note:  This criterion 
must be met at the Screening/Baseline visit); 
4. Have an NCS sum of the sural sensory nerve action potential (SNAP), tibial 
compound muscle action potential (CMAP), ulnar SNAP, ulnar CMAP, and 
peroneal CMAP of ≥2 points (Note:  This criterion must be met at the 
Screening/Baseline visit);  
5. Have a Karnofsky performance status of ≥60%; 
6. Have an absolute neutrophil count (ANC) ≥1500 cells/mm³, and a platelet count 
≥50,000 cells/mm³; 
7. Have aspartate transaminase (AST) and alanine transaminase (ALT) levels 
≤2.5 × the upper limit of normal (ULN), total bilirubin  within normal limits , 
international normalized ratio (INR) ≤2.0 (patients on anticoagulant therapy  with 
an INR of ≤3.5 will be allowed ). Patients with total bilirubin ≤ 2 × ULN are 
eligible if the elevation is secondary to documented Gilbert’s syndrome  (elevation 
of unconjugated bilirubin with normal conjugated bilirubin) and the patien t has ALT 
and AST levels within normal ranges; 
8. Have a serum creatinine ≤ 2 × ULN;  
9. No a ctive infection with hepatitis B or hepatitis C by serology ; 
10. Women of child-bearing potential must have a negative pregnancy test, cannot be 
breastfeeding, and must be using 2 highly effective methods of contraception 
prior to screening, throughout study participation, and for 75 days after the last 
dose of study drug.  Highly effective methods of birth control are defined in  
Section  4.7; 
11. Males with partners of child -bearing potential, must agree to use 1 barrier method 
(e.g., condom) and 1 additional method (e.g., spermicide) of contraception 
throughout study participation and for 75 days after the last dose of study drug; 
males must also abstain from sperm donation after the first dose of study drug 
through study participation and for 75 days after the last dose of study drug; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 47 of 109 
12. Must be willing and able to comply with protocol-required visit schedule and visit 
requirements and provide written informed consent. 
4.3 Exclusion Criteria  
A patient will be excluded if they meet any of the following criteria at the time of 
Screening visit: 
1. Had a prior liver transplant or is planning to undergo liver transplant during the 
study period; 
2. Has other known causes of sensorimotor or autonomic neuropathy 
(e.g., autoimmune disease, monoclonal gammopathy, etc.);  
3. Has known primary amyloidosis or leptomeningeal amyloidosis; 
4. Has known type I diabetes; 
5. Has had type II diabetes mellitus for ≥5 years; 6. Has vitamin B12 levels below the lower limit of normal ( LLN );  
7. Has untreated hypo - or hyperthyroidism;   
8. Has had a major surgery within the past 3 months or has a major surgery planned 
during any point of the study period; 
9. Has known human immunodeficiency virus (HIV) infection; 10. Has an active infection requiring systemic antiviral or antimicrobial therapy that 
will not be completed prior to the first dose of study drug administration; 
11. Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;  
12. Has a New York Heart Association heart failure classification >2;  
13. Had acute coronary syndrome within the past 3 months; 
14. Has uncontrolled cardiac arrhythmia or unstable angina; 15 Has a known history of alcohol abuse within the past 2 years or daily heavy 
alcohol consumption (females: more than 14 units of alcohol per week; males: 
more than 21 units of alcohol per week [unit: 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer]); 
16. Received an investigational agent or device within 30 days of anticipated study 
drug administration or 5 half-lives of the investigational drug, whichever is longer ;  
17. Participated in a clinical trial with antisense oligon ucleotide, must have completed 
a 3-month wash-out prior to start of the study drug administration in this study;  
18. Is currently taking tafamidis, doxycycline, or tauroursodeoxycholic acid 
(TUDCA) ; if previously on any of these agents, must have completed a 14 -day 
wash -out prior to start of study drug administrat ion in this study ; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 48 of 109 
19. Is currently taking diflunisal; if previously on this agent, must have at least a 
3-day wash -out prior to start of study drug administration in this study;  
20. Had a prior severe reaction to a liposomal product or a known hypersensitivity to 
oligonucleotides or any component of patisiran ( ALN -TTR02 ); 
21. Is unable to take the required premedications;  
22. Anticipated survival is less than 2 years, in the opinion of the Investigator; 
23. Is considered unfit for the study by the Investigator. 
24. Is under legal protection  (defined as “any person who becomes incapable of 
protecting his/her interests due to a medically diagnosed impairment of his /her 
mental faculties that may limit or prevent the expression of his /her will”) . 
4.4 Assignment to Treatment Group/Patient Number  
4.4.1 Randomization Procedures  
Patients will be randomly assigned in a 2:1 ratio  to receive either 0.3 mg/kg patisiran  or 
placebo (normal saline 0.9%). 
Patients will be randomized via an interactive response system  (IRS) .  Either designated 
unblinded site person nel or the pharmacist may request randomization for the patient, but 
only the pharmacist or unblinded personnel will be allowed to receive the treatment code.  
The treatment code will be delivered to the unblinded personnel and the pharmacist will 
use the necessary number of vials for that patient based on their weight. 
Treatment arms will be balanced at entry for NIS ( 5-49 vs 50-130), early onset V30M 
(<50 years of age at onset) vs all other mutations (including late onset V30M), and 
previous tetramer stabilizer use (tafamidis or diflunisal) vs no previous tetramer stabilizer 
use. 
4.4.2 Patient Numbering  
At enrollment, each patient will be  uniquely identified in the study by a combination of 
his/her center number and screening number.  The center number will be  assigned by the 
Sponsor.  Upon signing the informed consent form, the patient will be  assigned a 
screening number by the IRS.  The Investigator or his/he r delegate will contact the IRS 
(via phone or web) after confirming that the patient fulfills all the inclusion criteria and none of the exclusion criteria.  The patient will be randomized via the IRS, assigned a 
patient  number and a study treatment.  A co mbination of the center number, screening 
number, enrollment number, and patient initials will create the unique patient identifier.  
In countries with regulations prohibiting the use of patient initials, a strategy consistent 
with local regulations will b e used to generate replacement values for the patient initials.  
4.4.3 Blinding Procedure  
Only the pharmacist and  designated site personnel  who dispense or administer  study drug 
will be unblinded to the study treatment.  All other site personnel will be blinded to the treatment.  Study personnel performing  assessment s related to the efficacy  endpoint s will 
be different from the Investigator and other personnel managing the patient, and all of 
these study personnel will be blinded to any clinical laboratory results that could 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 49 of 109 
potentially unblind them (e.g., TTR levels, vitamin A  levels , thyroid function tests).  In 
addition, the study personnel performing assessments related to the efficacy endpoints 
will also be blinded to the results of any previ ous assessments (e.g., Screening/Baseline, 
Baseline, or 9 -month assessments). 
All patients will be blinded to treatment and will receive an IV infusion once every 
21 days  using identical volumes for placebo and patisiran .  The tubing and the lines will 
be covered so that it will not be possible to detect a difference in active versus  placebo 
drug.   
Furthermore, unblinded source documentation containing all descriptions of pharmacy 
preparations and infusions or distribution of study drug  or randomization da ta will be 
stored separate from all other study data/records and from other pharmacy staff not 
participating on the study.  
Unblinding is only to occur in the case of patient emergencies or when necessary from a regulatory reporting perspective (e.g. , Suspe cted Unexpected Serious Adverse Reactions 
[SUSAR ] occurring in the EU), and at the conclusion of the study. 
Patients who discontinue study drug at 9 months due to rapid disease progression will remain blinded throughout the study. 
4.4.4 Breaking the Blind  
In the event that the Investigator requests to know a patient’s study treatment assignment, 
the Investigator will first contact the CRO Medical Monitor to discuss the need for 
unblinding.  In case of an emergency, the treatment allocation for each patient will be 
available from the unblinded site personnel, pharmacist, or the IRS system.  
If a patient becomes pregnant or seriously ill during the study, the blind should be broken only if knowledge of the treatment administered will affect treatment options available to the patient.  Before breaking the blind, the PI or Sub- investigator should attempt to 
contact the CRO Medical Monitor.  If the Medical Monitor is immediately unreachable, 
the PI or Sub-investigator should break the blind as necessary using the code br eaking 
information provided and contact the Medical Monitor as soon as possible.  A record 
should be kept of when the blind was broken, who broke it, and why. 
4.5 Early Patient Discontinuation or Withdrawal 
Patients are free to discontinue treatment or withdraw from  the study at any time and for 
any reason, without penalty to their continuing medical care. 
There are 3 ways for a patient to discontinue treatment and/or withdraw from the study: 
1) The patient or investigator decides to discontinue study treatment, but the patient 
agrees to remain in the study and undergo follow- up assessments (as described in 
Section 6.3). 
2) The patient experiences protocol-defined rapid disease progression at Month 9 and elects to discontinue study treatment but remain in the study and return for protocol-specified visits, including follow-up assessment at Month 18 (as described in Section 4.6).  
3) The patient decides to no longer participate in the study and withdraws consent. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 50 of 109 
A patient will be considered to have completed the study if the patient does not withdraw 
consent from the study and completes protocol-specified procedures up through the 18-
month efficacy assessment visit.  
4.5.1 Reasons for Treatment Discontinuation or Withdrawal 
The Investigator may discontinue treatment or withdraw a patient from the study if the 
patient: 
• Is in violation of the protocol; 
• Experiences a serious or intolerable AE ; 
• Becomes pregnant;  
• Requires a prohibited medication (see Section 5.8);  
• Requests  to discontinue treatme nt or be withdrawn from the study; 
• Is found to be considerably noncompliant with the protocol- required patisiran  dosing 
visits . 
A patient may discontinue treatment or be withdrawn from the study if, in the 
Investigator’s opinion, they are unable to continue.  The Investigator will also withdraw 
the patient from the study upon the request of Alnylam , including if Alnylam terminates 
the study.  Upon occurrence of a serious or intolerable AE, the Investigator will confer with Alnylam b efore discontinuing treatment .   
In general, patients who discontinue treatment will be encouraged to remain on the study 
to complete study assessments, particularly the Month 9 and Month 18 assessments, so 
that their experience is captured in the final analyses.  However, a patient may withdraw consent to participate in the study at any time.  
Missing an occasional dose of study drug  will not necessarily result in the patient being 
withdrawn from the study.  However, if a patient misses 2 consecutive doses of study 
drug, the Investigator at the site and the Medical Monitor will determine whether 
treatment should be discontinued.   
4.5.2 Handling of Withdrawals  or Patients who Discontinue from Treatment  
In the event a patient  discontinues treatment, withdraws , or is withdrawn from the study, 
the CRO Medical Monitor must be informed immediately.  If there is a medical reason 
for withdrawal, the patient will remain under the supervision of the Inves tigator for 
protocol- specified safety follow -up procedures.   
If a patient discontinues treatment, withdraws , or is withdrawn from the study, the 
primary reason for discontinuation must be recorded in the appropriate section of the 
CRF and all efforts will be made to complete and report the observations as thoroughly as possible.   
If a patient withdraw s or is withdrawn from the study , the site staff is to encourage the 
patient to complete the Early Withdrawal visit.  Patients who withdraw or are withdrawn 
from the study, or pati ents who remain on the study and permanently discontinue study 
treatment  for reasons other than rapid disease progression at Month 9 (see Section 4.6), 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 51 of 109 
will not be eligible  to participate in the planned extension study in which patients will 
receive open -label administration of 0.3 mg/kg patisiran  once every 21 days. 
4.5.3 Replacements  
No replacements will be allowed for patients who withdraw early from the study.  
4.6 Discontinuation Due to Rapid Disease Progression  
At the 9 -month time point, i f the clinical  adjudication committee determines that a patient 
is exhibiting rapid disease progression ( defined as ≥ 24 point increase in mNIS+7 from 
baseline [based on an average of 2 measurements] and  FAP stage progression relative to 
baseline), the patient’s treating physician will provide the patient with the option of 
discontinuing study drug and receiving local standard of care treatment for FAP.  
Patients  who discontinue due to rapid disease progression will remain on study through 
complet ion of the 18- month efficacy assessments  (blinding will be maintained 
throughout) , following a modified visit schedule as shown in Table 1-3.  P atients who 
complete the 18 -month efficacy assessments can elect to participate in an extension study 
in which patients will receive open -label administration of 0.3 mg/kg patisiran  once every 
21 days.  Patients who discontinue study drug due to rapid disease pr ogression and also 
decide to withdraw from the study will not have any additional visits after the Day 273 
assessments are completed  and will not be eligible to participate in the  planned  extension 
study. 
4.7 Pregnancy  and Breastfeeding  Restrictions / Contraception Requirements  
Women of child-bearing potential must have a negative pregnancy test, cannot be 
breastfeeding, and must be using 2 highly effective methods of contraception prior to 
screening, throughout study participation, and for 75 days after the last dose of study 
drug.  Highly effective methods of birth control result in a low failure rate (i.e., less than 
1% per year)43.  Acceptable forms of effective contraception are defined as follows: 
• Hormonal:  established use of oral, implantable, injectable, or transdermal hormonal methods of conception; 
• Placement of an intrauterine device (IUD) ; 
• Placement of an intrauterine system (IUS);  
• Mechanical/barrier method of contraception:  condom or occlusive cap (diaphragm or cervical/vault cap) in conjunction with spermicide (foam, gel, film, cream or 
suppository ); 
Note:  Failure rates indicate that, when used alone, the diaphragm and condom are not  
highly effective forms of contraception. Therefore the use of additional spermicides 
does confer additional theoretical contraceptive protection.  However, spermicides 
alone are inefficient at preventing pregnancy when the whole ejaculate is spilled. Therefore, spermicides are not a barrier method of contraception and should not be 
used alone. 
• Surgical sterilization of male partner (with the appropriate post- vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the study, the vasectomized male partner should be the sole partner for that patient); 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 52 of 109 
• Sexual true abstinence: when this is in line with the preferred and usual lifestyle of 
the patient . Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception. 
Patients should be instructed to use two different forms of effective contraception from the list above.  Examples of two forms of highly effective contraception are as follows:  
• Oral, implantable, injectable, or transdermal contraceptives in conjunction with 
condom or diaphragm and spermicide; 
• IUD in conjunction with condom or diaphragm and spermicide; 
• Surgical sterilization of partner in conjunction with con dom or diaphragm and 
spermic ide. 
Males  (including men who have had vasectomies) with partners of child -bearing 
potential, must agree to use 1 barrier method (e.g., condom) and 1 additional method 
(e.g., spermicidal  foam, gel, film, cream, or suppository ) of contraception throughout 
study participation and for 75 days (i.e., a whole spermatogenic cycle) after the last dose 
of study drug.  Males must also abstain from sperm donation after the first dose of study drug through study participation and for 75 days after last dose of study drug.  
Pregnancy reporting guidelines are provided in Section 8.12. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 53 of 109 
5 STUDY MEDICATION 
5.1 Presentation of Study Drug  
Patisiran ( ALN -TTR02 ) Solution for Injection is an RNAi therapeutic consisting of an  
siRNA targeting TTR mRNA formulated in a LNP .  The patisiran  drug product is a 
sterile formulation of TTR siRNA  with lipid excipients (DLin -MC3 -DMA, DSPC, 
cholesterol , and PEG 2000-C-DMG) in is otonic phosphate buffered saline.  Patisiran  
Solution for Injection contains 2 mg/mL of TTR siRNA drug substance. 
The patisiran  drug product is packaged in 10 mL glass vials with a fill volume of 5.5 mL.  
The container closure system consists of a United S tates Pharmacopeia/European 
Pharmacopoeia (USP/EP) Type I borosilicate glass vial, a Teflon -faced butyl rubber 
stopper, and an aluminium flip -off cap.  
The control drug for this study will be a placebo (normal saline 0.9% for IV 
administration).   Control drug will be provided by a central supplier. 
5.2 Preparation of Study Drug  
Each investigational site will be re sponsible for IV preparation and labeling , according to 
separate handling instructions, and allocating treatments to the patients.  
The pharmacist  or unblinded study personnel will prepare the study drug under aseptic 
conditions.  The total amount to be infused into each patient at each dosing visit will be 
200 mL.  To maintain the blind, all IV infusion bags and lines will have amber-colored 
covers  added prior to leaving the pharmacy.  
Additional study drug preparation details are provided in the patisiran  (ALN -TTR02 ) 
Pharmacy Manual.  
5.2.1 Preparation of Patisiran  
The amount (in mg) of patisiran  to be administered will be determined based on the 
patient’ s body weight (kg).  For each dose administered, the weight obtained during the 
previous visit will be used to calculate the dose of study drug.  In the event that the 
weight obtained on the previous dosing day is not available, the weight obtained predose on the dosing day can be used for dose calculation.  Patients who weigh 105 kg or more 
will receive patisiran  dosing based on an assumption of a body weight of 104 kg. 
Sterile normal saline (0.9% NaCl) will be added to a sterile infusion bag, and the 
calculated volume of patisiran  will be withdrawn from the vials and injected into the 
infusion bag. 
5.2.2 Preparation of Placebo 
Normal saline (0.9% NaCl), provided by a central supplier, will be infused into patients  
randomized into the control group.  Depending on the availability, saline may need to be 
withdrawn from a larger bag or additional saline may need to be added to a sterile 
infusion bag to ensure the 200 mL volume. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 54 of 109 
5.3 Drug Administration 
5.3.1 Premedication  
Prior to each dose of study drug, in order to reduce the risk of experiencing an IRR, 
patients will receive the following premedications  at least 60 minutes prior to the 
infusion: 
• Intravenous dexamethasone (10 mg) or equivalent; 
• Oral paracetamol/acetaminophen  (500 mg) or equivalent; 
• Intrav enous H2 blocker (e.g., ranitidine 50 mg, famotidine 20 mg, or equivalent other 
H2 blocker dose); 
• Intravenous H1 blocker: diphenhydramine 50 mg (or equivalent other IV H1 blocker 
available at the study site).  Hydroxyzine or fexofenadine 25 mg per os ( PO, orally)  
or cetirizine 10 mg PO may be substituted for any patient who does not tolerate IV 
diphenhydramine or other IV H1 blocker . 
Patients will be started on the above premedication regimen.   However, modifications 
may be made to the premedication regimen  after consultation with  the medical monitor 
either due to a patient’s inability to tolerate one or more of the premedications or to the occurrence of IRRs unresponsive to slowing of the infusion rate. 
• If a patient is having difficulty tolerating the stero id premedication regimen (e.g., 
patient develops uncontrolled hyperglycemia, altered mental status , or other 
complication ), then lowering of the steroid premedication may be allowed for that 
patient after consultation with the medical monitor.   
• If after co nsultation with the medical monitor, it is agreed that an individual patient’s  
steroid premedication  will be lowered, then the following steps must be followed : 
1) If the current steroid dosage is 10 mg intravenous dexamethasone or equivalent, 
then the patient may be lowered in increments no greater than 2.5 mg intravenous dexamethasone or equivalent. 
2) After each incremental lowering below 10 mg intravenous dexamethasone or equivalent, the patient must receive three consecutive intravenous doses of patisiran w ithout IRR and continued signs or symptoms of steroid intolerance 
before further reductions in steroid premedications.   
3) The premedication steroid dosage should not be reduced below 5 mg intravenous dexamethasone or equivalent. 
Alternatively, if a patient experiences an IRR when 10 mg or less of intravenous 
dexamethasone or equivalent is used as the steroid premedication, then proceed to Section 5.9. 
Further details (including a table of equivalent premedications) can be found in the 
patisiran  (ALN -TTR02 ) Pharmacy Manual.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 55 of 109 
5.3.2 Study Drug Administration 
Patients who are randomized into the active treatment group will receive 0.3 mg/kg 
patisiran  once every 21 days (± 3 days) .  Patients who are randomized into the control 
group will receive placebo (normal saline 0.9%) once every 21 days (± 3 days). 
The body weight that was obtained during the previous visit must  be used to calculate the 
dose of study drug.  In the event that the body weight obtained on the previous dosing 
day is not available, the body weight obtained pre-dose on the dosing day can be used for 
the dose calculation.   Patients who weigh 105 kg or more will receive patisiran  dosing 
based on an assumption of a body weight of 104 kg. 
Study drug (either patisiran  or placebo) will be administered under the supervision of the 
unblinded site personnel, as a 70-minute IV infusion (approximately 1 mL/minute for the 
first 15 minutes followed by approximately 3 mL/min ute fo r the remainder of the 
infusion).  The study drug will be administered via a controlled infusion device with an 
extension set containing a 1.2 micron filter supplied by Alnylam or designee.  Infusion 
products must not contain polyvinyl chloride, di(2- ethyl hexyl)phthalate (PVC, DEHP).  
As described in Section 4.4.3, the tubing and the lines will be covered so that it will not 
be possible to detect a difference in active versus placebo drug.  
• If the patient experiences an IRR the infusion time may be extended up to 3 hours in 
the event of a mild or moderate IRR.  
1) If the patient experiences a mild or moderate IRR that resolves by slowing the infusion rate then no further premedication changes are recommended. 
2) If the patient experiences a severe IRR, then  study drug administration will not 
be resumed until the case is discussed with the m edical monitor (see Section 
5.9).   
• If the infusion time for a patient was extended due to an IRR, that modified infusion duration should be continued throughout the duration of the study for that particular 
patient.   Returning the patient’s infusion duration to 70 minutes will require a 
discussion with t he medical monitor . 
• For the first 3 infusions of study drug on this study, the patient’s infusion site should 
be assessed for signs of any localized reaction during the infusion and for 30 minutes 
after the end of the infusion, and the patient will remain at the clinical site for 1 hour following completion of dosing. 
If a patient does not receive a dose of study drug within the dosing window (±3 days), the dose will be considered missed and not administered . 
Additional details can be found in the patisiran  (ALN -TTR02 ) Pharmacy Manual.  
In addition, patients will receive an oral daily supplemental dose of the recommended daily allowance of vitamin A . 
5.4 Storage of Study Drug 
All study drug must be stored in a secure , temperature controlled  location and may be 
dispensed only by a staff member specifically authorized by the Investigator  or by a 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 56 of 109 
pharmacist , as appropriate.  All study drug will be stored upright and refrigerated at 
approximately 5 ± 3oC.  Any deviation from the recommended storage conditions must 
be reported to the CRO and/or Alnylam and use of the study drug halted until 
authorization for its continued use has been given by Alnylam or designee.  
No special procedures for the safe handling o f patisiran  are required.  An unblinded 
Alnylam Monitor or designee will be permitted , upon request, to audit the supplies, 
storage, dispensing procedures, and records. 
No study product(s) may be administered to any person not enrolled in the study. 
Additional preparation details are provided in the patisiran ( ALN -TTR02 ) Pharmacy 
Manual.  
5.5 Labeling and Packaging of Study Drug 
All packaging and labeling as well as the p reparation  of patisiran  and placebo will be in 
compliance with Good Manufacturing Practice (GMP) specifications, as described in the 
Manufacture of Investigational Medicinal Products Volume 4 Annex 13, and any other or 
local applicable regulations.  
Study drug labels will include all appropriate local labeling requirements on the vial and 
external label.  Sample labels will be submitted to health authorities, per local country 
submission requirements.  
5.6 Measurement of Patient Compliance 
Treatment compliance with study drug administration is dependent on the proper 
preparation and administration of IV infusions by unblinded study site personnel as well 
as attendance by the patient to the clinic.  T reatment compliance with study drug 
administration will be verified by unblinded study staff  observation.  A dose will be 
considered completed if 80% or more of the total volume of the IV solution has been 
administered to the patient.  Patients  will be permitted to miss an occasional dose of study 
drug.  However, if a patient misses 2 consecutive doses, the PI, in consultation with the 
Medical Monitor, will discuss whether the patient will be able to continue on the study. 
Patients failing to complete the 18-month efficacy assessment visit  will not be eligible to 
receive patisiran  on the open -label extension study. 
5.7 Study Drug Accountability  
The Investigator will maintain accurate records of receipt and the condition of all study 
drugs including dates of receipt.  In addition, accurate records will be kept of the weight used to calculate each dispensed patisiran  dose, and when and how much study drug is 
dispensed and used by each patient in the study.  Any reasons for departure from the protocol dispensing regimen must also be recorded. 
Drug accountability records and inventory will be available for verification by unblinded 
Alnylam Monitor or designee that will not have a role in any other aspect of managing 
the study .  Remaining study drug (all used, partially used , and unused vials) will be 
returned to Alnylam or its specified designee/depot or destroyed at the site according to 
applicable regulations. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 57 of 109 
Study drug must not be used for any purpose other than the present study.  Study drug 
which has been dispensed for a patient and returned  unused must not be redispensed. 
Further instructions about study drug accountability are detailed in the patisiran ( ALN -
TTR02 ) Pharmacy Manual.  
5.8 Concomitant Medication / Treatment  
Use of the following medications/treatments is prohibited during study participation (with the exclusion of patients who have rapid disease progress ion and discontinue study drug 
after the 9-month efficacy  assessments ): 
• Any investigational agent other than patisiran ; 
• Tafam idis (use prior to screening permitte d); 
• Diflunisal (use prior to screening permitted); 
• Doxycycline /TUDCA (use prior to screening permitted) ; 
• Corticosteroids other than those administered as premedications prior to the dose of 
patisiran , those used to treat an infusion reaction, or topical or inhaled corticosteroids.  
However, for patients with chronic inflammatory disorders (e.g., asthma, rheumatoid 
arthritis, etc .), systemic ally administered  steroids may be permitted provided that: 1) 
the dose is <20 mg /day prednisone or equivalent if admini stered chronically, or 2) for 
doses ≥20 mg /day,  administration is limited to no more than 5  consecutive days. 
Medications and treatments other than those specified above, including palliative and 
supportive care approved by the investigator for disease- related symptoms,  are permitted 
during the study. 
Investigator should review over-the-counter ( OTC ) and or herbal preparations to ensure 
that these are not potentially disease modifying.  
Use of all concomitant medications and treatments will be  recorded on the patient’s CRF 
through the time points shown in Table 1-1, Table 1-2, and Table 1-3.  This will include 
all prescription drugs, herbal preparations, OTC medications, vitamins, and minerals.  
Any changes in medications during the study will also be recorded on the CRF. 
Any concomitant medication  or treatment that is required for the patient’s welfare may be 
given by the Investigator.  However, it is the responsibility of the Investigator to ensure 
that details regarding the medication or treatment are recorded on the CRF, and coded 
using an internationally recognized and accepted coding dictionary. 
5.9 Suggested Guidelines for Management of Infusion- related Reactions  
Criteria for categorizing IRRs are provided in Appendix 3. 
• In the event of an IRR, the infusion of study drug may be stopped and the patient 
closely monitored until resolution of the reaction.  Drugs that may be used to 
facilitate resolution and permit resumption of study drug  administration include, but 
are not limited to: paracetamol/acetaminophen (or equivalent), additional histamine H1/H2 receptor antagonists (eg, ranitidine), NSAIDs, adrenaline, supplemental oxygen, IV fluids, and/or corticosteroids. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 58 of 109 
• Following resolution of a mild or moderate IRR that required interruption of the study 
drug infusion, resumption of administration may occur at the Investigator’s discretion 
at a slower infusion rate (but not to exceed 3 hours) for that dose and for all subsequent doses of stud y drug .  If the infusion is delayed, the administration of the 
infusion should be completed no more than 6 hours from the initial start of the infusion.   
•  Study drug a dministration will not be resumed for any patient following a severe IRR 
until the case is discussed with the Medical Monitor. 
• If after consultation with the medical monitor it is agreed that an individual patient’s  
steroid premedication  will be increased then the following steps are recommended : 
1) If the IRR occurred while the patient received 10 mg intravenous 
dexamethasone or equivalent at least 60 minutes before the infusion and did not resolve with slowing of the infusion rate, then the patient should be increased by 
multiples of 5 mg intravenous dexamethasone or equivalent at least 60 minutes 
before the infusion and/or 5 mg oral dexamethasone or equivalent the night before the intravenous infusion.  
2) Increased dose of premedication steroids should NOT exceed the combination of 20 mg intravenous dexamethasone or equivalent on the day of infusion and 8 mg oral dexamethasone or equivalent taken the night before the infusion.  
3) If the IRR occurred while the patient received less than 10 mg intravenous dexamethasone or equivalent, then the patient should return to the prior dose of intravenous dexamethasone or equivalent that did not result in an IRR. 
The patient’s infusion site should be assessed for signs of any localized reaction during the infusion and for 30 minutes after the end of the infusion.  The patient will remain at the study site for 1 hour following completion of dosing for observation and completion 
of assessments.   Patients will be instructed to call the Investigator if they experience 
symptoms such as fever, chills, myalgia, or nausea/vomiting after discharge from the site . 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 59 of 109 
6 STUDY VISITS  
The duration of a patient’s participation in this study is approximately 21 months 
(inclusive of a 42- day screening period and up to a 56-day post last dose study visit).   
Screening  evaluations are to be performed within 42 days before receiving the first dose 
of study drug, as indicated in Table 1-1.  Patients dete rmined to be eligible based on 
Screening assessments will receive blinded study drug IV infusion of either patisiran  
(ALN -TTR02 ) or placebo  once every 21 days.  Patients will remain at the study site for 
1 hour following completion of dosing for observation and completion of assessments. 
In order to decrease the variability in the efficacy  assessment  testing , there will be a 
limited number of sites within any one territory that conduct efficacy  assessments at 
Screening/Baseline, B aseline, 9-month, and 18-month visits (referred to as “Central 
Assessment Sites [CAS ]”); these sites can also screen, dose, and manage patients.  There 
will also  be sites that screen, dose, and manage the patients  (“Patient Care Sites [PCS])”, 
while sending the patients to the nearest CAS for their Screening/Baseline, B aseline, 
9- and 18-month efficacy  assessment s. 
Prior to starting the study and screen ing patients in the protocol, the CAS and PCS  will 
create a delegation of responsibilities document that clearly details which site is 
responsible for which tests and safety parameters to ensure adherence to the protocol.  This document will become part of the study site specific documentation. 
All patients who discontinue from the study early will return to the study site for their 
Early Withdrawal assessments.  
6.1 Screening, Screening/Baseline,  and Baseline  Visits (Days –42 to Day 0) 
Screening  evaluations will be conducted over 3 or more visits ( Screening , 
Screening/Baseline, and Baseline).  All screening visits must occur within 42 days of the 
first dose of study drug (Day 0).  Table 1-1 provides an overview of the s chedule of 
events required at each  screening  visit. 
Prior to s creening activities, the patient will sign and date an informed consent form 
(ICF) and receive a copy of the signed ICF.  No study procedures should be performed 
prior to informed consent being obtained.  The Investigator or another person authorized 
by the Investigator will also sign and date the informed consent prior to giving a copy to 
the patient.  The ICF will be filed in the patient’s medical record.  
In conjunction with the decision of the Medical Monitor(s), patients may be allowed to 
rescreen after a minimum of 5 days have elapsed from their last screening assessment.  
6.1.1 Screening  
The following activities must be performed during the Screening  visit as part of the initial 
review of patient eligibility : 
• Assess study eligibility using the inclusion and exclusion criteria ; 
• Obtain medical history information , including inquiry into HIV status; 
• Obtain demographic information; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 60 of 109 
• Determine Karnofsky Performance Status (see Appendix 1);  
• Determine New York Heart Association classification of heart failure (see Appendix 
2); 
• Collec t and r eview  documentation for TTR genotype; 
• Perform a physical examination ; 
• Measure weight;  
• Measure height; 
• Measure vital signs ; 
• Collect blood samples for clinical laboratory tests, including:  
• Paraprotein (assessed by  immunofixation electrophoresis [ IFE]); 
• Vitamin B 12; 
• Serology; 
• Hematology ; 
• Serum chemistries ; 
• Coagulation studies; 
• Thyroid function tests. 
• Collect urine sample for urinalysis ; 
• Perform a pregnancy test (for females  of child-bearing potential only); 
• Obtain information on concomitant medications ; 
• Perform NIS and NCS.  Note:  The documented results of previously performed NIS 
and NCS may be used to qualify a patient for this study if these tests were performed 
within 60 days prior to the date of informed consent.  These studies  may be 
completed as per local protocol. 
6.1.2 Screening/Baseline Visit  
Patients who meet all of the Screening  criteria (including NIS  and NCS assessments) will 
complete the screening process during 2 subsequent visits (which will be conducted at 
CAS for patient s screened at PCS): a Screening/Baseline visit and a Baseline visit. 
The Screening/Baseline visit must be performed within 21 days prior to the first dose of study drug (Day 0). 
The following assessments must be performed during the Screening/Baseline visi t: 
• Perform the following efficacy assessments:  
• mNIS+7 *; 
• NIS+7 *; 
*Note:  Components that are shared between the mNIS+7 and NIS+7 (including 
NIS and NCS) will be performed only once. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 61 of 109 
• PND score;  
• Collect blood sample for long- term frozen storage  of serum  to permit testing of 
additional proteins related to FAP; 
• Measure vital signs;  
• Measure weight;  
• Obtain information on concomitant medications; 
• Obtain an interval medical history ; 
• Confirm  that NIS , PND,  and NCS results meet study eligibility requirements.  
Inclusion Criteria 3 (i.e., NIS of 5 to 130 [inclusive] and PND score of ≤3b) and 4 
(i.e., NCS sum of the sural SNAP, tibial CMAP, ulnar SNAP, ulnar CMAP, and 
peroneal CMAP of ≥2 points).  
Note:  The following assessments may be performed at a single time p oint during either 
the Screening/Baseline visit or as noted below, at the discretion of the investigator. 
At the Screening/Baseline or Baseline visit:  
• Perform a 12 -lead ECG ; 
• Complete the Norfolk QOL-DN, and COMPASS -31 questionnaires; 
• Complete the  C-SSRS questionnaire; 
At any time after the patient is deemed eligible for participation in the study, but before 
the first administration of study drug:  
• Perform a t imed 10- meter walk test . 
At any time after the patient is deemed eligible for participation in the study through the 
Day 0 visit: 
• Perform a grip strength test; 
• Perform an echocardiogram;  
• Complete the EQ -5D and R- ODS  questionnaires; 
At any time after the patient is deemed eligible for participation in the study through the 
Day 21 vis it: 
• Perform an ophthalmology exam; 
• Complete the pharmacoeconomics questionnaire. 
6.1.3 Baseline Visit  
The Baseline visit will occur at least 24 hours (approximately), but no greater than 
7 days , from the Screening/Baseline visit.  The following activities should  be performed 
during the Baseline visit: 
• Perform a 12 -lead ECG  (if not completed at the Screening/Baseline visit); 
• Measu re vital signs; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 62 of 109 
• Measure weight;  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins related to FAP;  
• Obtain information  on concomitant medications; 
• Perform the following efficacy  assessments:  
• mNIS+7 *; 
• NIS+7 *; 
*Note:  Components that are shared between the mNIS+7 and NIS+7 
(including NIS and NCS) will be performed only once. 
• PND score (see Appendix 5); 
• FAP stage  (see Appendix 6); 
• If the patient has provided separate informed consent  for the skin biopsies, 
obtain 2 sets of tandem 3-mm skin punch biopsies ( 4 biopsies total; 1 set from 
the distal lower leg, when a patient ’s clinical status allows, and 1 set from the 
distal thigh) . Skin biopsies will be performed at a CAS; 
• mBMI (Note:  The site will only measure the patient’s weight.  Using this 
weight, mBMI will be calculated programmatically in the clinical database; 
the site will not perform the calculation .); 
• Collect blood samples for NT-proBNP and troponin I; 
• Norfolk QOL- DN (if not completed at the Screening/Baseline visit); 
• COMPASS -31 (if not completed at the Screening/Baseline visit). 
• Complete  the C-SSRS questionnaire (if not completed at the Screening/Baseline 
visit); 
• Obtain an interval medical history.  
The following activities may als o be completed at the Baseline visit if not completed at 
the Screening/Baseline visit, as described in Section 6.1.2: 
• Timed 10- meter walk test; 
• Grip strength test; 
• Echocardiogram; 
• EQ-5D and R- ODS  questionnaires; 
• Ophthalmology examination  at a CAS ; 
• Pharmacoeconomics questionnaire. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 63 of 109 
6.2 Treatment Visits  
Patients who are determined to be el igible for the study will be enrolled on Day 0. 
On all study visit days, patients should take their vitamin A supplement after completing 
the blood draws.  
Prior to dosing, all patients will receive premedication s in order to reduce the risk of 
experiencing an IRR as described in Section  5.3.1. 
6.2.1 Day 0 
6.2.1.1 Pre-dose on Day 0 
On Day 0, patients will undergo the following procedures prior to study drug 
administration: 
• Measure weight ; 
• Measure vital signs ; 
• Timed 10- meter walk test (if not completed at the Screening/Baseline or Baseline 
visits) ; 
• Collect blood samples for clinical laboratory tests, including:  
• Serum chemistr ies; 
• Anti-drug antibody testing. 
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins related to FAP;  
• Collect blood sample for plasma PK assessment  within 1 hour of planned study drug 
dosing start ; 
• Collect urine sample for PK assessment  within 1 hour of planned study drug dosing 
start; 
• Obtain information on concomitant medications ; 
• Randomize the patient (S ee Section 4.4.1); 
• Administer premedications  at least 60 -minutes prior to the start of administration of 
study drug (see Section 5.3.1); 
• Document any  AEs . 
The following activities are to be completed on Day 0 pre- or post-dosing if not completed at the Screening/Baseline or Baseline visits, as described in Section 6.1.2: 
• Grip strength test; 
• Echocardiogram; 
• EQ-5D and R- ODS  questionnaires. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 64 of 109 
6.2.1.2 Administration of Study Drug  on Day 0 
As described in Section 5.3.2, after completion of all pre-dose evaluations and 
procedures, study drug  will be administered by a controlled infusion device as a 
70-minute  IV infusion (approximately 1 mL/min ute for the first 15 minutes followed by 
approximately 3  mL/min ute for the remainder of the infusion) or at a more prolonged 
infusion rate (up to 3 hours) if required due to prior IRR.  The patient’s infusion site 
should be assessed  for signs of any localized reaction  during the infusion and for 
30 minutes after the end of the infusion. 
The infusion time may be extended up to 3 hours in the event of a mild or moderate IRR.  
Study drug administration will not be resumed for any patient following a severe infusion 
reacti on until the case is discussed with the Medical Monitor.   
Suggested guidelines for management of IRRs  are provided in Section 5.9.   
6.2.1.3 Post-dose on Day 0 
The patient’s infusion site should be assessed for signs of any localized reaction during 
the infusion and for 30 minutes after the end of the infusion.  The patient will remain at 
the study site for 1 hour following completion of dosing for observation and completion of assessments:  
• Measure vital signs ; 
• Collect a PK sample at t he end of infusion (+5 minutes); 
• Obtain information on concomitant medications ; 
• Document any  AEs . 
The following activities may also be completed on Day 0 if not completed at the Screening/Baseline or Baseline visits, as described in Section 6.1.2: 
• Ophthalmology examination  at a CAS ; 
• Pharmacoeconomics questionnaire. 
6.2.2 Routine Study Visits  
The procedures described below are to be performed for all routine study visits  (from 
Day 21 through Day 546), with the exception of the 9-month and 18-month effica cy 
assessment s (occurring on Days 253-272 and Days 553-560, respectively) .  All visits 
have a window of “±3 days” except for the Day 273 visit which has a window of 
“+3 days”  to allow adequate time for the assessment of the patient’s 9-month mNIS+7 
and FAP stage testing, which will determine if the patient me t the criteria for Rapid 
Disease Progression.  
Patients will u ndergo the following procedures before study drug dosing: 
• At all dosing visits, administer premedications at least 60 minutes prior to the start of 
administration of study drug (see Section  5.3.1);  
• At all dosing visits, measure weight;  
• At all dosing visits, measure vital signs;  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 65 of 109 
• On Days 252 and 546, p erform a physical examination ; 
• On Days 126 and 399, perform a 12- lead ECG;  
• On Days 21, 126, 252, 273, 399, and 546, collect blood sample for serum TTR 
protein, RBP, and vitamin A.  Additionally, aliquots of serum samples will be taken 
for long-term frozen storage , to permit testing of additional proteins related to FAP; 
• On Days 84, 189, 357, 462, and 546, c ollect blood sample s for serum chemistry tests; 
• On Day 546, collect blood sample for INR; 
• On Days 21, 126, 252, 399, and 546, collect a blood sample for anti -drug antibody 
assessment;  
• On Days 252 and 546, collect blood samples for clinical laboratory tests, including : 
• Hematology ; 
• Thyroid function tests.  
• On Days 252 and 546, c ollect urine sample for urinalysis;  
• On Days 21, 126, 252, 399, and 546, collect a plasma PK sample pre- dose (within 
1 hour of planned study drug dosing); 
• On Day s 21, 126, 252, 399, and 546, collect a urine PK sample pre-dose (within 
1 hour of planned dosing start); 
• Perform ophthalmology examination s on Day 21 (if baseline examination was not 
completed  prior to the Day 21 visit), once between Days 231(±3) and 272 at a CAS, 
and once between Days 546(±3) and 560 at a CAS; 
• Complete the pharmacoeconomics questionnaire on Day 21, if not completed prior to 
the Day 21 visit; 
• At all dosing visits, o btain information on concomitant medications; 
• At all dosing visits, document any AEs . 
Following the completion of all required pre-dose activities and assessments, administer 
the study drug at all dosing visits, as described in Section 6.2.1.2. 
Following dosing, c ollect plasma PK samples as follows: 
• On Days 126 and 399, collect a plasma PK sample at the end of the infusion 
(+5 minutes); 
• On Days 21, 252, and 546, collect a plasma PK sample 30 minutes after the end of the 
infusion (+15 minutes). 
6.2.3 Efficacy Assessment  Visits (9 Months and 18 Months) 
Efficacy assessment will be performed on all patients at approximately 9 and 18 months 
(Days 253-272 and 553-560, respectively) .  Patients will not receive any study drug on 
these days.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 66 of 109 
As described in Section 4.6, in consultation with the Investigator on Day 273 (+3 days), 
patients who meet the criteria for Rapid Disease Progression based on the 9-month efficacy assessments may continue study drug dosing or discontinue study drug dosing.  
Patients who discontinue study drug dosing may receive additional therapy for FAP, as 
per the local standard of care.  These patients will remain on the study and follow the modified schedule of assessments shown in Table 1-3 and described in Section 6.4.  
Blinding will be maintained throughout.  
The 9 - and 18- month efficacy assessment visits will take place over 2 days.  
• Perform the following efficacy  assessments: 
• mNIS+7 *; 
• NIS+7 *;  
• Timed 10- meter walk test *; 
• Grip strength test*; 
*Note:  For the mNIS+7 , NIS+7 , timed 10 -meter walk test, and grip strength test, 
an independent assessment will be performed on each day .  Each site will make 
every effort to have these assessments performed by the same Investigator.  
Assessments are to be performed at least 24 hours (approximately) apart from 
each other but no greater than 7 days apart.  For the mNIS+7 and NIS+7, 
components that are shared (including NIS and NCS) will be performed only once 
on each assessment day . 
• PND score (see Appendix 5);  
• FAP stage  (see Appendix 6);  
• If the patient has provided separate informed consent  for the skin biopsies, 
obtain 2 sets of tandem 3-mm skin punch biopsies (4 biopsies total); 1 set 
from the distal lower leg when a patient’s clinical status allows, and 1  set from 
the distal thigh . Skin biopsies will be performed at a CAS; 
• mBMI ( Note:  The site will only measure the patient’s weight.  Using this 
weight, mBMI will be calculated programmatically in the clinical database; 
the site will not perform the calculation. );
  
• Echocardiogram; 
• Collect blood samples for NT-proBNP and troponin I; 
• Norfolk QOL- DN; 
• EQ-5D; 
• R-ODS;  
• COMPASS -31. 
• Measure weight o n both efficacy assessment days; 
• Measure vital signs on both efficacy assessment days;  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 67 of 109 
• Complete the C-SSRS questionnaire; 
• Complete the pharmacoeconomics questionnaire; 
• Perform a 12- lead ECG;  
• Collect blood samples for: 
• TTR protein, RBP, and vitamin A; 
• Additional aliquots of serum for long- term frozen storage , to permit testing of 
additional proteins related to FAP. 
• Perform an ophthalmology examination (2 exams with 1 being completed between 
Days 231(±3) and 272 at a CAS, and 1 completed between Days 546(±3) and 560 at a 
CAS ); 
• Obtain information on concomitant medications; 
• Document any AEs.  
6.2.4 Follow-Up Visits 
Patients will return to the study site for 2 follow- up visits , 21 days and  56 days after 
receiving their last dose of study drug.  If a patient enrolls in the extension study, they 
will only have to complete the 21- day follow -up assessments ( End of Study [ EOS ]; 
Day 567) and not the 56- day follow -up assessments (Day 602).  Patients who do not 
enroll in the extension study will need to complete both follow-up visits ( EOS [Day 567] 
and Day  602).  
6.2.4.1 Twenty-One-Day Follow-up Visit  (End of Study) 
The following procedures will be performed at the 21- Day Follow -up visit ( EOS; 
Day 567). 
• Perform  a physical examination; 
• Measure weight;  
• Measure vital signs; 
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins related to FAP;  
• Perform a pregnancy test (for females of child -bearing potential only); 
• Obtain information on concomitant medications; 
• Document any AEs.  
6.2.4.2 Fifty-Six-Day Follow -up Visit 
This visit will only be conduc ted for patients who do not enroll in the extension study. 
The following procedures will be performed at the 56-D ay Follow-up visit (Day 602): 
• Perform a physical examination ; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 68 of 109 
• Measure vital signs ; 
• Collect blood sample for serum chemistry testing ; 
• Perform a pregnancy test (only for fema les of child -bearing potential ); 
• Obtain conc omitant medications information ; 
• Document any AEs.  
6.3 Early Withdrawal Visit  and Follow- up Visits for Patients who Permanently 
Discontinue Study Treatment   
6.3.1 Early Withdrawal Visit 
For patients who withdraw early from the study, every effort will be made to have them 
return to the study site to have the following procedures performed.  These visits will take 
place over 2 days. 
• Perform the following efficacy assessments:  
• mNIS+7*; 
• NIS+7*; 
• Timed 10- meter walk test*; 
• Grip strength test* . 
*Note:  For the mNIS+7, NIS+7, timed 10- meter walk test, and  grip strength test, 
an independent assessment will be performed on each day.  Each site will make 
every effort to have these assessments performed by the same Investigator.  
Assessments are to be performed at least 24 hours (approximately) apart from 
each other but no greater than 7 days apart.  For the mNIS+7 and NIS+7, 
components that are shared (including NIS and NCS) will be performed only once on each assessment day.  
• PND score (see Appendix 5);  
• FAP stage  (see Appendix 6);  
• If the patient has provided separate informed consent  for the skin biopsies, 
obtain 2 sets of tandem 3 -mm skin punch biopsies (4 biopsies total); 1 set 
from the distal lower leg when a patient’s clinical status allows, and 1  set from 
the distal thigh; 
• mBMI (Note:  The site will only measure the patient’s weight.  Using this 
weight, mBMI will be calculated programmatically in the clinical database; 
the site will not perform the calculation.); 
• Echocardiogram; 
• Collect blood samples for NT-proBNP and troponin I; 
• Norfolk QOL- DN; 
• EQ-5D; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 69 of 109 
• R-ODS;  
• COMPASS -31. 
• Complete the pharmacoecon omics and C- SSRS questionnaires. 
• Measure weight o n both efficacy assessment days. 
• Measure vital signs on both efficacy assessment days.  
• Perform a physical examination.  
• Collect a 12 -lead ECG.  
• Collect blood samples for clinical laboratory tests, including:  
• Hematology ; 
• Serum chemistries ; 
• Thyroid function tests; 
• Anti-drug antibody testing. 
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins r elated to FAP.  
• Collect urine sample for urinalysis.  
• Perform a pregnancy test (only for females of child -bearing potential).  
• Collect a blood sample for plasma PK assessment;  
• Collect a urine sample for PK assessment;  
• Obtain information on concomitant medicat ions; 
• Document any AEs.  
6.3.2 Follow-up Visits for Patients who Permanently Discontinue Study Treatment   
Patients who permanent ly discontinue study treatment  at any time after their first dose of 
study drug (due to decision made by treating physician or by the patient)  may consent to 
return fo r follow -up visits at Months 9 and/or 18.  If  the patient discontinues study 
treatment  >24 weeks  prior to the Month 9 evaluation visit, the patient will complete 
follo w-up visits at 9 and 18 months;  if the patient discontinues study treatment after the 
Month 9 evaluation visit and >24 weeks  before the Month 18 evaluation visit, the patient 
will complete  a follow-up visit at 18 months.   
These visits will take place over 2 days ( at least 24 hours [approximately] , but not more 
than 7 days apart).  The following procedures will be performed:  
• Perform the following efficacy assessments:  
• mNIS+7*; 
• NIS+7*; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 70 of 109 
*Note:  For the mNIS+7 and NIS+7, an independent assessment will be 
performed on each day.  Each site will make every effort to have these assessments performed by the same Investigator.  Assessments are to be 
performed at least 24 hours (approximately) apart from each other but no greater 
than 7 days apart.  For the mNIS+7 and NIS+7, components that are shared 
(including NIS and NCS) will be performed only once on each assessment day. 
• PND score (see Appendix 5);  
• FAP stage  (see Appendix 6);  
• mBMI (Note:  The site will only measure the patient’s weight.  Using this 
weight, mBMI will be calculated programmatically in the clinical datab ase; 
the site will not perform the calculation.); 
• Norfolk QOL- DN; 
• EQ-5D 
• Perform a physical examination; 
• Measure weight o n both efficacy assessment days; 
• Measure vital signs on both efficacy assessment days;  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.   
• Determine Karnofsky Performance Status (see Appendix 1);  
• Determine New York Heart Associati on classification of heart failure (see  Appendix 
2); 
• Collect a blood sample for plasma PK assessment;  
• Collect data on subsequent FAP treatment regimens. 
 
6.4 Modified Visit Schedule for Patients who Discontinue Study Drug for 
Rapid Disease Progression at Month 9  
As described in Section 4.6, in consultation with the Investigator, patients who meet the 
criteria for Rapid Disease Progression based on the 9 -month efficacy assessments may 
continue study drug dosing or discontinue study drug dosing.  Patients who discontinue 
study drug dosing may receive additional therapy for FAP, as per the local standard of 
care.  These patients will remain on the study and follow a modified visit schedule as 
shown in Table 1-3 and described in detail below.  B linding will be maintained 
throughout. 
6.4.1 Modified Day 273 
The following procedures will be performed on Day 273 (+3 days): 
• Consult with the patient  on a subsequent plan of care, which may include receiving 
therapy for FAP as per the local standard of care;  
• Measure vital signs;  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 71 of 109 
• Collect information on concomitant medications; 
• Document any AEs.  
Patients who discontinue treatment and also decide t o discontinue from the study at the 
time of this visit will not have any additional visits after the Day 273 assessments are 
completed.  
6.4.2 Modified Day 294 
The following procedures will be performed: 
• Perform a physical examination; 
• Measure vital signs;  
• Collect blood sample for serum chemist ry testing;  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins related to FAP;  
• Collect a blood sample for plasma PK assessment ; 
• Collect a urine sample for PK  assessment ; 
• Perform a pregnancy test (only for fema les of child -bearing potential);  
• Obtain concomitant medications information  (this will be the final collec tion of 
concomitant medications ); 
• Document any AEs  (following this visit, only AEs  that are considered related to study 
procedures will be collected) ; 
• Collect data on subsequent FAP treatment regimens. 
6.4.3 Modified Day 378 and Day 462 
Study personnel will contact the patient by phone to query for general health status and 
data on subsequent FAP treatment regimens. 
6.4.4 Modified Day 546 
The following procedures will be performed: 
• Perform a physical examination; 
• Measure weight;  
• Measure vital signs;  
• Collect blood samples for clinical lab oratory tests, including: 
• Hematology;  
• Serum chemistries  and INR ; 
• Thyroid function tests; 
• Anti-drug antibody testing. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 72 of 109 
• Collect urine sample for urinalysis;  
• Perform a pregnancy test (only for fema les of child -bearing potential);  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen  storage , to permit testing 
of additional proteins related to FAP;  
• Collect a blood sample for plasma PK assessment;  
• Collect a  urine sample for PK assessment;  
• Complete the pharmacoeconomics  questionnaire; 
• Document any study -procedure- related AEs;  
• Collect data on subsequent FAP treatment regimens. 
6.4.5 Modified 18 -Month Efficacy Assessment  Visit 
This visit will take place over 2 days.  The following procedures will be performed: 
• Perform the following efficacy assessments:  
• mNIS+7*; 
• NIS+7*; 
• Timed 10- meter walk test*; 
• Grip strength test*; 
*Note:  For the mNIS+7, NIS+7, timed 10- meter walk test, and grip strength test, 
an independent assessment will be performed on each day.  Each site will make every effort to have these assessments performed by the same Investigator.  
Assessments are to be performed at least 24 hours (approximately) apart from 
each other but no greater than 7 days apart.  For the mNIS+7 and NIS+7, 
components that are shared (including NIS and NCS) will be performed only once 
on each assessment day.  
• PND score (see Appendix 5);  
• FAP stage  (see Appendix 6);  
• If the patient has provided separate informed consent  for the skin biopsies, 
obtain 2 sets of tandem 3 -mm skin punch biopsies (4 biopsies total); 1 set 
from the distal lower leg when a patient’s clinical status allows, and 1  set from 
the distal thigh; 
• mBMI (Note:  The site will only measure the patient’s weight.  Using this 
weight, mBMI will be calculated programmatically in the clinical database; 
the site will not perform the calculation.); 
• Echocardiogram; 
• Collect blood samples for NT-proBNP and troponin I; 
• Norfolk QOL- DN; 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 73 of 109 
• EQ-5D; 
• R-ODS;  
• COMPASS -31. 
• Measure weight o n both efficacy assessment days; 
• Measure vital signs on both efficacy assessment days;  
• Collect a 12 -lead ECG;  
• Complete the C -SSRS questionnaire; 
• Document any study-procedure- related AEs . 
6.4.6 Modified Twenty -One-Day Follow- up Visit (End of Study)  
The following procedures will be performed: 
• Perform a physical examination; 
• Measure weight;  
• Measure vital signs;  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long- term frozen storage, to permit testing 
of additional proteins related to FAP;  
• Document any study-procedure- related AEs ; 
• Collect data on subsequent FAP treatment regimens. 
6.4.7 Modified Early Withdrawal Visit  
If the patient on the modified visit schedule discontinues from the study any time after 
the Day 273 assessments are completed  (i.e., Day 274 onward) , every effort will be made 
to have the patient  return to the study site for the Modified Early Withdrawal visit.  This 
visit will take place over 2 days  (at least 24 hours [approximately] , but not more than 
7 days apart) .  The following procedures will be performed: 
• Perform the following efficacy assessments:  
• mNIS+7*; 
• NIS+7*; 
• Timed 10- meter walk test *; 
• Grip strength test*; 
*Note:  For the mNIS+7, NIS+7, timed 10- meter walk test, and grip strength test, 
an independent assessment will be performed on each day.  Each site will make every effort to have these assessments performed by the same Investigator.  
Assessments are to be performed at least 24 hours (approximately) apart from 
each other but no greater than 7 days apart.  For the mNIS+7 and NIS+7, 
components that are shared (including NIS and NCS) will be performed only once 
on each assessment day.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 74 of 109 
• PND score (see Appendix 5);  
• FAP stage  (see Appendix 6);  
• If the patient has provided separate informed consent  for the skin biopsies, 
obtain 2 sets of tandem 3-mm skin punch biopsies (4 biopsies total); 1 set 
from the distal lower leg when a patient’s clinical status allows, and 1  set from 
the distal thigh; 
• mBMI (Note:  The site will only measure the patient’s weight.  Using this weight, mBMI will be calculated programmatically in the clinical database; the site will not perform the calculation.); 
• Echocardiogram; 
• Collect blood samples for NT-proBNP and troponin I; 
• Norfolk QOL- DN; 
• EQ-5D; 
• R-ODS;  
• COMPASS -31. 
• Complete the pharmacoecon omics and C-SSRS questionnaires; 
• Perform a physical examination; 
• Measure weight o n both efficacy assessment days; 
• Measure vital signs on both efficacy assessment days;  
• Collect a 12 -lead ECG;  
• Collect blood sample for serum TTR protein, RBP, and vitamin A.  Additionally, 
aliquots of serum samples will be taken for long -term frozen storage , to permit testing 
of additional proteins related to FAP; 
• Collect blood samples for clinical laboratory tests, including:  
• Serum chemistries; 
• Thyroid function tests; 
• Anti-drug antibody testing. 
• Perform a pregnancy tes t (only for fema les of child -bearing potential);  
• Document any study-procedure- related AEs ; 
• Collect data on subsequent FAP treatment regimens. 
6.5 Unscheduled Visits  
Unscheduled visits for study assessments may occur if deemed necessary  by the study 
personnel. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 75 of 109 
7 STUDY ASSESSMENTS  
7.1 Demographic Data and Medical History 
At the Screening visit, patient demographic data and a complete medical history  will be 
obtained, including review of documentation of TTR genotype.  At the 
Screening/Baseline visit and Baseline visit, an interval medical history will be obtained, 
capturing only changes since the Screening visit. 
At the Screening visit, HIV status will be obtained.  The Investigator will assess the 
patient according to the Karnofsky Scale (see Appendix 1) and the New York Heart 
Association Classification of Heart Failure  (see Appendix 2).  
7.2 Efficacy Assessments  
Efficacy a ssessment s will occur at  Screening/Baseline, Baseline, 9 months, 18 months, 
and E arly Withdrawal (if applicable) .  A central neurologic testing core facility will 
review the data derived from the various neuropathy measures at each participating site to 
ensure compliance with testing procedures and quality of the data.  A central 
echocardiography core lab will analyze the echocardiogram data.  A core lab will also be 
responsible for processing and analyzing skin punch biopsy samples. 
The study personnel performing assessments related to the efficacy endpoints will be 
blinded to the results of any previous assessments (e.g., S creening/ Baseline, Baseline,  or 
9-month assessments).  
Further details on performing these assessments will be  provided in the Study Reference 
Manual.  
7.2.1 Modified Neurological Impairment Score +7 
The mNIS+7 assessment  tool is a composite measure of neurol ogic impairment which 
includes the following measures: 
• Clinical exam -based neurologic impairment score ( NIS-weakness and reflexes ); 
• Electrophysiologic measures of small and large nerve fiber function (+7) including: 
• NCS Σ5 ; 
• QST  by body surface area including TP and HP . 
• Autonomic function (postural blood pressure). 
A summary  of the scoring of the components of the mNIS+ 7 is provided in Appendix 4. 
At each time point, 2 independent assessments will be performed.  Each site will make 
every effort to have these assessments performed by the same blinded study personnel, 
who will be different from the Investigator and other personne l managing the patient.  
Assessments are to  be performed at least 24 hours (approximately) apart from each other 
but no greater than 7 days apart.  In order to limit potential intra-operator bias, results of 
any of the prior assessment s will not be available to the examiner when performing the 
second assessment . 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 76 of 109 
Every effort will be made to use the same devices for NCS and QST for a patient 
throughout the duration of the study.   
7.2.2 Neurological Impairment Score +7 
The NIS+7 consists of the  following measures: 
• Full NIS  (including weakness , sensation, and reflexes); 
• Electrophysiologic measures of small and large nerve fiber function (+7) including: 
• NCS  Σ5; 
• VDT . 
• HRdb . 
A summary  of the scoring of the components of the NIS+7  is provided in Appendix 4. 
At each time point, 2 independent assessments will be performed in the same manner as 
described above for mNIS+7 .  Every effort will be ma de to use the same devices for NCS 
and VDT  for a patient throughout the duration of the study.   
Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at each assessment.  
7.2.3 Familial Amyloidotic Polyneuropathy Stage and Polyneuropathy Disability 
Score 
Changes in ambulation will be evaluated through the PND score and FAP stage (see 
Appendix 5 and Appendix 6, respectively ).
44,45 
7.2.4 Intraepidermal Nerve Fiber Density and Sweat Gland Nerve Fiber Density  
Quantification of nerve fibers in skin will be assessed via IENFD and SGNFD.  Patients  
who have provided additional voluntary consent for skin biopsy will undergo tandem 
3mm skin punch biopsies for IENFD and SGNFD assessment.  At each time point, 1  set 
of biopsies will be taken from the distal lower leg, when a patient’s clinical status allows, 
and 1 set from the distal thigh  (4 biopsies total).   
A repeat baseline biopsy may be performed if the initial sample is not of sufficient quality. 
Details on sample collect ion, process ing, and stor age will be provided in the S tudy 
Laboratory Manual.  
7.2.5 Modified Body Mass Index  
Sites will measure body weight at the time points specified in  Table 1-1, Table 1 -2, and 
Table 1-3.  Using that data, t he mBMI  will be calculated (BMI  × albumin ).  This 
calculation will take place programmatically in the clinical database; the sites will not 
perform the calculation.  
7.2.6 Timed Ten-meter Walk Test  
To perform the timed 10- meter walk, t he patient will be asked to walk 10 meters.  The 
walk must be completed without assistance from another person; ambulatory aids such as 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 77 of 109 
canes and walkers are permitted.  The time required for the patient to walk 10  meters will 
be recorded.  At the 9-month, 18-month, and Early Withdrawal visits , the assessments 
will be conducted on 2 days, at least 24 hours (approximately) , but not more than 7 days 
apart.  
7.2.7 Grip Strength  Test 
Hand grip strength will be measured by dynamometer.  Sites will be trained on 
dynamometer and testing for the study.  When performing the test, patient s will stand, 
holding the dynamometer in their dominant hand, with their arm parallel to the body 
without squeezing the arm against the body.  Tests will be performed in triplicate  on the 
same day  for each time  point.   
Every effort will be made to use the same dynamometer for a patient throughout the duration of the study. 
At the 9 -month, 18-month, and Early Withdrawal  visits, the assessments will be 
conducted on 2 days, at least 24 hours (approximately), but not more than 7 days apart.  
7.2.8 Composite Autonomic Symptom Score  
To evaluate changes in autonomic symptoms, patients will complete the COMPASS -31 
questionnaire.  The questionnaire consists of 31 clinically s elected questions evaluating  
6 autonomic domains (orthostatic intolerance, secretomotor, gastrointestinal, bladder, and 
pupillomotor).
46 
7.2.9 Norfolk Quality of Life - Diabetic Neuropathy Questionnaire  
Quality of life will be assessed through the Norfolk QOL -DN questionnaire, a 
standardized 47- item patient- reported outcomes measure that is sensitive to the different 
features of diabetic neuropathy (DN) -small fiber, large fiber, and autonomic nerve 
function.47 
7.2.10 EuroQoL Quality of Life Questionnaire  
Quality of life will be assessed through the use of the EQ -5D, a standardized 5-question 
instrument for use as a measure of health outcomes.48 
7.2.11 Rasch-built Overall Disability Scale  
An assessment of the disability each patient experiences will be assessed through the 
R-ODS .49  The R -ODS is comprised of a 24- item linearly weighted scale that specifically 
captures activity and social participation limitations in patients.  
7.2.12 Echocardiogram  and Biomarkers of Cardiac Functi on 
Cardiac structure and function will be assessed through echocardiograms as well as 
measurement of serum levels of the cardiac biomarkers NT -proBNP and troponin I.   
Echocardiograms will be performed at the time points specified in  Table 1-1, Table 1 -2, 
and Table 1-3 and interpreted  at a central echocardiography core lab .  Image acquisition, 
storage, and transfer guidelines will be provided in a Study Manual.  

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 78 of 109 
Blood samples will be drawn to m easure levels of NT -proBNP and troponin I at the time  
points specified in Table 1-1, Table 1 -2, and Table 1-3.  Details on s ample collect ion, 
processing , and storage will be provided in a Study Laboratory Manual. 
7.3 Pharmacodynamic Assessments  
Pharmacodynamic sample collection, processing, and storage guidelines will be provided 
in a Study Laboratory Manual. 
7.3.1 Transthyretin  
Blood for serum TTR levels will be collected at the Baseline visit and prior to the 
administration of study drug at the time points specified in  Table 1-1, Table 1 -2, and 
Table 1-3.   
Serum TTR will be assessed using both ELISA (enzyme linked immunosorbent assay) 
and turbidimetric assays.  
7.3.2 Retinol Binding Protein  
Blood for serum RBP levels will be collected at the Baseline visit and prior to the 
administration of study drug at the time points specified in  Table 1-1, Table 1 -2, and 
Table 1-3.  
Serum RBP will be quantified using nephelometry. 
7.3.3 Vitamin A  
Blood for serum vitamin A levels will be collected at the Baseline visit and prior to the 
administration of study drug at the time points specified in  Table 1-1, Table 1 -2, and 
Table 1-3.  S upplemental vitamin A  will be taken at the time points specified in  Table 
1-1, Table 1 -2, and Table 1-3. 
7.3.4 Exploratory Biomarkers 
To explore the expression of hepatocyte derived proteins to further characterize the 
biological effects of siRNA and/ or to explore possible metabolite profiling of patisiran  
(ALN -TTR02 ), serum and plasma samples will be collected at the time points specified 
in Table 1-1, Table 1 -2, and Table 1-3. 
Details on biomarker sample collect ion, processing, and stor age will be  provided in a 
Laboratory Manual.  
Biological samples for biomarker research and possible metabolic profiling can be 
retained on behalf of A lnylam for a maximum of 15 years following the last patient’s last 
visit in the study.  
7.4 Pharmacokinetic Evaluations 
Details on PK sample collection , processing, and storage will be provided in a Laboratory 
Manual .  Plasma and urine samples will be evaluated  using a validated ATTO-Probe-
HPLC (high performance liquid chromatography) assay to determine siRNA 
concentration and by LC/MS/MS for DLin- MC3 -DMA and PEG 2000-C-DMG 
concentrations. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 79 of 109 
7.4.1 Plasma Pharmacokinetics  
Plasma samples will be collected at the time points shown in  Table 1-1, Table 1 -2, and 
Table 1-3 for assessment of siRNA, DLin -MC3 -DMA and PEG 2000-C-DMG.   PK 
parameters, including population PK will be analyzed, whenever possible as outlined in 
Section 9.2.6. 
7.4.2 Urine Pharmacokinetics  
Urine samples and urine volume void will be obtained at specified time points as 
specified in  Table 1-1, Table 1 -2, and Table 1-3.  R enal clearance (CL R) will be 
determined whenever possible for si RNA and 4 -dimethylaminobuttyric acid, metabolite 
of DLin -MC3 -DMA, excreted in the urine.  PK parameters will be analyzed, whenever 
possible, as outlined in Section 9.2.6. 
7.5 Safety Assessments 
All safety assessment measures will be recorded in the patient’s medical record and CRF.  
7.5.1 Physical Examination 
A complete physical examination (including general appearance; head, ears, eyes, nose, 
and throat [ HEEN T]; cardiovascular ; dermatologic; abdominal; genito-urinary; lymph 
nodes; hepatic; musculoskeletal ; respiratory ; and neurological) is to be at the study visits 
listed in  Table 1-1, Table 1 -2, and Table 1-3.   
7.5.2 Body Weight and Height 
Body weight will be measured at the study visits listed in  Table 1-1, Table 1 -2, and Table 
1-3.  The rules for using body weight to calculate dose are described in Section 5.3.2.  
Height will only be measured at Screening.  
7.5.3 Vital Signs  
Vital signs will b e measured at the time points specified in  Table 1-1, Table 1 -2, and 
Table 1-3.  Vital signs include systolic/diastolic blood pressure, pulse rate, respiratory 
rate, and temperature, and will be measured in the supine position using an automated 
instrument after the patient has rested comfortably for 10  minutes.  Each patient’s blood 
pressure should be taken using the same arm.  T emperature will be recorded in Celsius  or 
Fahrenheit.  Heart  rate will be counted for a full minute and recorded in beats per minute.  
Respirations will be counted for a full minute and recorded in breaths per minute. 
For the safety of the patient, additional vital signs may be added at the discretion of the 
Invest igator. 
7.5.4 Electrocardiogram  
Computerized 12- lead ECG recordings will be obtained  in triplicate  at each time point 
listed in  Table 1-1, Table 1 -2, and Table 1-3 and read locally  by a cardiologist  or 
qualified physician .  Each lead shall be recorded for at least 3 beats at a speed of 25 
mm/s.  
The following electrophysiologic parameters will be assessed: rhythm, ventricular rate, PR interval, QRS duration, and QT interval.  If the ECG machine does not c alculate the 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 80 of 109 
heart rate corrected QT interval  (QTc) , either Bazett’s and/or Fridericia’s formula will be 
used to calculate the QTc . 
For any clinically significant abnormal results, the Investigator must contact the CRO  
Medical Monitor to discuss continued participation of the patient in the study (e.g., 
ischemic ECG changes, wave/interval changes, or arrhythmia).  
7.5.5 Clinical Laboratory Tests 
Blood samples for clinical laboratory testing will be collected prior to study drug dosing 
at the time points listed in  Table 1-1, Table 1 -2, and Table 1-3.  Samples will be  sent to a 
central laboratory for analysis .  Details on sample collection, processing, and shipping 
will be provided in a Laboratory Manual.  
In the event of an unexplained clinically relevant abnormal laboratory test occurring after study drug administration, the test should be repeated and followed up at the discretion of the Investigator until it has returned to the normal range or stabilized , and/or a diagnosis 
is made to adequately explain the abnormality.  
The following clinical laboratory parameters are to be determined:  
Hematology  
• Hematocrit  • Neutrophils, absolute and %  
• Hemoglobin  • Lymphocytes, absolute and %  
• Red blood cell (RBC) count  • Monocytes, absolute and %  
• White blood cell (WBC) count  • Eosinophils, absolute and %  
• Mean corpuscular volume  • Basophils, absolute and %  
• Mean corpuscular hemoglobin  • Platelet count  
• Mean corpuscular hemoglobin concentration   
Serum Chemistries   
• Aspartate transaminase (AST)  • Alkaline phosphatase  
• Alanine transaminase (ALT)  • Bilirubin (total and direct)  
• Sodium  • Glucose  
• Potassium  • Phosphate  
• Blood urea nitrogen (BUN)  • Albumin  
• Creatinine  • Calcium  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 81 of 109 
Coagulation Studies   
• Prothrombin time (PT)  • International Normalized Ratio (INR)  
• Activated partial thromboplastin time (aPTT)   
Thyroid Function Tests   
• Thyroid stimulating hormone (TSH)  • Triiodothyronine ( Free T3) 
• Thyroxine ( Free T4)   
Anti-drug Antibodies   
• Anti-PEG antibodies  
Urinalysis   
• Visual inspection  for color and appearance  • Leukocytes  
• pH • Bilirubin  
• Specific gravity  • Nitrite  
• Ketones  • Urobilinogen  
• Protein  • Microscopic inspection of sediment  
• Glucose   
Serology  
• Hepatitis B surface antibody (HbsAb) • Anti–hepatitis C virus antibody (anti -HCVAb)  
• Hepatitis B surface antigen (HbsAg)  
Cardiac Biomarkers  
• N-terminal prohormone of B-type natriuretic peptide ( NT-proBNP) • Troponin I 
Other  
• β-human chorionic gonadotropin (women of child-bearing potential only ; may be a urine- or 
serum -based  test) 
• Vitamin  B12  
• Paraprotein by IFE 
7.5.5.1 Pregnancy Test  
The pregnancy test may be urine- or serum -based, at the discretion of the Investigator.  
The test  will only be performed for women of child- bearing  potential .  The timing of the 
tests is specified in  Table 1-1, Table 1 -2, and Table 1-3; additional testing may be done 
any time pregnancy is suspected.  The results must be known prior to administration of 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 82 of 109 
study drug.  Patients who are pregnant are not eligible for study participation.  Patients 
who become pregnant while on study will be followed until the pregnancy outcome is 
known (see Section 8.12).  
7.5.6 Ophthalmology Examination 
The timing of the ophthalmology examinations is specified in Section  6.2.2 and in Table 
1-1 and  Table 1-2.  The se examinations will be performed at a CAS and will include 
assessment of visual acuity, slit -lamp evaluation, intraocular pressure, dilated indirect 
ophthalmoscopy, color fundus photography, visual f ield, and electroretinography (ERG).  
Visual acuity should be evaluated at the beginning of each specified visit in the study 
(i.e., prior to slit- lamp examination).  Manifest refraction will be performed at each 
specified visit prior to visual acuity testing and will be used to obtain a correction for 
visual acuity evaluations.  Visual acuity testing should be done with best (most recent) correction. ERG evaluations will be centrally read .  
Further details regarding the ophthalmology examinations will be provided in the Study 
Reference Manual.   
7.5.7 Adverse Events  and Study -Procedure -Related Adverse Events  
Adverse events will be assessed and recorded at the time points specified in  Table 1-1, 
Table 1 -2, and Table 1-3.   
As shown in Table 1-3, only study-procedure- related AEs (e.g., skin -biopsy- related AE, 
venipuncture- related AE) will be collected after Day 294 for patients who meet the 
criteria for Rapid D isease Progression at Month 9 and receive their last dose of study 
drug on Day 252 but remain on the study.  
Section 8 provides assessment and reporting  guidelines. 
7.5.8 Concomitant Medications and Treatments  
Use of all concomitant medications and treatments will be recorded on the patient’s CRF 
through the time points shown in Table 1-1, Table 1-2, and Table 1-3.  This will include 
all prescription drugs, herbal preparations, OTC medications, vitamins, and minerals.  
Any changes in medications during the study will also be recorded on the CRF.  
Secti on 5.8 provides guidelines on concomitant medications and treatments. 
7.6 Other Assessments  
7.6.1 Pharmacoeconomics Questionnaire  
The burden of disease and he althcare utilization will be assessed using a patient- reported , 
21-question pharmacoeconomics questionnaire.  This assessment will be performed at a 
CAS.  
7.6.2 Suicidality Questionnaire  
The Columbia–Suicide Severity Rating Scale (C -SSRS) will be used to assess p atient’s 
mental status as it relate s to suicidal ideation and behavior.
50  This questionnaire will be  
administered to the patient by trained study personnel. 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 83 of 109 
7.6.3 Phone Contact for Health Status Update  and FAP Treatment  
Patients following the Modified Schedule of Assessments will be called on the telephone 
by study personnel at the time points specified in  Table 1-3.  Patients will be asked  about 
their general health status and any treatments they may have received for FAP.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 84 of 109 
8 REPORTING ADVERSE EVENTS  
8.1 Adverse Event Definition  
An AE is any untoward medical occurrence in a patient or clinical investigational patient  
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment.  
An AE can therefore be any unfavorable and unintended sign (including an abnorma l 
laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
Disease progression (including worsening of neuropathy impairment) will not be 
considered an AE. 
All IRRs will be recorded as AEs.  
For patients who meet the criteria for rapid disease progression at Month 9 and receive 
their last dose of study drug on Day 252 but remain on the study, AEs will be followed 
through Day 294.  Following Day 294, only study- procedure- related AEs will be 
collected (e.g., skin -biopsy-related AE, venipuncture- related AE).   
8.2 Serious Adverse Event Definition  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death; 
• Is life -threatening (an event  which places the patient at immediate risk of death from 
the event as it occurred.  It does not include an event that had it occurred in a more severe form might have caused death);  
• Requires inpatient hospitalization or prolongation of existing hospitaliz ation; 
• Results in persistent or significant disability/incapacity;  
• Is a congenital anomaly or birth defect; 
• An important medical event that may not be immediately life -threatening or result in 
death or hospitalization but may jeopardize the patient or may require intervention to 
prevent one of the other outcomes listed in the definition above (e.g., such events 
include allergic bronchospasm, blood dyscrasias or convulsions, or the development 
of drug dependency or abuse). 
8.3 Eliciting Adverse Event Information  
The patient should be asked about medically relevant changes in his/her health since the 
last visit.  The patient should also be asked if he/she has been hospitalized, had any 
accidents, used any new medications, or changed concomitant medication routines (both prescription and OTC). 
In addition to patient observations, AEs will be documented from any clinically relevant 
laboratory findings, physical examination findings, ECG changes, or other findings. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 85 of 109 
8.4 Adverse Event Reporting  
The Investigator is responsible for reporting all AEs that are observed or reported after 
the first dose of study drug regardless of their relationship to study drug through until the end of the reporting periods defined in Section 8.5.  For patients who meet the criteria for 
Rapid Disease Progression at Month 9 and receive their last dose of study drug on Day 252 but remain on the study, AEs will be followed through Day 294.  Following 
Day 294, only study-procedure- related AEs will be collected (e.g., skin -biopsy- related 
AE, venipuncture- related AE).   
Any medical condition that is present when a patient is screened and does not deteriorate should not be reported as an AE .  However, if it does deteriorate at any time during the 
study, it should be reported as an AE. 
All AEs must be fully recorded in the site’s source records and in  the patient s’ CRF, 
whether or not they are considered to be drug-related.  Each AE should be described in 
detail: onset time and date, description of event, severity, relationship to investigational 
product, action taken, and outcome (including time and date of resolution, if applicable). 
Adverse events should be followed through until the end of the reporting periods defined 
in Section 8.5 or until recovery to the normal state has been achieved, whichever occurs 
first.  In the event of a patient not returning to the clinical unit, the outcome of this event 
will be recorded as lost at follow -up. 
For patients who withdraw from the study early, ongoing AEs will be followed until 
resolution or 28 days from last dose, whichever occurs first. 
8.5 Adverse Event Reporting Period  
AEs and SAEs will be reported according to the following timeframes: • For patients who complete the study, AEs will be assessed through the End of Study 
visit on D ay 567 or the Follow -up visit on Day 602 (depending whether or not the 
patient plans to roll over to the open-label extension study).  A ll AEs that occur after 
the start of study  drug administration on Day 0 must be reported in detail on the 
appropriate CRF page and followed to satisfactory resolution, or through the end of 
study visit on D ay 567 or Day 602 (depending whether or not the patient plans to roll 
over to the open label extension study) after the last dose of study drug 
administration .  SAEs will be followed through the end of study visit on D ay 567 or 
Day 602 (depending whether or not the patient plans to roll over to the open label 
extension study), or until satisfactory resolution, or until the SAE is considered by the 
Investigator to be chronic or the patient is stable , whichever  occurs first . 
• For patients who meet the criteria for Rapid Disease Progression at Month 9 and 
receive their last dose of study drug on Day 252 but remain on the study, AEs will be 
followed through Day 294.  Following Day 294, only study-procedure- related AEs 
will be collected (e.g., skin -biopsy-related AE, venipuncture- related AE).  SAEs will 
be followed by the Investigator until satisfactory resolution or the Investigator deems the SAE to be chronic or stable. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 86 of 109 
• For patients who withdraw from the study earl y, ongoing AEs will be followed until 
resolution or 28 days from last dose, whichever occurs first.  SAEs will be followed 
by the Investigator until satisfactory resolution or the Investigator deems the SAE to 
be chronic or stable. 
8.6 Assessment of Causality  
Causal relationship assessment to drug treatments is required for purposes of reporting 
AEs.  To promote consistency, the following guidelines should be taken into 
consideration along with good clinical and scientific judgment when determining the 
relation ship of drug treatments to an AE : 
Definitely Related:  A clinical event, including laboratory test abnormality, occurring 
in a plausible time relationship to the medication administration, 
and which cannot be explained by concurrent disease or other drugs or chemicals.  The response to withdrawal of the drug 
should be clinically plausible. 
Possibly Related:  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to the medication administration, but 
which could also be explained by concurrent disease or other 
drugs or chemicals.  Information on the drug withdrawal may be lacking or unclear.  
Unlikely Related:  A clinical event, including laboratory test abnormality, with little or no temporal relationship to medication administration, and which other drugs, chemicals, or underlying disease provide 
plausible explanations. 
Not Related:  A clinical event, including laboratory test abnormality , that has no 
temporal relationship to the medication or has more likely alternative etiology.  
8.7 Assessment of Severity  
Adverse events are to be graded according to the categories detailed below.  
Mild:  Mild events are those which are easily tolerated with no disruption of normal daily activity. 
Moderate:  Moderate events are those which cause sufficient discomfort to 
interfere with daily activity.  
Severe:  Severe events are those which incapacitate and prevent usual 
activity.  
Changes in severity should be documented in the medical record to allow assessment of 
the duration of the event at each level of severity.  Adverse events characterized as 
intermittent require documentation of the start and stop of each incidence.  When changes 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 87 of 109 
in the severity of an AE occur more frequently than once a day, the maximum severity 
for the experience th at day should be noted.  If the severity category changes over a 
number of days, then those changes should be recorded separately (with distinct onset 
dates).  
8.8 Action Taken for Adverse Event  
Action taken in regards to study drug will be defined as: 
• None; 
• Infusion interrupted and restarted at a later time;  
• Infusion stopped and wa s not restarted at a later time;  
• Infusion cycle delayed . 
8.9 Outcome of Adverse Event  
Outcome will be defined as:  
• Resolved (with or without sequelae); 
• Ongoing;  
• Lost to follow-up. 
8.10 Coding of Adverse Events  
The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code AEs.  
8.11 Serious Adverse Event Reporting  
An assessment of the seriousness of each AE will be made by the Investigator.  Any AE 
and laboratory abnormality that meets the above seriousness criteria ( Section 8.2)  must 
be reported immediately to the CRO , always within 24 hours from the time that site 
personnel first learn of the event.  All SAEs must be reported regardless of the relationship to study drug. 
The initial report should include at least the following information:  
• Patient’s study number; 
• Description and date of onset of the event; 
• Criterion for serious ; 
• Preliminary assignment of causality to study drug.  
SAE reporting will be via electronic data capture (EDC).  
To report the SAE, compl ete the S
 AE form electronically in the electronic data capture 
(EDC) system for the study.  When the form is completed, Safety personnel 
will be notified electronically and will retrieve the form.  If the event meets serious criteria and it is not possible to access the EDC system, send an email to   
  or call the  SAE hotline (phone 
number will be provided in the Study Manual ), and
  fax the completed back -up paper 
SAE form to (fax n umber will be provided in the Study Manual ) within 

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 88 of 109 
24 hours of awareness.  When the EDC system becomes available, the SAE information 
must be entered into the EDC system within 24 hours of the system becoming available.  
 Safety personnel will be  available for SAE reporting on a 24-hour basis.  
Incoming reports will be  reviewed during normal business hours. 
 Within 24 hours of receipt of follow-up information, the investigator must update the SAE form electronically in the EDC system for the study an d submit any supporting 
documentation (e.g., patient  discharge summary or autopsy reports) to  Safety 
personnel via fax or e- mail.  If it is not possible to access the EDC system, refer to the 
procedures outlined above for initial reporting of SAEs.  
Appropriate remedial measures should be taken by the Investigator using his/her best 
medical judgment to treat the SAE.  These measures and the patient’s response to these measures should be recorded.  All SAEs, regardless of relationship to study drug, will be 
followed by the Investigator until satisfactory resolution or the Investigator deems the 
SAE to be chronic or stable.  Clinical, la boratory, and diagnostic measures should be 
employed by the Investigator as needed to adequately determine the etiology of the event.   
The Investigator will be responsible for reporting all SAEs to the local independent ethics 
committee (IEC)  or Institutional Review Board ( IRB) when required by national 
regulations. 
Alnylam or its representative will be responsible for the reporting of all relevant events to 
the concerned regulatory authorities according to all applicable regulations. 
In Europe, in accordance with the Directive 2001/20/EC, the Competent Authorities and 
the Ethics Committees in the concerned Member States will be notified of fatal and life -
threatening Suspected Unexpected Serious Adverse Reactions (SUSARs) as soon as 
possible but no later than 7 calendar days after Alnylam or its representative has first 
knowledge of the minimum criteria for expedited reporting.  Non -fatal and non- life-
threatening  SUSARs should be reported no later than 15 calendar days after Alnylam or 
its representative has  first knowledge of them. 
The Investigator may be informed by Alnylam or its representative of SAEs from other 
Investigators or clinical studies which may have relevance to this clinical study .  These 
SAEs should also be reported promptly to the IEC /IRB  that approved the study.  All SAE 
reports should be transmitted to the IEC/ IRB with a cover letter or transmittal form, and a 
copy of that transmittal should be maintained in the Investigator’s files and forwarded to Alnylam as part of the TMF on study completion. 
8.12 Pregnancy Reporting  
A female patient with a positive pregnancy test at Screening  is ineligible for this study .  If 
a female patient is found to be pregnant during the course of the study or during the 
first month after receiving the last dose of study drug , the Investigator should report the 
pregnancy to the CRO within 24 hours of being notified of the pregnancy.  Details of the 
pregnancy will be recorded on the pregnancy reporting form.  The patient should receive 
any necessary counseling regarding the risks of continuing the pregnancy and the 
possible effects on the fetus.   

 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 89 of 109 
The pregnancy should be followed by the Investigator until completion. At the 
completion of the pregnancy, the Investigator will document the outcome of the pregnancy.  If the outcome of the pregnancy meets the criteria for an SAE 
(i.e., postpartum complication, spontaneous abortion, stillbirth, neonatal death, or congenital anomaly), then the Investigator should follow the procedures for reporting an SAE outlined above. 
Pregnancy occurring in the partner of a patient participating in the study should also be 
reported to the Investigator, who will then report this to the CRO and follow to outcome 
as described above.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 90 of 109 
9 STATISTICAL METHODS  
9.1 Sample Size  
Approximately 200 patients will be enrolled in this study .  Of those 200 patients, no more 
than 40 patients will have a NIS range of 101 to 130.  An mNIS+7progression rate 
(primary endpoint) in the placebo group of 24 ± 16 points in 18 months was estimated 
using natural history data from FAP patients.   A sample of 154 patients provides 90% 
power for a 2-sided test with an 8.95 point (37.5%) mean difference between treatment 
groups in the primary endpoint at 2-sided alpha = 0.05.  Assuming a 25% random 
premature discontinuation rate (due to liver transplantation or other factors), the sample 
size for thi s study is approximately 200.  Additional patients may be enrolled based on a 
recommendation to increase the sample size in the interim analysis.  
9.2 Statistical Methodology 
A full statistical analysis plan will be finalized prior to database lock.  
9.2.1 Populations to be Analyzed  
The following patient populations (i.e., analysis sets) may be evaluated and used for presentation of the data:  
• Modified ITT (mITT) population:  All patients who were randomized and receive d at 
least 1 dose of study drug; 
• Per protocol (PP) population:  All patients who completed the 18-month efficacy 
assessment visit  and did not have any major protocol violations; 
• Safety population:  All patients who received  at least 1 dose of study drug  (analyzed 
as treated , not as randomized). 
The primary population for efficacy analyses will be the mITT population; key efficacy 
results will also be analyzed secondarily for the PP population.  For efficacy analyses, 
patient s will be grouped according to the treatment to which they were randomize d.  The 
primary population for safety analysis will be the safety population.  Patient s will be 
grouped according to treatment received for summaries of safety.  
9.2.2 Baseline Evaluations 
Demographic and baseline disease characteristic data will be summarized.  Data to be tabulated will include sex, age, and race, as well as disease- specific information.  
9.2.3 Efficacy Analyses 
9.2.3.1 Primary Efficacy Endpoint 
The primary analysis will compare change in mNIS+7 from baseline between treatment groups of the mITT population.  An analysis of covariance (ANCOVA) model, with baseline mNIS+7 value and age as continuous covariates and genotype (V30M vs Non-
V30M), prior tetramer stabilizer  (tafamidis or diflunisal)  use (Yes vs No), and treatment 
group ( patisiran  [ALN -TTR02 ] vs Placebo)  as factors will be employed to analyze the 
primary mNIS+7 endpoint.  The mNIS+7 change from baseline will be assessed at 78 weeks.  Primary endpoint data that are missing will be inferred using multiple 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 91 of 109 
imputation (MI) (see Section 9.2.10).  Analyses will be conducted using PROC MI and 
PROC MIANALYZE in SAS 9.2 (or later).  The efficacy of patisiran  will have been 
established if the estimate of the parameter associated with treatment variable 
demonstrates that patisiran  improves mNIS+7 relative to placebo with a p- value (2 -sided) 
less than or equal to 0.05, based on the MI methodology. 
Sensitivity an alyses will assess the robustness of the primary analysis in the mITT and PP 
populations for different methods of handling missing data, including mixed model 
repeated measures (MMRM), complete cases (CC), and last observation carried forward (LOCF) . 
9.2.3.2 Secondary Efficacy Endpoints 
Secondary efficacy endpoints will be analyzed using methods similar to those employed for the primary analysis, e.g. ANCOVA with multiple imputations , as appropriate.  
Type I error control for secondary endpoints will be achieved by a hierarchical ordering 
procedure.  Endpoints w ill be tested in the following prespecified hierarchy:  
• Norfolk QOL- DN questionnaire; 
• NIS-W score;  
• mBMI ; 
• Timed 10- meter walk test ; 
• COMPASS -31. 
If and only if a comparison is significant at p<0.05, the next endpoint in the hierarchy 
may be tested.  
9.2.3.3 Exploratory Efficacy Endpoints 
Continuous exploratory efficacy variables, including those closely related to the mNIS+7 
primary endpoint, may be compared using methods similar to those employed for the 
primary analysis, e.g. ANCOVA with multiple imputations, as appropriate.  Binary 
secondary endpoints will be assessed by the Cochran -Mantel -Haenszel test, stratified by 
the randomization stratification factors.    
9.2.4 Safety Analyses 
A summary of study drug exposure, including the durations of the infusions and doses, and the proportions of patients with modifications in the duration s of infusions will be 
produced. 
Adverse events will be summarized by MedDRA system organ class and preferred term.  
Separate tabulations will be produced for all treatment emergent AEs, treatment -related 
AEs (those considered by the Investigator as at least possibly drug related), SAEs, and discontinuations due to AEs.  By-patient listings will be provided for deaths, SAEs, and events leadi ng to discontinuation of treatment. 
Descriptive statistics will be provided for clinical laboratory data  and vital signs data, 
presented as both actual values and changes from baseline relative to each on -study 
evaluation and to the last evaluation on stud y. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 92 of 109 
Descriptive statistics will be provided for ECG interval data and presented as both actual 
values and changes from baseline relative to each on -study evaluation and to the last 
evaluation on study. Details of any abnormalities will be included in patient listings.  
9.2.5 Pharmacodynamics 
Summary tables and graphical displays of observed values and changes from baseline in serum TTR will be used to assess the durability of suppression over the course of the 
study.  Similar analyses will be performed for the secondary PD biomarkers (RBP and 
vitamin A).  
9.2.6 Pharmacokinetics  
Pharmacokinetic analyses will be conducted using non- compartmental and/or 
compartmental evaluation.  Whenever possible, t he PK parameters of siRNA, 
DLin -MC3 -DMA,  and PEG
2000-DMG (lipid) in sparse plasma samples collected  from all 
patient s.  PK  parameters will be calculated using a validated version of WinNonlin® 
Enterprise (Version 5.2 or higher) with NCA Model 200.  
Population PK analyses, will be performed whenever possible, on available siRNA, 
DLin -MC3 -DMA, and PEG 2000-C-DMG from sparse plasma samples obtained from all 
patient s during the duration of the study using Phoenix NLME (Version 1.1 or later).  
Summary tables and figures and inferential statistics will be generated with Phoenix NLME (Ve rsion 1.1 or later) or similar software.  
Pharmacokinetic/PD analysis will be conducted whenever possible, of sparse plasma 
samples collected during the study period.  The analysis will include, but not limited to, the determination of the relationship between exposure to siRNA, DLin- MC3 -DMA, and 
PEG
2000-C-DMG and the extent of suppression of TTR, RBP, and vitamin A and their 
correlation will be evaluated.   Correlation between TTR versus RBP and vitamin A will 
also be performed.  The  strength of the relationship will be assessed using statistical 
estimators.  As part of the PK/PD analysis, additional PD baseline analysis on serum 
TTR, RBP, and vitamin A may be conducted to include the PD data obtained post- PD 
recovery period.  The PD and PK/PD analysis will be performed with WinNonLin or 
Phoenix NLME (Version 1.1 or later) or similar software.  The PD and PK/PD 
parameters summary tables and figures and inferential statistics will be generated and 
will not be limited to descriptive statistics.  
9.2.7 Summary of Effi cacy Assessments  
Summary statistics of observed values and changes from baseline will be provided for the 
mNIS+7 composite score. Summaries will also be provided for the components of the 
composite score (e.g., the NIS weakness and reflex scores, the NCS Σ5, and QST values). 
The NIS+7 score, including its components (e.g. full NIS, HRdb, VDT) will also be 
summarized.  
Patient reported quality of life and disability  will be assessed by summary statistics for 
the Norfolk  QOL -DN, EQ-5D, and R- ODS. Summary statistics will be provided for 
observed values and changes from baseline.  Patient reported autonomic neuropathy 
symptoms will be assessed by descriptive statistics for the COMPASS -31. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 93 of 109 
Descriptive statistics will also be provided for observed values and change s from baseline 
in motor function (10- meter walk test and test of grip strength), nutritional status 
(mBMI), sensory and autonomic innervation (IENFD and SGNFD ), and ambulation 
(FAP stage and PND score).   Descriptive statistics will also be provided for pr oportions 
of patients in each group that meet the rapid progression definition at 9 months and those 
that meet the responder criterion at 18 months. 
9.2.8 Other Assessments  
The observed values and changes from baseline in burden of disease and healthcare 
utiliza tion will be evaluated  and summarized  using descriptive statistics.  Data on 
suicidality will be summarized by treatment group using descriptive statistics.  
9.2.9 Interim Analysis  
Because the sample size estimates are based on limited data for variance and disease progression, it is intended that an interim analysis will be conducted by an independent committee when approximately 50% of patients have completed their 9-month mNIS+7  
assessment .  This interim analysis will be blinded and will only estimate the overall 
variance observed in the primary endpoint.  Since the interim analysis examines only the pooled variance of all patients in a blinded fashion, it does not require an adjus tment to 
the overall alpha level for the test of the primary endpoint.  Based on the results of the interim analysis, the committee can recommend either increasing the study size or making no adjustment to the sample size.  Details regarding the Interim An alysis 
Committee are provided in  Section  10.3.3. 
9.2.10 Missing Data 
Patient s who discontinue due to rapid disease progression will have their 78-week  
mNIS+7 change from baseline value imputed using a stepwise regression approach for 
identification of explanatory variables ( e.g., demographics, stratifying variables , and 
baseline/9 -month mNIS+7 data when available ); treatment assignment will not be 
included in the imputation.  I mputed datasets  will then be analyzed as complete cases via 
the ANCOVA model specified for the primary analysis, and then combined to produce inferential results . Further details on imputations and sensitivity analyses will be included 
in the SAP that will be finalized before database lock.  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 94 of 109 
10 STUDY MANAGEMENT  
The Investigator is accountable for the conduct of the study .  If any responsibilities are 
delegated, the Investigator should maintain a list of appropriately qualified staff to whom 
he/she has delegated specified significant trial related duties.  
10.1 Data Handling and Quality Assurance 
10.1.1 Case Report Forms  
The Investigator and designees agree to maintain accurate CRFs and source 
documentation as part of these case histories.  Source documents are the originals of any documents used by the Investigator or hospital/institution that allow verification of the 
existence of the patient and substantiate the integrity of the da ta collected during the trial.  
Alnylam will supply CRFs for each patient.  Case report forms must be completed only 
by persons designated by the Investigator.  Corrections must be made so as not to 
obliterate original data and must be identified and dated by the person who made the 
correction.  All data entered into the CRF must also be available in the source documents.  The Investigator will allow designated Alnylam representatives and regulatory bodies to 
have direct access to the source documents to ver ify the data reported in the CRFs.  
Each completed CRF must be reviewed and signed by the Investigator or designee in a 
timely manner.  The completed CRF will be the records maintained by Alnylam.  A copy 
of the CRF will remain in the Investigator’s files.  
10.1.2 Monitoring  
The clinical monitor, as a representative of Alnylam, has an obligation to follow the study closely.  In doing so, the monitor will visit the Investigators and sites periodically as well 
as maintain frequent telephone and written  contact.  The m onitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation and discussion of the conduct of the study with the Investigator and staff. 
All aspects of the study will be carefully monito red by Alnylam or its designee for 
compliance with applicable government regulations in respect to Good Clinical Practice 
(GCP) and current standard operating procedures. 
10.1.3 Inspections  
The Investigator will permit trial-related monitoring, audits and review by the IEC  or IRB  
and/or Regulatory Authorities, providing direct access to source data/documents.  The 
study may be subject to audit by Alnylam or its representatives or by regulatory 
authorities.  If such an audit occurs, the Investigator must agree to a llow access to the 
required patient records.  In the event of an audit, the Investigator agrees to allow 
Alnylam, representatives from Alnylam, or regulatory agencies access to all study 
records.  
10.2 Regulatory Guidelines  
This study will be performed in accord ance with the clinical trial agreement, the protocol, 
all applicable government laws, regulations, and guidances where the study is being conducted including policies with foundations in the World Health Organization (WHO) 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 95 of 109 
Declaration of Helsinki , the Inte rnational Conference on Harmonization  (ICH) of 
Technical Requirements for Registration of Pharmaceuticals for Human Use, the Health 
Insurance Portability and Accountability Act of 1996 (“HIPAA”), and all other applicable 
medical privacy laws and regulation s. 
10.2.1 Institutional Review Board/ Independent Ethics Committee  
National regulations and ICH require that approval be obtained from an IRB or an IEC 
prior to participation of patients in research studies.  Prior to the study onset, the protocol, any protocol am endments, ICFs, advertisements to be used for patient recruitment, and 
any other written information regarding this study to be provided to a patient or patient’s 
legal guardian must be approved by the IRB or IEC.  
All IRB and IEC approvals must be dated and contain IRB/ IEC Chairman or designee 
authorization and must identify the IRB/ IEC (e.g.,  name and address ), the clinical 
protocol by title and/or protocol number, and the date of approval or favorable opinion 
was granted for the clinical research.  
No drug will be released to the site to dose a patient until written IRB/ IEC authorization 
has been received by Alnylam  or designee. 
The Investigator is responsible for obtaining continuing review of the clinical research at least an nually or more often if specified by the IRB or IEC.  The Investigator must supply 
Alnylam with written documentation of the approval of the continued clinical research. 
The Investigator will make all attempts to ensure that the IRB or IEC is constituted a nd 
operates in accordance with Federal and ICH GCP and any local regulations.  
10.2.2 Regulatory Authorities 
Regulatory authorities will receive the protocol, amendments, reports on SAEs, and the 
Integrated Clinical Trial Report according to national and any local  regulations. 
10.2.3 Modification of the Protocol  
Major changes in this research activity, except those to remove an apparent immediate 
hazard to the patient, must be reviewed and approved by Alnylam and the IRB or IEC 
that approved the study.  Amendments to the protocol must be submitted in writing to the 
Investigator’s IRB or IEC and the Regulatory  Authority for approval prior to patients 
being enrolled under the amended protocol. 
10.2.4 Informed Consent Form  
Written informed consent in compliance with 21 Code of Federal Regulations (CFR) § 50 
and ICH will be obtained from each patient prior to undergoing any protocol- specific 
tests or procedures that  are not part of routine care.   
Alnylam or the CRO designee will provide an ICF template to the Investigator for use in developing a site-specific ICF.  Prior to submission of the site- specific ICF to the IRB or 
IEC, the site -specific ICF must be reviewed and approved by Alnylam or designee.  Any 
changes requested by the IRB or IEC must also be agreed upon.  The final IRB/ IEC 
approved ICF must be provided to Alnylam.  Revisions to the ICF required during the study must be agreed upon, and a copy of the revised ICF provided to Alnylam. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 96 of 109 
At the time of recruitment, each prospective patient (or legal guardian) will be given a 
full explanation of the study and be allowed to read the ICF.  Once the Investigator is 
assured that the patient/legal guardian understands the commitments of participating in 
the study, the patient/legal guardian will be asked to sign and date the ICF.  A  copy of the 
fully signed and dated ICF will be given to the patient.  The original will be maintained in 
the patient’s medical record at the site.  All active patients will sign an updated ICF if 
revisions are made to the ICF during the course of the stud y. 
10.2.5 Study Reporting Requirements  
The Investigator will submit reports of SAEs as outlined in this protocol.  In addition, the 
Investigator agrees to submit progress reports to his/her IRB or IEC per their local 
reporting requirements, or at least annually and at the conclusion of the study.  The reports will be made available to Alnylam or designee.  
Deviations from the protocol necessary to protect patient safety should be reported to the 
CRO within 24 hours of knowledge of the event. 
Any communications from regulatory agencies in regard to inspections, other studies that  
impact this protocol or the qualifications of study personnel should be promptly reported to the CRO . 
10.2.6 Financial Disclosure Reporting Obligations  
Each Investigator (including principal and any sub -investigators) directly involved in the 
treatment or evaluation of study patients is required to provide financial disclosure information according to all applicable legal requirements.  In addition, Investigators 
must commit to promptly updating this information if any relevant changes occur during the study and for a period of one year after the completion of the study. 
10.3 Study Committees  
10.3.1 Data Monitoring Committee 
A Data Monitoring Committee  (DMC) will be involved in the conduct of this study.  The 
DMC has the responsibility for monitoring the progress of the clinical study and the 
safety of the study participants.  The D MC will perform periodic reviews of data and 
study conduct during the course of the clinical trial, as  defined in the D MC Charter f or 
this clinical trial.  The membership of the D MC and reporting structure are defined in the 
DMC Charter.  
10.3.2 Clinical Adjudication Committee  
An independent clinical adjudication committee will perform a blinded adjudication of 
the results of those patients w ho have clinical evidence of rapid disease progression 
(defined as ≥24 point increase in mNIS+7 from baseline [based on an average of 
2 measurements] and  FAP stage progression relative to baseline)  at 9 months.  Each 
review will follow procedures detailed in the committee’s charter.  
10.3.3 Interim Analysis Committee  
An Interim Analysis Committee ( IAC), comprised of 2 statisticians  (1 blinded and 
1 unblinded) independent of the conduct of the study, will be responsible for the 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 97 of 109 
implementation of the interim analysis  and for the calculations and recommendations 
surrounding whether an adjustment to the sample size is warranted, and if so, the 
appropriate adjustment, based on the study’s primary endpoint data from the interim 
analysis.  The Sponsor, the CROs, and all ot her parties conducting the study will remain 
blinded to all interim analyses until study completion.  The IAC will follow the procedure 
outlined in the committee’s charter.  
10.4 Ancillary Research  
Research ancillary to this main protocol may not be performed by individual study sites without prior discussion and approval by Alnylam.  
10.5 Study Record Retention  
Essential documents should be retained for the period of time required by applicable local 
law.  The essential documents include the signed and dated final protocol, signed and 
dated amendments(s), if applicable, signed and dated Curriculum Vitae (CVs) of the Investigators, copies of the completed CRFs, signed ICFs, IEC /IRB  approval and all 
related correspondence, financial agreements, regulatory approval, drug accountability, study correspondence, and patient identification codes.  Records will not be destroyed without informing Alnylam in writing and giving Alnylam the opportunity to store the 
records for a longer period of time at Alnylam’s expense. 
The Intern ational Conference on Harmonization requires that patient identification codes 
be retained for at least 15  years after the completion or discontinuation of the study. 
10.6 Discontinuation of the Study by Alnylam  
Alnylam reserves the right to discontinue the study for clinical or administrative reasons 
at any time.  If the site does not recruit at a reasonable rate, the study may be discontinued at that site .  Should the study be terminated and/or the site closed for 
whatever reason, all documentation and study d rug pertaining to the study must be 
returned to Alnylam or its representative, and the Investigators, IEC /IRB  and Regulatory 
Authorities will be promptly informed of the termination and the reason for the decision.  
The Investigator should promptly inform the patients and assure appropriate therapy and 
follow-up. 
10.7 Study Documentation  
Prior to beginning the study, the Investigator will be asked to comply with ICH E6 and 
21 CFR by providing at least the following essential documents: 
• An original signed Investigator agreement page of the protocol and any amendments; 
• An IEC /IRB and Alnylam approved ICF; 
• IEC/IRB approval of the protocol, and any amendments; 
• Completed and signed FDA form 1572; 
• Curriculum vitae for the Investigator signed and dated by the Investigator indicating 
that it is current; 
• Financial disclos ure information (if applicable); 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 98 of 109 
• Other documents which the Investigator should provide before study start include: 
• Curriculum vitae  for all Sub -investigators; these should be signed and dated 
by the Sub- investigators indicating that they are current;  
• Financial disclosure information for all Sub- investigators (if applicable);  
• Advertisements for patient recruitment and any other written information to be 
given to patients , family members  or legal gu ardians and IEC /IRB  approval of 
any advertisements and any other written information; 
• IEC/IRB  composition:  If the Investigator or any of the Sub- investigators is a 
member of the IEC /IRB , assurance that he/she refrained from voting should 
be provided; 
• Labo ratory accreditation and reference ranges for any laboratory values for 
local laboratories.  
10.8 Confidentiality  
The Investigator must ensure that the patients’ anonymity will be maintained.  On the CRFs or other documents submitted to Alnylam or designees, pat ients should not be 
identified by their names, but by the assigned patient number and initials.  If patient 
names are included on copies of documents submitted to Alnylam or designees , the 
names (except for initials) will be obliterated and the assigned pa tient number added to 
the document.  Documents not for submission to Alnylam (e.g. signed ICFs) should be maintained by the Investigator in strict confidence.  
Following the principles of the Good Clinical Practice, if local regulations specify a 
patient’s number and initials will be used to identify the patient on their study records.  
Laboratory samples may be labeled with an independent numbering code, and the label 
will not contain any other personal identification information.  The numbering code associ ated with these labels will be held by the study CRO and Alnylam, thereby 
allowing no unwarranted access to the information.  When reporting results for interim safety assessment , the interim analysis,  and at the end of the study, the code will be 
shared p er standard operating procedures with the responsible member of the 
Biostatistical and Data Management Departments of  the CRO.  The numbering code will 
also be held for samples in storage until marketing approval of patisiran ( ALN -TTR02 ) in 
the countries where this study was conducted, or until clinical development of patisiran  is 
halted.  Throughout sample collection, storage (limited, staff only access area containing locked sample storage, and limited access sample tracking) and processing, the samples will only be handled by appropriate personnel per the laboratory’s standard operating 
procedures. 
The Investigator must treat all of the information related to the study and the compiled 
data as confidential , whose use is for the purpose of conducting the s tudy.  Alnylam must 
approve any transfer of information not directly involved in the study. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 99 of 109 
10.9 Publications/Reports  
Following completion of the study, the data may be considered for publication in a 
scientific journal or for reporting at a scientific meeting.   A copy of the manuscript must 
be provided and confirmed received  at Alnylam at least 30  days prior to its submission. 
No submission of a manuscript may be made until the results from all of the study sites  
have been received and analyzed by Alnylam, or t he study has been terminated at all 
centers.  A separate, individual publication of the results of the study will be delayed until 
initial publication of the results of the multicenter study, or a decision not to publish is 
made.  If an initial draft is no t produced within 18 months of completion of the study at 
all centers, or the timeframe for publication is not satisfactory, the Investigator may 
disclose the results after providing a copy and Alnylam confirms receipt  of the 
manuscript 30 days prior to submission. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 100 of 109 
11 REFERENCES  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 101 of 109 
1  Yazaki M., Tokuda T , et al . Cardiac amyloid in patients with familial amyloid 
polyneuropathy consists of abundant wild- type transthyretin.  Biochem Biophys Res 
Commun. 2000; 274(3): 702-706. 
2  Stangou AJ and Hawkins  PN. Liver transplantation in transthyretin -related familial 
amyloid polyneuropathy. Current Opinion in Neurology. 2004;17(5): 615-620. 
3 Reixach NS. Deechongkit, et al. Tissue damage in the amyloidoses: Transthyretin 
monomers and nonnative oligomers are the major cytot oxic species in tissue culture. Proc 
Natl Acad Sci U S A. 2004;101(9): 2817-2822. 
4  Suhr OB , Herlenius G , et al. Liver transplantation for heredi tary transthyretin 
amyloidosis. Liver Transpl . 2000; 6(3): 263 -276. 
5  Benson MD. Famil ial amyloidotic polyneuropathy. Trends Neurosci. 1989;12(3):88-92. 
6  Connors LH, Yamashita  T, et al. A rare transthyretin mutation (Asp18Glu) associated 
with cardiomyopathy. Amyloid. 2004;11(1):61-66. 
7  Buxbaum JN. (2007). Transthyretin and the Transthyretin Amyloidoses. Protein Reviews: 
Protein Misfolding, Aggregation, and Conformational Diseases. V. N. a. F. Uversky, A. New York, Springer US. 7: 259-283. 
8  Suhr OB. Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) 
patients' symptoms and complications.  Amyloid . 2003;10 (Suppl 1):77-83. 
9  Ando Y, Nakamura M, et al. Transthyretin -related famil ial amyloidotic polyneuropathy. 
Arch Neurol . 2005;62(7): 1057-1062. 
10  Coelho T, Adams D, Silva A, et al. Safety and Efficacy of an RNAi Therapeutic 
Targeting Transthyreti n (TTR) for TTR Amyloidosis. NEJM .  2013, accepted for 
publication. 
11  Carvalho M, Alves  M, et al. Octreotide-- a new treatment for diarrhoea in famil ial 
amyloidotic polyneuropathy. J Neurol Neurosurg Psychiatry. 1992;55(9):860-861. 
12  Connors LH, Yamashita T, et al. A rare transthyretin mutation (Asp18Glu) associated 
with cardiomyopathy. Amyloid. 2004;11(1):61-66. 
13  Soares ML, Coelho  T, et al. Susceptibility and modifier genes in Portuguese transthyretin 
V30M amyloid polyneuropathy: compl exity in a single -gene disease.  Hum Mol Genet. 
2005;14(4): 543-553. 
14  Benson MD and Kincaid  JC. The molecular biology and clinical features of amyloid 
neuropathy. Muscle Nerve. 2007;36(4): 411-423. 
15  Roberts WC and Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis 
of 54 necropsy patients. Am J Cardiol . 1983; 52(1):137-146. 
16  Eriksson  P and Olofsson BO. Pacemaker treatment in familial amyloidosis with 
polyneuropathy. Pacing Clin Electrophysiol. 1984;7(4):702-706. 
17  Shah KB, Inoue Y, et al. Amyloidosis and the heart: a comprehensive review.  Arch Intern 
Med 2006;166(17):1805-1813. 
18  Plante -Bordeneuve V and Said  G. Familial amyloid polyneuropathy. Lancet Neurol . 
2011;10(12):1086-1097. 
  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 102 of 109 
                                                                                                                                                 
19  Stangou A J and Hawkins  PN. Liver transplantation in transthyretin -related familial 
amyloid polyneuropathy. Current Opinion in Neurology. 2004;17(5):615-620. 
20  Bergethon PR, Sabin  TD, et al. Improvement in the polyneuropathy associated with 
familial amyloid polyneuropathy after liver transplantation. Neurology. 1996;47(4):944-
951. 
21  Garzuly , F., R. Vidal, et al. Familial meningocerebrovascular amyloidosis, Hungarian 
type, with mutan t transthyretin (TTR Asp18Gly).  Neurology. 1996; 47(6): 1562-1567. 
22  Sekijima, Y., R. L. Wiseman, et al. The biological and chemical basis for tissue- selective 
amyloid disease.  Cell.2005;121(1): 73-85. 
23  Sekijima, Y., P. Hammarstrom, et al. Energetic characteristics of the new transthyretin 
variant A25T may explain its atypical ce ntral nervous system pathology. Lab Invest 
2003; 83(3): 409 -417. 
24  Bispo M, Marcelino P, et al. High incidence of thrombotic complications early after liver 
transplantation for familial amyloidotic polyneuropathy. Transpl Int. 2009;22(2): 165-171. 
25  Statement from Advisory Group for National Specialised Services (AGNSS) regarding 
Eculizumab and Tafamidis.   Dated 23 January 2013.  
http://www.specialisedservices.nhs.uk/news/view/132 , last accessed on 7 August 2013.  
26  Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. 
Silence. 2010;1(1):14. 
27  Elbashir SM, Lendeckel W, Tuschi T. RNA interference is mediated by 21- and 22-
nucleotide RNAs. Genes Dev. 2001;15:188-200. 
28  Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by 
systemic administration of modified siRNAs. Nature. 2004;432:173-178. 
29  Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006;193:1650-1657. 
30  Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammator y synthetic siRNA 
mediating potent gene silencing in vivo. Mol Ther. 2006;13:494-505. 
31  Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti- HBV 
activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002-1007. 
32  Zimmermann TS, Lee AC, Akinc A, et al. RNAi- mediated gene silencing in non -human 
primates. Nature. 2006;441(7089):111-4.  
33  Maurer N, Mori A, Palmer L, et al. Lipid- based systems for the intracellular delivery of 
genetic drugs. Mol Membr Biol. 1999;16:129-140. 
34  Akinc A, Querbes W, De S, Qin J, et al. Targeted delivery of RNAi therapeutics with 
endogenous and exogenous ligand- based mechanisms. Mol Ther. 2010;18(7):1357 -1364. 
35  Akinc A , Zumbuehl A, et al. A combinatorial library of lipid- like materials for  deliv ery 
of RNAi therapeutics.  Nat Biotechnol . 2008;26(5):561-569. 
36  Lachmann HJ, et al. Outcome in systemic AL amyloidosis in relation to changes in 
concentration of circulating free immunoglobulin light chains following chemotherapy. 
Br J Haematol, 2003;122:78-84. 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 103 of 109 
                                                                                                                                                 
37  Lachmann HJ, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J 
Med. 2007;356:2361-71. 
38  Gillmore JD, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6:2342-7. 
39  Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A alpha-chain 
amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. 2010;115:2998-3007. 
40  Biesalski, H.K., et al., Biochemical but not clinical vitamin A deficiency results from mutations in the gene for retinol binding protein. Am J Clin Nutr, 1999. 69(5): p. 931-6. 
41  Episkopou, V., et al., Disruption of the transthyretin gene results in mice with depressed 
levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci U S A, 1993. 90: p. 2375-2379. 
42  Conceiciao IM, Miranda LC, et al.  Bone mineral density in familial amyloid polyneuropathy and in other neuromuscular disorders. Eur J Neurol.  2005;12(6):480-2. 
43  MHRA Clarification of contraceptive wording in clinical trials conducted in the UK. 
http://www.mhra.gov.uk/home/groups/l-
unit1/documents/websiteresources/con2033037.pdf  Version 2 Amended 21 May 2010. 
Accessed 30 July 2013. 
44  Yamamoto S, Wilczek HE, Nowak G, et al.  Liver transplantation for familial 
amyloidotic polyneuropathy (FAP): a single- center experience over 16 years. Am J 
Transplant. 2007;7:2597-604. 
45  Coutinho P, DeSilva AM, Lima JL , Bar bosa AR . Forty years of experience with type I 
amyloid neuropathy: review of 483 cases. In: Glenner GG, Pinho P, Costa E, Falcao de 
Freitas A, Eds. Amyloid and Amyloidosis . Amsterdam: Excerpta Medica; 1980:88-98. 
46  Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS -31: a refined and 
abbreviated composit e autonomic symptom score. Mayo Clin Proc. 2012;87:1196-1201. 
47  Vinik EJ, Hayes RP, Oglesby A,  et al.  The development and validation of the Norfolk 
QOL -DN, a new measure of patients' perception of the effects of diabetes and diabetic 
neuropathy.  Diabete s Technol Ther. 2005 Jun;7(3):497-508. 
48  The EuroQol Group.  EuroQol -a new facility for the measurement of health -related 
quality of life. Health Policy .1990;16(3):199-208. 
49  van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch -built Overall Disability Scale (R -
ODS) for immune -mediated peripheral neuropathies. Neurology. 2011;76:337-45.  
50  Posner K, Brown GK, Stanley B, et al. The Columbia- Suicide Severity Rating Scale: 
initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168:1266-77. 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 104 of 109 
12 APPENDICES  
Appendix 1: Karnofsky Scale 
 
Able to carry on normal activity 
and to work; no special care needed.  100 Normal no complaints; no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
80 Normal activity with effort; some signs or 
symptoms of disease.  
Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.  70 
Cares for self; unable to carry on normal 
activity or to do active work.  
60 Requires occasional assistance, but is able 
to care for most of his personal needs.  
50 Requires considerable assistance and 
frequent medical care.  
Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly. 40 
Disabled; requires special care and 
assistance.  
30 Severely disabled; hospital admission is 
indicated although death not imminent.  
20 Very sick; hospital admission necessary; 
active supportive treatment necessary.  
10 Moribund; fatal processes progressing 
rapidly.  
0 Dead  
  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 105 of 109 
Appendix 2: New York Heart Association Classification of Heart Failure 
 
Class Symptomatology 
I No symptoms.  Ordinary physical activity such as walking and 
climbing stairs does not cause fatigue or dyspnea. 
II Symptoms with ordinary physical activity.  Walking or climbing 
stairs rapidly, walking uphill, walking or stair climbing after meals, in cold weather, in wind or when under emotional stress causes undue fatigue or dyspnea. 
III Symptoms with less than ordinary physical activity.  Walking one to two blocks on the level and climbing more than one flight of stairs in normal conditions causes undue fatigue or dyspnea. 
IV Symptoms at rest.  Inability to carry on any physical activity without fatigue or dyspnea. 
 
  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 106 of 109 
Appendix 3: Categoriza tion of Infusion -Related Reactions  
 
Signs and symptoms of an infusion- related reaction (IRR)  usually develop during or 
shortly after drug infusion and generally resolve completely within 24 hours of 
completion of infusion.  Signs/symptoms may include: allergic reaction/hypersensitivity 
(including drug fever), arthralgia (joint pain), bronchospasm, cough, dizziness, dyspnea (shortness of breath), fatigue (asthenia, lethargy, malaise), headache, hypertension, 
hypotension, myalgia (muscle pain), nausea, pruritus/itching, rash/desquamation, 
rigors/chills, sweating (diaphoresis), tachycardia, urticaria (hives, welts, wheals), vomiting.  
Categorization of IRRs  is as follows:  
 
Categorization Description  
Mild  Mild reaction:  infusion may be continued; if intervention is indicated it is minimal and additional treatment (other than 
paracetamol for delayed reactions) is not required.  
Moderate  Moderate reaction:  requires treatment including more intensive 
therapy (e.g., IV fluids, nonsteroidal anti- inflammatory [NSAIDs]) 
in addition to infusion interruption but responds promptly to medication.  Treatment is indicated for ≤24 hours. 
Severe  More than moderate reaction:  not rapidly responsive to medication or to interruption of infusion; and/ or prolonged (treatment is 
indicated for >24 hours); recurrence of severe symptoms following 
initial improvement.  
 
  
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 107 of 109 
Appendix 4: Neuropathy Scores and Their Components  
 
Assessment Tool  Total 
Points Components (points)  
NIS+7  
 270 • Neurologic exam of lower limbs, upper limbs and cranial 
nerves (NISa) 
• Weakness (192) 
• Sensation (32) 
• Reflexes (20)  
• Nerve conduction studies ∑5 (18.6)a 
• Sural SNAP, tibial motor n. distal latency, peroneal SNAP/motor n. conduction velocity/motor n. distal 
latency  
• Vibra tion detection threshold (3.7) 
• Heart rate response to deep breathing (3.7) 
Modified NIS+7 304 • Neurologic exam of lower limbs, upper limbs and cranial 
nerves (mNISa) 
• Weakness (192) 
• Reflexes (20)  
• Nerve conduction studies ∑5 (10)a 
• Ulnar CMAP and SNAP, sural SNAP, tibial CMAP, peroneal CMAP  
• Quantitative sensory testing: QST- BSA
TP+HP5  (80) 
• Postural blood pressure (2)  
a Components that are shared between the mNIS+7 and NIS+7 (including NIS and NCS) will be performed once at 
each assessment.  
 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 108 of 109 
Appendix 5: Polyneuropathy Disability Score 
 
Stage Description  
0 No symptoms 
I Sensory disturbances but preserved walking capability 
II Impaired walking capacity but ability to walk without a stick or crutches  
IIIA 
IIIB Walking with the  help of one stick or crutch. 
Walking with the help of two sticks or crutches. 
IV Confined to a wheelchair or bedridden. 
 
 Patisiran ( ALN- TTR02 ) 
 ALN -TTR02 -004 
 08 September 2015  
 
Final Protocol (Version 6 .0)  Confidential  
Page 109 of 109 
Appendix 6: Familial Amyloid otic Polyneuropathy Stage 
 
Stage Description  
0 No symptoms 
I Unimpaired ambulation; mostly mild sensory, motor, and autonomic 
neuropathy in the lower limbs 
II Assistance with ambulation required, mostly moderate impairment 
progression to the lower limbs, upper limbs, and trunk. 
III Wheelchair -bound or bedridden; severe sensory, motor, and autonomic 
involvement of all limbs.  
 
 
APOLLO Global Protocol Amendment Summary 
Version 4.0 – 30 Jan 2018 
1 ALN-TTR02 -004 
APOLLO Global Protocol Amendment Summary  
Version 4.0 – 30 January  2017 
 
Protocol 
Version 
No. Date  Summary of Changes  
1.0 
(Original)  15 August 
2013  N/A 
2.0  18 October 
2013  • Secondary endpoints reordered and methods of analysis were modified  
o EuroQOL questionnaire was made an exploratory endpoint  
o Removal of the analysis by families  
• Clarification that study personnel performing the efficacy assessments will remain b linded to the 
results of any previous assessment until the study has been completed  
• Change of the schedule of assessments in tables 1 -1,1-2, and 1 -3 and Sections 6.1.1, 6.1.2, and 6.1.3  
• Inclusion criteria modified to allow an INR of ≤3 only for patients on warfarin  
• Definition of “highly effective birth control” was clarified in Section 4.7  
• Premedication regimen was modified to reflect those used in earlier trials of ALN -TTR02  
• Addition that either Bazett’s or Friderica’s correction may be used in the case that an ECG machine 
does not calculate QTc  
• Description of the pharmacoeconomics questionnaire was corrected to reflect the inclusion of 21, 
rather than 16, questions  
3.0  21 March 
2014  • Additional clarification that entry criteria, besides Inclusion Criteria #3 [Have a NIS of 10 to 100 
(inclusive)] and #4 [  
], will be assessed at the Screening Visit only  
• Inclusion Criterion #1 [Male or female of 18 to 80 years of age (inclusive)]  modified to allow for 
enrollment of subjects up to 85 years of age (inclusive)  
• Lower limit of the Neuropathy Impairment Score (NIS) from 10 to 5 in Inclusion Criterion #3 [Have a NIS 
of 10 to 100 (inclusive)]  
• Inclusion Criterion #4  
 
 
• Inclusion Crite rion #6 [Have an absolute neutrophil count (ANC) ≥1500 cells/mm³, a platelet count 
≥100,000 cells/mm³, and hemoglobin ≥10 g/dL (or ≥100 g/L)] modified from a platelet count of ≥ 
100,000 cells/mm3 to ≥50000 cells/mm3 
• Inclusion Criterion #7 [Have aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 × the upper limit of normal (ULN), total bilirubin within normal limits, albumin >3 g/dL (or >30 g/L), international normalized ratio (I NR) ≤1.2 (patients on warfarin with an INR of ≤3 will be allowed)] 
modified to increase INR value from ≤3 to ≤3.5  
• Exclusion Criterion #1 [Has vitamin A levels below the lower limit of normal (LLN)] was clarified to exclude patients with vitamin A levels consistent with vitamin A deficiency  (ie, <20 µg/dL)  
• Exclusion Criterion #18 was removed ( [Participated in a clinical trial with an antisense oligonucleotide 
for more than 3  months; if in a clinical trial with antisense oligonucleotide for ≤3 months, must have 
completed a 3 ‑month wash -out prior to start of study drug administration in this study] 
• Diflusinal was removed from Exclusion Criterion #19 [Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid; if pre viously on any of these agents, must have completed a 
14-day wash -out prior to start of study drug administration in this study] and added as new Exclusion 
Criterion #20 [Is currently taking diflunisal; if previously on this agent, must have at least a 3-d ay wash -
out prior to start of study drug administration in this study] to clarify that a 3 -day washout period prior  
to start of study drug for this particular agent  is sufficient for that agent
 
 
  

 
APOLLO Global Protocol Amendment Summary 
Version 4.0 – 30 Jan 2018 
2 Protocol 
Version 
No. Date  Summary of Changes  
4.0  24 April 
2014  • The screening window was expanded from  28 days to 42 days to make it less restrictive for traveling 
patients.  
• Corrected typographical errors identified in the SOA in version 3.0  
5.0  04 August 
2014  • Inclusion Criterion #3 [Have an NIS of 5 to 100 (inclusive) (Note:  This criterion must be met at the 
Screening/Baseline Visit)] changed to the upper limit NIS from 100 to 130 and added requirement for a 
Polyneuropathy Disability (PND) score of ≤3b.  
• Inclusion Criterion #7 [Have aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2 .5 × 
the upper limit of normal (ULN), total bilirubin within normal limits, albumin >3 g/dL (or >30 g/L), 
international normalized ratio (INR) ≤1.2 (patients on anticoagulant therapy with an INR of ≤3.5 will be 
allowed)] modified to remove albumin criterio n and to increase INR criterion from ≤1.2 to ≤2.0  
• Inclusion Criterion #8 [Have a serum creatinine ≤1.5 × ULN] modified from serum creatinine ≤1.5 to ≤2 
× ULN  
• Inclusion Criterion #9 [Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV] 
clarified to exclude only patients with an active hepatitis B or hepatitis C infection  
• Inclusion Criterion #10 [Women of child -bearing potential must have a negative pregnancy test, cannot 
be breastfeeding, and must be using 2  highly effective method s of contraception prior to screening, 
throughout study participation, and for 1  month after last dose of study drug.  Highly effective methods 
of birth control are defined in Section 4.7] modified to extend the period from 1 month to 75 days aft er 
last dose of study drug for WOCBP  
• Inclusion Criterion #11 [Males with partners of child -bearing potential, must agree to use 1 barrier 
method (e.g., condom) and 1 additional method (e.g., spermicide) of contraception  throughout study participation and for 1 month after the last dose of study drug; males must also abstain from sperm donation after the first dose of study drug through study participation and for 1  month after last dose 
of study drug] modified to extend the period that males with partners of child -bearing potential must 
use 1 barrier method and 1 additional method of contraception from 1 month to 75 days after the last dose of study drug  
• Exclusion Criterion #1 [Has vitamin A levels consistent with vitamin A deficiency (<20 µg/dL)] removed  
• Exclusion Criterion #16 [Has a known history of alcohol abuse or daily heavy alcohol consumption 
(females: more than 14 units of alcohol per week; males: more than 21 units of alcohol per week [unit: 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer])] clarified to patients with a history of 
alcohol abuse within the past 2 years or daily heavy alcohol consumption 
• Exclusion Criterion #17 [Participated in a clinical trial with antisense oligonucleotide, must have completed a 3 -month wash -out prior to start of the study drug administration in this study] added to 
exclude patients who participated in a clinical trial with antisense oligonucleotide unless there is a 3 month wash -out period  
• Exclusion Criterion #24 [Is under legal protection] modified to define “under legal protection”  
• The protocol has been modified to permit select changes to the premedication  regimen for an 
individual having difficulty tolerating the premedication  regimen only after consultation with the study 
medical moni tors. 
• The sample size was modified to limit the number of patients with a Neu ropathy Impairment Score 
(NIS) in the range of 101 to 130 to no more than 40 of the 200 planned patients to prevent 
overenrolling patients with more severe impairment.  
 
APOLLO Global Protocol Amendment Summary 
Version 4.0 – 30 Jan 2018 
3 Protocol 
Version 
No. Date  Summary of Changes  
6.0  08 
September 
2015  • Implemented a reduced dose of dexamethasone for the protocol -specified premedication regimen  
• Included that specified patients who are intolerant of 1 0 mg IV dexamethasone or equivalent on the 
day of infusion may be considered for further step -wise reduction in dexamethasone or equivalent 
after consultation with the medical monitor  
• The risk benefit assessment has been updated to reflect liver function test abnormalities and risk for 
osteoporosis  
• Because patients may be at risk for osteoporosis, it has been added that, if appropriate, study 
participants should receive therapy for the prevention and early treatment of osteoporosis   
• Inclusion #4  
Note:  This criterion must be met at 
the Screening/Baseline visit)] added ulnar SNAP and ulnar CAP measurements to  the qualifying NCS  
• Inclusion #7 [Have aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 × the upper 
limit of normal (ULN), total bilirubin within normal limits, international normalized ratio (INR) ≤2.0 
(patients on anticoagulant the rapy with an INR of ≤3.5 will be allowed)] changed to permit patients 
with a total bilirubin level elevation to ≤ 2 x upper limit of normal  to enroll  
• Exclusion #14 [Has uncontrolled clinically significant cardiac arrhythmia or unstable angina] changed t o 
include clarification that patients with any uncontrolled cardiac arrhythmia or unstable angina are not 
permitted to enroll in the study 
• Included the option for patients to permanently discontinue study treatment and remain on- study 
• Provided clarificatio n about local personnel responsible for reading ECGs to include that ECGs will be 
read locally by a cardiologist or qualified physician  
 
